Subject Index

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Click on a letter to get an alphabetic listing of Subjects.

Chapters in boldface indicate a major discussion of a topic.

Please also note that due to the impressive size of this index it was necessary to break it down in to smaller groups. The Alphabet above will take you to any letter you please and the grouping of letters is indicated by spaces between the letters.

Main Menu
Search
Contributor Index

Subject Index D

Dacarbazine (DTIC), (Foundations Volume 3, Chapter 33) (Foundations Volume 3, Chapter 41)

Dacryadenitis, suppurative, acute, (Foundations Volume 3, Chapter 36)

Dacryoadenitis, (Clinical Volume 2, Chapter 34) (Clinical Volume 2, Chapter 35) (Clinical Volume 2, Chapter 40) (Foundations Volume 2, Chapter 49)

antibiotics in, (Clinical Volume 4, Chapter 26)

computed tomography, (Clinical Volume 2, Chapter 24)

Epstein-Barr virus, epidemiology, (Foundations Volume 2, Chapter 43)

inflammatory pseudotumor and, (Clinical Volume 2, Chapter 27)

in sarcoidosis, (Clinical Volume 2, Chapter 35) (Clinical Volume 4, Chapter 44)

Dacryoadenoma, (Clinical Volume 4, Chapter 10)

Dacryocele, (Clinical Volume 2, Chapter 31)

Dacryocystectomy, for lacrimal sac tumors, (Clinical Volume 4, Chapter 13)

Dacryocystitis, (Foundations Volume 3, Chapter 7) (Clinical Volume 4, Chapter 13) (Foundations Volume 2, Chapter 49) (Foundations Volume 3, Chapter 7)

acute, medical treatment, (Clinical Volume 4, Chapter 13)

antibiotics in, (Clinical Volume 4, Chapter 26)

dacryocystography in, (Clinical Volume 4, Chapter 13)

dacryocystorhinostomy for, (Clinical Volume 4, Chapter 13 )

differential diagnosis, (Clinical Volume 4, Chapter 13)

epidemiology, (Foundations Volume 2, Chapter 43)

neonatal, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

treatment, (Foundations Volume 3, Chapter 36) (Clinical Volume 4, Chapter 13)

Dacryocystocele, (Clinical Volume 2, Chapter 31)

Dacryocystography

abnormal findings in, (Clinical Volume 4, Chapter 13)

in epiphora, (Clinical Volume 5, Chapter 79)

intubation microdacryocystography, (Clinical Volume 4, Chapter 13)

normal, (Clinical Volume 4, Chapter 13)

Dacryocystorhinostomy, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79 )

complications, (Clinical Volume 4, Chapter 13) (Clinical Volume 6, Chapter 105)

contraindications, (Clinical Volume 6, Chapter 105)

endonasal, (Clinical Volume 4, Chapter 13)

endoscopic, (Clinical Volume 5, Chapter 79)

indications, (Clinical Volume 6, Chapter 105)

in lacrimal system obstruction, (Clinical Volume 6, Chapter 105)

postoperative care, (Clinical Volume 5, Chapter 79)

repeat, (Clinical Volume 4, Chapter 13)

results, (Clinical Volume 6, Chapter 105)

revision, (Clinical Volume 5, Chapter 79)

Silastic intubation combined with, (Clinical Volume 5, Chapter 79)

technique, (Clinical Volume 4, Chapter 13) (Clinical Volume 6, Chapter 105)

standard, (Clinical Volume 5, Chapter 79)

transcanalicular, (Clinical Volume 4, Chapter 13)

Dacryolithiasis, (Clinical Volume 4, Chapter 13)

Dacryoplasty, balloon, (Clinical Volume 5, Chapter 79)

Dacryops, (Clinical Volume 2, Chapter 40)

Dacryoscintigraphy, (Clinical Volume 4, Chapter 13)

in epiphora, (Clinical Volume 5, Chapter 79)

Dacryostenosis, (Clinical Volume 4, Chapter 13) (Foundations Volume 1, Chapter 32)

after rhinoplasty, (Clinical Volume 4, Chapter 13)

congenital, (Clinical Volume 5, Chapter 79)

irrigation and probing for, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

Dactinomycin (Actinomycin D, Cosmegen), (Foundations Volume 3, Chapter 33) (Foundations Volume 3, Chapter 41)

Dalen-Fuchs nodules, 3; (Clinical Volume 4, Chapter 57) (Foundations Volume 3, Chapter 4) (Clinical Volume 4, Chapter 51)

Danazol, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dapiprazole, (Foundations Volume 3, Chapter 29) (Clinical Volume 1, Chapter 41)

effect on iris, (Foundations Volume 3, Chapter 29)

Dapsone

for cicatricial pemphigoid, (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27)

effects on immune system, (Foundations Volume 2, Chapter 31)

effects on ocular inflammatory disease, (Foundations Volume 2, Chapter 31)

for leprosy, (Clinical Volume 5, Chapter 63)

prophylactic, (Clinical Volume 5, Chapter 63)

in ocular inflammation, (Foundations Volume 2, Chapter 31)

side effects, (Foundations Volume 2, Chapter 31)

for toxoplasmosis, (Clinical Volume 4, Chapter 46)

Daranide. See Dichlorphenamide (Daranide)

Daraprim. See Pyrimethamine

Dark adaptation, (Foundations Volume 2, Chapter 16)

abnormalities, (Foundations Volume 2, Chapter 16)

in diabetic retinopathy, (Clinical Volume 3, Chapter 30)

drugs affecting, (Clinical Volume 5, Chapter 37)

testing, (Foundations Volume 2, Chapter 14)

tests, (Clinical Volume 2, Chapter 2)

"Dark current, ” photoreceptor, (Foundations Volume 2, Chapter 13)

Darkfield examination, (Foundations Volume 2, Chapter 40)

Dark field illumination, (Clinical Volume 1, Chapter 30)

Dark-light, (Foundations Volume 2, Chapter 13) (Foundations Volume 2, Chapter 20)

Darkness

retinal blood flow and, (Foundations Volume 2, Chapter 5)

sense of, (Clinical Volume 2, Chapter 2)

Darkness reflex, (Foundations Volume 2, Chapter 9)

Dark-noise. See Dark-light

Dark room test, in angle-closure glaucoma, (Clinical Volume 3, Chapter 53)

Darts, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Da Vinci, Leonardo, (Clinical Volume 1, Chapter 31)

4D Base-out test, in monofixation syndrome, (Clinical Volume 1, Chapter 14)

Deafness

congenital labyrinthine, with Duane retraction syndrome, (Clinical Volume 1, Chapter 20)

late-onset sensorineural, albinism with, (Foundations Volume 3, Chapter 57)

sensorineural, late-onset, X-linked ocular albinism with, (Clinical Volume 4, Chapter 38)

Debridement

in chemical injuries, (Clinical Volume 4, Chapter 28)

in herpes simplex keratitis, (Clinical Volume 4, Chapter 19)

Debrisoquin metabolism, side effects of -blockers and, (Foundations Volume 3, Chapter 40)

DEC. See Diethylcarbamazine

Decadron. See Dexamethasone

Decentered ablation, (Clinical Volume 6, Chapter 48)

Decentered ablations, (Clinical Volume 6, Chapter 47)

Decentration of lenses, contact lens, (Clinical Volume 1, Chapter 55)

Decibels

in automated perimetry, (Clinical Volume 3, Chapter 49)

of light intensity, (Foundations Volume 2, Chapter 109)

Declination, (Clinical Volume 1, Chapter 47)

Decompression, barometric, ocular effects, (Foundations Volume 3, Chapter 6)

ocular, anesthesia and, (Clinical Volume 6, Chapter 1)

optic nerve sheath, in acute retinal necrosis syndrome, (Clinical Volume 3, Chapter 28)

Decompressive surgery

orbital

in idiopathic intracranial hypertension, (Clinical Volume 2, Chapter 14)

in thyroid disease, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 36) (Clinical Volume 5, Chapter 21) (Clinical Volume 5, Chapter 81 )

in pseudotumor cerebri, (Clinical Volume 2, Chapter 5)

in retinal vein occlusion, central, (Clinical Volume 3, Chapter 15)

in traumatic optic neuropathy, (Clinical Volume 2, Chapter 14)

Decongestants

adverse effects, (Foundations Volume 3, Chapter 43)

Deep dyslexia, (Clinical Volume 2, Chapter 7)

Deep filiform dystrophy, (Clinical Volume 4, Chapter 16)

Deep inferior orbitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

transantral orbitotomy, (Volume 5, Chapter 86)

Deep lamellar endothelial keratoplasty, (Clinical Volume 6, Chapter 26)

Deep medial orbitotomy, (Volume 5, Chapter 86)

frontoethmoidal orbitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

procedure, (Volume 5, Chapter 86)

transcaruncular obitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

procedure, (Volume 5, Chapter 86)

Deep orbital approaches, (Volume 5, Chapter 86)

canthotomy approach, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

procedure, (Volume 5, Chapter 86)

eyelid crease lateral orbitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

lateral obitotomy, (Volume 5, Chapter 86)

transcoronal lateral orbitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

transcranial orbitotomy, (Volume 5, Chapter 86)

indications, (Volume 5, Chapter 86)

procedure, (Volume 5, Chapter 86)

Deep sclerectomy with collagen implant (DSCI), (Clinical Volume 6, Chapter 15)

Deep sclerectomy with viscocanalostomy (DSVC), (Clinical Volume 6, Chapter 15)

Defensins, (Foundations Volume 2, Chapter 45) (Foundations Volume 2, Chapter 101)

Deferoxamine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Defocus, retinal image blur and, (Clinical Volume 1, Chapter 33)

Degeneration

cerebellar

in ataxia-telangiectasia, (Clinical Volume 5, Chapter 36)

optic atrophy and, (Clinical Volume 2, Chapter 5)

chorioretinal. (See Chorioretinal degeneration)

choroidal, (Clinical Volume 4, Chapter 66) (Clinical Volume 4, Chapter 66) See also Atrophy, choroidal

conjunctival, (Foundations Volume 3, Chapter 8) (Clinical Volume 4, Chapter 16)

corneal, (Clinical Volume 4, Chapter 16 )

amyloid, (Clinical Volume 4, Chapter 16)

arcus juvenilis, (Clinical Volume 4, Chapter 16)

arcus senilis, (Clinical Volume 4, Chapter 16)

band keratopathy, (Clinical Volume 4, Chapter 16)

central or diffuse, (Clinical Volume 4, Chapter 16)

coat white ring, (Clinical Volume 4, Chapter 16)

furrow, (Clinical Volume 4, Chapter 16)

iron lines, (Clinical Volume 4, Chapter 16)

keloids, (Clinical Volume 4, Chapter 16)

lipid, (Clinical Volume 4, Chapter 16)

marginal

pellucid, (Clinical Volume 4, Chapter 16)

Terrien’s, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 16)

videokeratography in, (Clinical Volume 1, Chapter 65)

Mooren’s ulcer, (Clinical Volume 4, Chapter 16)

nodular, Salzmann’s, (Clinical Volume 4, Chapter 16) (Clinical Volume 6, Chapter 28)

peripheral, (Clinical Volume 4, Chapter 16)

pingueculae, (Clinical Volume 4, Chapter 16)

postirradiation thinning, (Clinical Volume 4, Chapter 16)

pterygia, (Clinical Volume 4, Chapter 16)

Salzmann’s, (Clinical Volume 4, Chapter 16)

spheroid, (Clinical Volume 4, Chapter 16)

white limbal girdle of Vogt, (Clinical Volume 4, Chapter 16)

elastotic, (Clinical Volume 6, Chapter 35)

epithelial cell, (Foundations Volume 2, Chapter 40)

hepatolenticular. (See Wilson’s disease)

“hydropic, ”, (3) 7: 12

keratinoid, (Clinical Volume 4, Chapter 16)

macular. (See also Macular degeneration)

juvenile, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 9)

polymorphic, of Braley, (Clinical Volume 3, Chapter 9)

senile (aging)

choroidal degeneration and atrophy and, (Clinical Volume 4, Chapter 66)

indocyanine green angiography, (Clinical Volume 3, Chapter 4A)

light toxicity and, (Clinical Volume 3, Chapter 37)

vitelliform, (Clinical Volume 3, Chapter 9)

myopic, (Clinical Volume 3, Chapter 36)

retinal, (Clinical Volume 3, Chapter 2) (Clinical Volume 3, Chapter 24) (Clinical Volume 3, Chapter 26 )

advanced-stage, (Clinical Volume 4, Chapter 66)

cystoid, (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 26)

reticular, (Clinical Volume 3, Chapter 26)

genetic approaches, (Clinical Volume 3, Chapter 2 )

lattice, (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 26 )

in pigmentary glaucoma, (Clinical Volume 3, Chapter 54B)

paving stone, (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 26)

peripheral

tapetochoroidal, (Clinical Volume 3, Chapter 26)

tractional, (Clinical Volume 3, Chapter 26)

trophic, (Clinical Volume 3, Chapter 26)

photocoagulation for, (Clinical Volume 6, Chapter 76)

pregnancy and, (Clinical Volume 5, Chapter 32)

trophic, (Clinical Volume 3, Chapter 26)

retinal. (See Retina, degeneration)

macular. (See Macula, degeneration)

scleral, (Clinical Volume 4, Chapter 23)

superficial reticular, of Koby, (Clinical Volume 4, Chapter 32)

tapetoretinal, (Clinical Volume 2, Chapter 13)

Degeneration, vitreous, age-related, (Foundations Volume 1, Chapter 16)

Degenerative myopia, (Foundations Volume 3, Chapter 61) (Clinical Volume 4, Chapter 66)

Degenerative verrucal endocardiosis, (Clinical Volume 5, Chapter 22)

Dego syndrome, (Clinical Volume 5, Chapter 27)

DeGrouchy syndrome, (Foundations Volume 3, Chapter 52)

Dehydrational crises, (Clinical Volume 5, Chapter 41)

Dehydrational crises, cataract in, (Clinical Volume 5, Chapter 41)

De Lange syndrome, (Foundations Volume 3, Chapter 52) (Foundations Volume 3, Chapter 59)

Delayed-blanch phenomenon, (Foundations Volume 2, Chapter 29)

Delayed hypersensitivity, (Foundations Volume 2, Chapter 35)

Delayed-onset postoperative endophthalmitis, (Foundations Volume 2, Chapter 40B) (Clinical Volume 4, Chapter 24)

Delayed reactions. See Hypersensitivity, type IV

Delayed rectifier, (Clinical Volume 1, Chapter 72A)

Deletion syndromes. See also (Foundations Volume 1, Chapter 40 specific syndromes)

partial, (Foundations Volume 3, Chapter 52)

mechanisms in, (Foundations Volume 3, Chapter 52)

Dellen, surgery of extraocular muscles and, (Clinical Volume 6, Chapter 83)

reoperation, (Clinical Volume 6, Chapter 98)

Dematiaceous fungi, (Foundations Volume 2, Chapter 54)

Demecarium (Humorsol)

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56)

ocular toxicity, (Clinical Volume 5, Chapter 37)

systemic toxicity, (Clinical Volume 5, Chapter 37)

Demeclocycline, ocular toxicity, (Clinical Volume 5, Chapter 37)

Demodex bevis, (Foundations Volume 2, Chapter 41)

Demodex folliculorum, (Foundations Volume 3, Chapter 7)

Demodex folliculorum, (Foundations Volume 2, Chapter 41) (Foundations Volume 3, Chapter 7)

Demodex folliculorum, and lid infection, (Clinical Volume 4, Chapter 22)

DeMorsier syndrome. See also Septo-optic dysplasia syndrome

Duane retraction syndrome and, (Clinical Volume 1, Chapter 20)

Demyelinating diseases

chiasmal syndromes in, (Clinical Volume 2, Chapter 6)

optic nerve and, (Foundations Volume 3, Chapter 16)

optic neuritis with, (Clinical Volume 2, Chapter 5)

retina and, (Foundations Volume 3, Chapter 13)

Dendritic cells, (Foundations Volume 2, Chapter 25)

bipolar, (Foundations Volume 1, Chapter 20)

Dendritic keratopathy, (Clinical Volume 4, Chapter 17)

Dendritic ulcers, in herpes simplex keratitis, (Clinical Volume 4, Chapter 19)

Denervation. See also Chemodenervation

ciliary ganglion, muscarinic agonists and, (Foundations Volume 3, Chapter 26)

inferior oblique, (Clinical Volume 6, Chapter 87)

extirpation and, (Clinical Volume 6, Chapter 87)

sympathetic. (See Horner’s syndrome)

Denervation hypersensitivity, (Foundations Volume 2, Chapter 7) (Foundations Volume 2, Chapter 9)

Dense filters, (Clinical Volume 3, Chapter 6)

Densitometry, of Scheimpflug photographs of lens, (Clinical Volume 1, Chapter 31)

Dentate processes, (Foundations Volume 1, Chapter 13)

Deorsumversion, (Clinical Volume 1, Chapter 2)

Deoxyribonucleic acid (DNA) probes, (Foundations Volume 1, Chapter 19A) (Foundations Volume 3, Chapter 51..) See also Molecular genetics, (Foundations Volume 2, Chapter 40)

chlamydial ocular diseases, (Foundations Volume 2, Chapter 77)

defined, (Foundations Volume 3, Chapter 51)

herpes simplex virus latency and, (Foundations Volume 2, Chapter 89)

mitochondrial, defects in, (Foundations Volume 3, Chapter 51)

mutations. (See Mutation)

in mycobacterial infection diagnosis, (Foundations Volume 2, Chapter 56)

polymorphic variations, (Foundations Volume 1, Chapter 19A) (Foundations Volume 3, Chapter 51)

resequencing, (Foundations Volume 1, Chapter 19A)

restriction enzymes, prenatal detection, (Foundations Volume 3, Chapter 56)

sample collection, (Foundations Volume 3, Chapter 55)

sequence determination and analysis, (Foundations Volume 1, Chapter 19A) (Foundations Volume 3, Chapter 55)

sequencing methods, alternative, (1) 19A: 17-19

single-strand gel electrophoresis, (Foundations Volume 3, Chapter 55)

in viral infection diagnosis, (Foundations Volume 2, Chapter 88)

Depakote, in migraine prophylaxis, (Clinical Volume 2, Chapter 16)

Department of Defense, eyewear standards of, (Clinical Volume 5, Chapter 45)

Depigmentation

with corticosteroids, (Foundations Volume 3, Chapter 31)

Depo-Medrol. See Methylprednisolone

Deprenyl

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 57)

glaucoma incidence and, (Clinical Volume 3, Chapter 57)

Deprivation amblyopia, (Foundations Volume 2, Chapter 24)

Depth of field, and depth of focus, (Clinical Volume 1, Chapter 33 )

Depth perception, (Clinical Volume 1, Chapter 33) See Binocular vision

Dermabrasion, after lid repair, (Clinical Volume 5, Chapter 75)

Dermal hypoplasia, focal, (Clinical Volume 5, Chapter 27)

Dermatan sulfate, catabolism, metabolic blocks, (Clinical Volume 4, Chapter 15) (Foundations Volume 1, Chapter 23)

Dermatitis, (Foundations Volume 3, Chapter 7) See also Skin disorders

atopic, (Foundations Volume 2, Chapter 28) (Foundations Volume 2, Chapter 29) (Foundations Volume 3, Chapter 8)

histology, (Foundations Volume 2, Chapter 29)

immunopathology, (Foundations Volume 2, Chapter 29)

atopic. (See Atopic dermatitis)

Brusting-Perry, in cicatricial pemphigoid, 5, (Clinical Volume 5, Chapter 27)

contact, (Foundations Volume 2, Chapter 29) (Clinical Volume 4, Chapter 2)

histology, (Foundations Volume 2, Chapter 29)

immunopathology, (Foundations Volume 2, Chapter 29)

of lids, (Clinical Volume 4, Chapter 22)

eczematoid. (See Eczema)

eczematoid, infectious, (Foundations Volume 2, Chapter 49)

Dermatitis, atopic, (Clinical Volume 5, Chapter 41)

Dermatitis herpetiformis, (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27) (Foundations Volume 2, Chapter 29)

defined, (Clinical Volume 5, Chapter 27)

diagnosis, (Clinical Volume 5, Chapter 27)

differential diagnosis, (Clinical Volume 4, Chapter 12)

epidemiology, (Clinical Volume 5, Chapter 27)

histology, (Foundations Volume 2, Chapter 29) (Clinical Volume 5, Chapter 27)

immunology, (Clinical Volume 5, Chapter 27)

immunopathology, (Foundations Volume 2, Chapter 29)

ocular involvement, (Clinical Volume 5, Chapter 27)

pathogenesis, (Clinical Volume 5, Chapter 27)

treatment, (Clinical Volume 5, Chapter 27)

Dermatoblepharitis, varicella-zoster virus

epidemics and outbreaks, (Foundations Volume 2, Chapter 43)

epidemiology, (Foundations Volume 2, Chapter 43)

vaccinia, (Foundations Volume 2, Chapter 97)

Dermatochalasis, (Foundations Volume 3, Chapter 7)

Dermatofibroma, (Foundations Volume 3, Chapter 7)

Dermatofibroma (histiocytoma), (Foundations Volume 3, Chapter 7)

Dermatofibrosarcoma protuberans, (Foundations Volume 3, Chapter 17)

Dermatologic agents, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dermatomyositis, (Clinical Volume 5, Chapter 26) (Foundations Volume 2, Chapter 33)

immunopathology, (Foundations Volume 2, Chapter 33)

lid and periorbital manifestations, (Foundations Volume 3, Chapter 7)

orbit in, (Clinical Volume 2, Chapter 35)

Dermatophytosis, (Foundations Volume 3, Chapter 7)

Dermatoses

dermatosis papulosa nigra, (Foundations Volume 3, Chapter 7)

inflammatory, (Foundations Volume 3, Chapter 7)

Dermatosis

blistering. (See Bullous disorders)

of lids, (Clinical Volume 4, Chapter 22)

Dermographism, white, (Foundations Volume 2, Chapter 29)

Dermoid, conjunctival, (Clinical Volume 4, Chapter 10)

Dermoid cysts, (Foundations Volume 3, Chapter 7)

corneal, in children, (Clinical Volume 6, Chapter 106)

epibulbar, in Goldenhar’s syndrome, (Clinical Volume 5, Chapter 29)

lacrimal gland fossa, (Clinical Volume 2, Chapter 40)

orbital, (Clinical Volume 2, Chapter 31)

computed tomography, (Clinical Volume 2, Chapter 24)

proptosis with, (Clinical Volume 2, Chapter 27)

ruptured, (Clinical Volume 2, Chapter 35)

Dermoids. See Tumor(s), dermoid

Dermolipoma, (Foundations Volume 3, Chapter 8)

Dermolipomas

conjunctival, (Clinical Volume 4, Chapter 10)

episcleral, (Clinical Volume 4, Chapter 23)

Descemet membrane, (Foundations Volume 1, Chapter 8) (Clinical Volume 4, Chapter 31) (Foundations Volume 1, Chapter 8)

anatomy, (Foundations Volume 1, Chapter 1)

microscopic, (Foundations Volume 2, Chapter 4)

breaks, in congenital glaucoma, (Clinical Volume 3, Chapter 51)

in cataract surgery, complications, (Foundations Volume 3, Chapter 6)

in diabetes mellitus, (Foundations Volume 3, Chapter 18)

embryology, (Foundations Volume 1, Chapter 2) (Foundations Volume 3, Chapter 53)

granulomatous reaction to, (Foundations Volume 3, Chapter 4)

lacerations, healing, (Foundations Volume 2, Chapter 4)

in Peters’ anomaly, (Foundations Volume 1, Chapter 9)

tears in

birth trauma causing, (Foundations Volume 1, Chapter 9) (Foundations Volume 3, Chapter 6)

description of, (Foundations Volume 1, Chapter 9)

wound healing, (Foundations Volume 3, Chapter 6)

after cataract extraction, (Foundations Volume 3, Chapter 6)

after penetrating keratoplasty, (Foundations Volume 3, Chapter 6)

Descemetocele, therapeutic hydrogel lenses and, (Clinical Volume 4, Chapter 11) (Foundations Volume 3, Chapter 9)

Desensitization, in allergic conjunctivitis, (Clinical Volume 4, Chapter 2)

Design of lenses for indirect ophthalmoscopy, (Clinical Volume 1, Chapter 63)

Desmoplastic trichoepithelioma, (Foundations Volume 3, Chapter 7)

Desmosomes, (Foundations Volume 1, Chapter 21)

Detachment

choroidal, (Clinical Volume 4, Chapter 31) See also Effusions, anterior chamber reformation and, ciliochoroidal drainage

postoperative, scleral buckling and, (Clinical Volume 6, Chapter 59)

ultrasonography, (Clinical Volume 3, Chapter 3)

ciliochoroidal, hypotony and, (Clinical Volume 3, Chapter 58)

retinal. (See Retinal detachment)

Detachment, vitreous, anomalous posterior, (Foundations Volume 1, Chapter 16)

retinal effects, (Foundations Volume 1, Chapter 16)

vitreous effects, (Foundations Volume 1, Chapter 16)

Detection acuity, (Clinical Volume 2, Chapter 2) See also Visual acuity

De Toni-Fanconi-Lignac syndrome, (Clinical Volume 4, Chapter 15) See also Cystinosis

Deuteranopes, (Foundations Volume 2, Chapter 19)

Developing countries, HIV manifestations in, (Foundations Volume 2, Chapter 36)

Developing nations, blindness in, (Clinical Volume 5, Chapter 53)

Developmental anomalies, (Foundations Volume 1, Chapter 39) (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 53) See also Congenital abnormalities; Teratology; specific anomalies

anophthalmia, (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 53)

of anterior chamber, (Foundations Volume 3, Chapter 53)

colobomas, (Foundations Volume 3, Chapter 53)

congenital cystic eye, (Foundations Volume 3, Chapter 53)

corneal, (Foundations Volume 3, Chapter 53)

cyclopia and synophthalmia, (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 53)

differentiation and, (Foundations Volume 3, Chapter 53)

embryogenesis and, (Foundations Volume 3, Chapter 53)

of eyelid and lacrimal apparatus, (Foundations Volume 3, Chapter 53)

of iris, (Foundations Volume 3, Chapter 53)

of lens, (Foundations Volume 3, Chapter 53)

of lid, (Foundations Volume 1, Chapter 5) (Foundations Volume 3, Chapter 8)

microphthalmia, (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 53)

with cyst, 2; 53: 9, (Foundations Volume 3, Chapter 2)

nanophthalmia, (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 53)

of optic nerve, (Foundations Volume 3, Chapter 53)

organogenesis and, (Foundations Volume 3, Chapter 53)

scleral, (Foundations Volume 3, Chapter 53)

of vitreous, (Foundations Volume 3, Chapter 53)

of zonule, (Foundations Volume 3, Chapter 53)

Developmental glaucoma. See Glaucoma, developmental

Developmental venous anomalies, cerebral, (Clinical Volume 2, Chapter 17)

Deviation, empiric probability maps, (Clinical Volume 2, Chapter 10)

Devic disease, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 6)

in pregnancy, (Clinical Volume 5, Chapter 32)

Dexamethasone

in endophthalmitis, (Clinical Volume 4, Chapter 24)

ocular toxicity, (Clinical Volume 5, Chapter 37)

penetrating keratoplasty and, (Clinical Volume 6, Chapter 26)

postoperative administration of, for children, (Clinical Volume 6, Chapter 81)

in traumatic optic neuropathy, (Clinical Volume 2, Chapter 5)

Dexamethasone (Decadron), (Foundations Volume 3, Chapter 31)

administration, (Foundations Volume 3, Chapter 31)

Cushing’s syndrome and, (Foundations Volume 3, Chapter 43)

in endophthalmitis, (Foundations Volume 3, Chapter 36)

in glaucoma prediction, (Foundations Volume 3, Chapter 31)

Dexmedetomidine, effect on aqueous humor, (Foundations Volume 3, Chapter 29)

Dextran, as hyperosmotic agent, (Foundations Volume 3, Chapter 28)

Dextroamphetamine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dextrocycloversion, (Clinical Volume 1, Chapter 2)

Dextroversion, (Clinical Volume 1, Chapter 2)

DFP. See Isoflurophate; Isoflurophate (DFP, Floropryl)

Diabetes mellitus, (Clinical Volume 3, Chapter 30) (Clinical Volume 5, Chapter 20) (Clinical Volume 5, Chapter 31) (Foundations Volume 2, Chapter 35) (Foundations Volume 3, Chapter 18) (Clinical Volume 3, Chapter 55) (Clinical Volume 5, Chapter 41)

accommodation in, (Clinical Volume 5, Chapter 20)

cataract from, (Clinical Volume 1, Chapter 73)

cataracts and, (Foundations Volume 3, Chapter 12) (Foundations Volume 3, Chapter 18)

child with

anesthesia in, 5, (Clinical Volume 6, Chapter 81)

cataract in, (Clinical Volume 6, Chapter 100)

surgery in, (Clinical Volume 6, Chapter 80)

cornea and conjunctiva in, (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 18)

cornea in, (Clinical Volume 3, Chapter 30) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 20)

corneal complications of vitrectomy and, (Clinical Volume 6, Chapter 56)

cranial neuropathy in, (Clinical Volume 3, Chapter 30)

duration, and risk of retinopathy, (Clinical Volume 3, Chapter 30)

glaucoma in, (Clinical Volume 3, Chapter 30) (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 54E) (Clinical Volume 3, Chapter 55) (Clinical Volume 5, Chapter 20)

immunopathology, (Foundations Volume 2, Chapter 35)

iris in, (Foundations Volume 3, Chapter 11) (Foundations Volume 3, Chapter 18) (Clinical Volume 3, Chapter 30)

ischemic optic neuropathy in, (Clinical Volume 2, Chapter 5)

juvenile

ischemic optic neuropathy in, (Clinical Volume 2, Chapter 5)

light-near dissociation, (Clinical Volume 2, Chapter 15)

recessive optic atrophy and, (Clinical Volume 2, Chapter 5)

lens in, (Foundations Volume 3, Chapter 18) (Clinical Volume 3, Chapter 30) (Clinical Volume 5, Chapter 20)

maternal, teratogenesis, (Foundations Volume 1, Chapter 39)

ocular complications, (Clinical Volume 3, Chapter 30) (Clinical Volume 5, Chapter 20 )

problems associated with, (Clinical Volume 5, Chapter 20)

ocular homeostasis and, (Foundations Volume 3, Chapter 1)

ocular ischemic syndrome and, treatment, (Clinical Volume 3, Chapter 12)

oculomotor palsy and, (Clinical Volume 2, Chapter 12)

optic nerve in, (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 18)

optic neuropathies, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 30)

pericytes in, (Foundations Volume 2, Chapter 5)

perioperative management, (Clinical Volume 6, Chapter 1)

platelet dysfunction in, (Clinical Volume 5, Chapter 23)

proliferative vitreoretinopathy in, (Clinical Volume 3, Chapter 39)

refractive power of eye in, (Clinical Volume 2, Chapter 15) (Clinical Volume 5, Chapter 20)

in retinal vein occlusion, central, (Clinical Volume 3, Chapter 15)

retinopathy, (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 18)

background, (Foundations Volume 2, Chapter 113D)

fluorescein angiography, (Foundations Volume 2, Chapter 113D )

macular edema, (Foundations Volume 2, Chapter 113D)

proliferative, (Foundations Volume 1, Chapter 16) (Foundations Volume 2, Chapter 113D)

retinal blood flow, (Foundations Volume 2, Chapter 5)

unexplained visual loss, (Foundations Volume 2, Chapter 113D)

retinopathy. (See Retinopathy, diabetic)

trigeminal nerve in, (Foundations Volume 1, Chapter 36)

uveal tract in, (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 18)

vitreous in, (Foundations Volume 2, Chapter 11) (Foundations Volume 3, Chapter 18) (Clinical Volume 5, Chapter 20)

hyaluronan and, (Foundations Volume 1, Chapter 16)

structural disorders, (Foundations Volume 1, Chapter 16)

Diabetic retinopathy, (Clinical Volume 5, Chapter 32)

Diabetic retinopathy in pregnancy, (Clinical Volume 5, Chapter 32)

Diabetic vitreopathy, (Foundations Volume 1, Chapter 16)

Diagnostic aids, ocular toxicity, (Clinical Volume 5, Chapter 37)

Diagnostic aspiration, retinitis and, (Clinical Volume 4, Chapter 45)

Diagonal nystagmus, (Clinical Volume 2, Chapter 11)

Dialysis

anterior, of the young, 3, (Clinical Volume 3, Chapter 9)

aqueous humor formation and, (Foundations Volume 2, Chapter 6)

ocular complications, (Clinical Volume 5, Chapter 31)

Diamidines, aromatic, in Acanthamoeba keratitis, (Foundations Volume 2, Chapter 66) (Foundations Volume 2, Chapter 80)

Diamox. See Acetazolamide

Diapedesis, (Foundations Volume 3, Chapter 1)

Diathermy

hemostasis and, (Clinical Volume 6, Chapter 3)

in retinal tear treatment, (Clinical Volume 6, Chapter 59)

in scleral buckling, (Clinical Volume 6, Chapter 59)

Diathesis, hemorrhagic, albinism and, (Clinical Volume 4, Chapter 38)

Diatrizoate meglumine/sodium, ocular toxicity, (Clinical Volume 5, Chapter 37)

Diazepam (Valium)

neuroprotection of axons and, (Clinical Volume 3, Chapter 57)

ocular toxicity, (Clinical Volume 5, Chapter 37)

in refractive keratoplasty, (Clinical Volume 6, Chapter 25)

Diazoxide, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dibucaine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dichlorphenamide (Daranide). See also (Foundations Volume 3, Chapter 30) See also Carbonic anhydrase inhibitors; Carbonic anhydrase inhibitors

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56)

in pars planitis, (Clinical Volume 4, Chapter 43)

systemic toxicity, (Clinical Volume 5, Chapter 37)

Dichoptic stimulation, (Foundations Volume 2, Chapter 24)

Dichromatism, congenital, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 6 )

Dichromats. See Color-defective vision

Diclofenac, for allergic conjunctivitis, (Clinical Volume 4, Chapter 2) See Nonsteroidal anti–inflammatory drugs (NSAIDs)

Dicloxacillin, (Clinical Volume 4, Chapter 26)

in infectious eczematoid dermatitis, (Clinical Volume 4, Chapter 22)

in Ritter’s disease, (Clinical Volume 4, Chapter 22)

systemic toxicity, (Clinical Volume 5, Chapter 37)

Diencephalic syndrome, (Clinical Volume 2, Chapter 6)

Diet. See Nutrition

cataract and, (Clinical Volume 1, Chapter 72C )

deficiencies in. (See Malnutrition)

dermatitis herpetiformis and, (Clinical Volume 5, Chapter 27)

Diethylcarbamazine (DEC, Hetrazan); , (Clinical Volume 5, Chapter 27)

in onchocerciasis diagnosis, (Foundations Volume 2, Chapter 79)

Diethylpropion, ocular toxicity, (Clinical Volume 5, Chapter 37)

Differential light sensitivity, (Clinical Volume 2, Chapter 2)

Differential light threshold, in automated perimetry, (Clinical Volume 3, Chapter 49)

sensitivity versus, (Clinical Volume 3, Chapter 49)

Differentiation, developmental, (Foundations Volume 3, Chapter 53)

corneal, (Foundations Volume 3, Chapter 53)

of eyelid and lacrimal apparatus, (Foundations Volume 3, Chapter 53)

of iris, (Foundations Volume 3, Chapter 53)

of lens, (Foundations Volume 3, Chapter 53)

of optic nerve, (Foundations Volume 3, Chapter 53)

retinal, (Foundations Volume 3, Chapter 53)

scleral, (Foundations Volume 3, Chapter 53)

vitreous, (Foundations Volume 3, Chapter 53)

Diffraction, (Clinical Volume 1, Chapter 30) (Clinical Volume 1, Chapter 33)

cone mosaic anatomy and, (Clinical Volume 1, Chapter 33)

effects, (Clinical Volume 1, Chapter 31)

retinal image blur and, (Clinical Volume 1, Chapter 33)

Diffractive bifocal intraocular lenses, (Clinical Volume 1, Chapter 68A)

Diffuse angiokeratoma. See Fabry’s disease

Diffuse interface keratitis, after LASIK, (Foundations Volume 3, Chapter 6)

Diffuse reflection, (Clinical Volume 1, Chapter 30)

Diffuse unilateral subacute neuroretinitis, (Foundations Volume 3, Chapter 4)

epidemiology, (Foundations Volume 2, Chapter 43)

fluorescein angiography of, (Foundations Volume 2, Chapter 113E)

treatment, (Foundations Volume 2, Chapter 66)

Diffusion, aqueous humor formation and composition, (Clinical Volume 3, Chapter 45) (Foundations Volume 2, Chapter 6)

Diflucan. See Fluconazole

Diflunisal. See Nonsteroidal anti-inflammatory drugs (NSAIDs)

Digenic retinitis pigmentosa, (Clinical Volume 3, Chapter 2)

DiGeorge syndrome, (Foundations Volume 3, Chapter 52)

Digital imaging, (Clinical Volume 1, Chapter 63)

Digitalis, toxicity, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 37)

Digital video oculography, (Clinical Volume 2, Chapter 9)

Digitoxin, ocular toxicity, (Clinical Volume 5, Chapter 37)

Digoxin, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dihexosyl ceramide metabolism, in Fabry disease, (Clinical Volume 3, Chapter 29)

Dihydroergotamine, for migraine, (Clinical Volume 2, Chapter 16)

Diisopropylfluorophosphate (Floropryl), (Clinical Volume 3, Chapter 56)

Diktyoma. See Medulloepithelioma

Dilacerated cataract, (Foundations Volume 1, Chapter 15)

Dilantin. See Phenytoin sodium

Dilated pupil, fixed, (Foundations Volume 2, Chapter 9)

Dilator muscle, in Chandler syndrome, (Clinical Volume 4, Chapter 16)

Dilator muscle of iris, (Foundations Volume 1, Chapter 11)

embryology of, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 11)

Diltiazem, for migraine, (Clinical Volume 2, Chapter 16)

Dimethylpolysiloxane, glaucoma and, (Clinical Volume 3, Chapter 54E)

Dimethylsulfoxide, for Acanthamoeba keratitis, (Foundations Volume 2, Chapter 80)

Dimness, sense of, (Clinical Volume 2, Chapter 2)

Dinitrochlorobenzene, in human papillomavirus, (Foundations Volume 2, Chapter 95)

Diode laser photocoagulation, indocyanine green angiography and, (Clinical Volume 3, Chapter 4A)

Diodoquin. See Iodoquinol (Diodoquin)

Diopter(s), (Clinical Volume 1, Chapter 33)

of convergence power of eye, (Clinical Volume 1, Chapter 71)

Monoyer and, (Clinical Volume 5, Chapter 51)

prism, (Clinical Volume 1, Chapter 33)

Diphenhydramine (Benadryl), in acute anaphylactic reaction, in allergic rhinoconjunctivitis, (Clinical Volume 4, Chapter 2)

Diphenylhydantoin. See Phenytoin

Diphtheria, (Clinical Volume 5, Chapter 33)

lid involvement in, (Clinical Volume 4, Chapter 22)

Diphtheroids, (Foundations Volume 2, Chapter 41)

Dipivefrin (dipivalyl epinephrine, Propine), effect on intraocular pressure, (Foundations Volume 2, Chapter 7)

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56)

in combination therapy, (Clinical Volume 3, Chapter 56)

dosage and administration of, (Clinical Volume 3, Chapter 56)

efficacy of, (Clinical Volume 3, Chapter 56)

indications for, (Clinical Volume 3, Chapter 56)

ocular toxicity, (Clinical Volume 3, Chapter 56) (Clinical Volume 5, Chapter 37)

side effects, in infants and children, (Foundations Volume 3, Chapter 43)

systemic toxicity, (Clinical Volume 3, Chapter 56)

Diplophthalmos, unilateral, (Foundations Volume 3, Chapter 2)

Diplopia, (Clinical Volume 2, Chapter 3)

in accommodative esodeviation, (Clinical Volume 1, Chapter 12)

after laser iridectomy, (Clinical Volume 6, Chapter 19)

in aneurysm, (Clinical Volume 2, Chapter 1)

cerebral, (Foundations Volume 2, Chapter 22)

cyclodiplopia, (Clinical Volume 1, Chapter 7)

cyclovertical, (Clinical Volume 1, Chapter 6)

disordered motility and, (Clinical Volume 2, Chapter 1)

Fresnel prisms, (Clinical Volume 1, Chapter 52)

fusional vergence amplitude and, (Clinical Volume 1, Chapter 7)

Hess screen, (Clinical Volume 2, Chapter 12)

monocular, (Clinical Volume 2, Chapter 1) (Clinical Volume 2, Chapter 2) (Clinical Volume 2, Chapter 3)

in myasthenia gravis, (Clinical Volume 5, Chapter 29)

in orbital disorders, (Clinical Volume 2, Chapter 22)

inflammatory, (Clinical Volume 2, Chapter 35)

thyroid, (Clinical Volume 2, Chapter 36)

in orbital floor fracture, (Clinical Volume 1, Chapter 21)

pain with, (Clinical Volume 2, Chapter 1)

physiologic, (Clinical Volume 1, Chapter 5)

physiologic basis of, (Foundations Volume 2, Chapter 24)

postoperative, (Clinical Volume 2, Chapter 12)

after scleral buckling, (Clinical Volume 6, Chapter 59)

residual, after reoperation of extraocular muscles, (Clinical Volume 6, Chapter 98)

small-angle, ghost images versus, (Clinical Volume 2, Chapter 2)

in strabismus, (Clinical Volume 1, Chapter 8)

thyroid-associated, (Clinical Volume 5, Chapter 21)

torsional, (Clinical Volume 1, Chapter 6)

tube shunts and, (Clinical Volume 6, Chapter 17)

uncrossed, (Clinical Volume 1, Chapter 33)

vertical, (Clinical Volume 1, Chapter 6) (Clinical Volume 2, Chapter 1)

postoperative, A and V patterns and, (Clinical Volume 6, Chapter 84)

Dipping, ocular, (Clinical Volume 2, Chapter 11)

Dipyridamole, and diabetic retinopathy, (Clinical Volume 3, Chapter 30)

Direct immunofluorescence, (Foundations Volume 2, Chapter 40)

in dermatologic disease diagnosis, (Foundations Volume 2, Chapter 29)

in viral infection diagnosis, (Foundations Volume 2, Chapter 88)

Direct ophthalmoscopy. See Ophthalmoscopy, direct

Dirofilariasis, (Foundations Volume 2, Chapter 79)

Disabilities, occupational ophthalmology and, (Clinical Volume 5, Chapter 47)

Disc

pinhole, (Clinical Volume 1, Chapter 31)

Placido’s, (Clinical Volume 1, Chapter 50)

Disc conditions. See Optic disc

Disc diffusion, (Foundations Volume 2, Chapter 40)

Disc diffusion testing, (Foundations Volume 2, Chapter 40)

Disciform degeneration, (Foundations Volume 3, Chapter 13)

Disconnection color anomia, (Foundations Volume 2, Chapter 22)

Discrimination, visual, (Clinical Volume 1, Chapter 33 )

brightness, (Clinical Volume 1, Chapter 33)

color, (Clinical Volume 1, Chapter 33)

contrast sensitivity, (Clinical Volume 1, Chapter 33)

distance, (Clinical Volume 1, Chapter 33)

light, (Clinical Volume 1, Chapter 33)

spatial, (Clinical Volume 1, Chapter 33 )

legible acuity, minimum, (Clinical Volume 1, Chapter 33)

modulation transfer function. (See Modulation transfer function (MTF))

perceptible acuity and, minimum, (Clinical Volume 1, Chapter 33)

separable acuity and, minimum, (Clinical Volume 1, Chapter 33)

vernier acuity and, (Clinical Volume 1, Chapter 33)

visible acuity and, minimum, (Clinical Volume 1, Chapter 33)

temporal, (Clinical Volume 1, Chapter 33)

Disc-shaped cataract, (Foundations Volume 1, Chapter 15)

Disc swelling, (Foundations Volume 3, Chapter 16)

in AIDS, (Foundations Volume 2, Chapter 36)

Disease. See also Infection(s); specific diseases

changes in extraocular muscles with, (Foundations Volume 2, Chapter 23)

pathologic principles, (Foundations Volume 3, Chapter 1 )

Disease mapping, (Foundations Volume 2, Chapter 43)

Disease susceptibility genes, HLA genes and, (Foundations Volume 2, Chapter 38)

Disequilibrium, (Clinical Volume 2, Chapter 18)

Disinfection

and enterovirus, (Foundations Volume 2, Chapter 92)

in microbiology laboratory, (Foundations Volume 2, Chapter 47)

Disinsertion

inferior oblique, (Clinical Volume 6, Chapter 87)

scleral flap, glaucoma filtering surgery and, (Clinical Volume 6, Chapter 24)

Dislocation of lens. See Ectopia lentis

Disorder of membrane channels, (Clinical Volume 5, Chapter 28)

Disparity

bitemporal, (Clinical Volume 1, Chapter 7)

fixation, (Clinical Volume 1, Chapter 5)

Disparity scaling, (Foundations Volume 2, Chapter 24) See also Binocular disparity

Disparity specificity, (Foundations Volume 2, Chapter 24)

Dispersal of light, refractive index and, (Clinical Volume 1, Chapter 30)

Dispersion, viscoelastic materials, (Clinical Volume 6, Chapter 9)

Disseminated intravascular coagulation, (Clinical Volume 5, Chapter 23)

in pregnancy, (Clinical Volume 5, Chapter 32) (Foundations Volume 3, Chapter 13)

Disseminated leishmaniasis, (Foundations Volume 2, Chapter 79)

Dissimilar images tests, (Clinical Volume 1, Chapter 6)

Dissimilar target tests, (Clinical Volume 1, Chapter 6)

Dissociated hyperdeviations, (Clinical Volume 1, Chapter 18) See also Dissociated strabismus complex; Dissociated vertical deviations

Dissociated nystagmus, (Clinical Volume 2, Chapter 11)

Dissociated strabismus complex, (Clinical Volume 1, Chapter 18 )

components, (Clinical Volume 1, Chapter 18)

incidence and associations, (Clinical Volume 1, Chapter 18)

ocular manifestations, (Clinical Volume 1, Chapter 18)

quantification of dissociated vertical deviation, (Clinical Volume 1, Chapter 18)

treatment, (Clinical Volume 1, Chapter 18 )

dissociated horizontal deviations, (Clinical Volume 1, Chapter 18)

dissociated vertical deviations, (Clinical Volume 1, Chapter 18)

nonsurgical management, (Clinical Volume 1, Chapter 18)

Dissociated vertical deviations, (Clinical Volume 1, Chapter 18) See also Dissociated strabismus complex

in congenital esotropia, (Clinical Volume 1, Chapter 12)

hypertropia and, (Clinical Volume 1, Chapter 18)

quantification, (Clinical Volume 1, Chapter 18)

surgery, (Clinical Volume 1, Chapter 18) (Clinical Volume 6, Chapter 87)

Fadenoperation, 5, (Clinical Volume 6, Chapter 91)

Dissociation, light-near

in Holmes-Adie’s pupil, (Clinical Volume 2, Chapter 15)

pupil in, (Clinical Volume 2, Chapter 15)

Dissolution rate of oral medications, bioinequivalence and, (Foundations Volume 3, Chapter 22)

Distance acuity, pantoscopic tilt and, (Clinical Volume 1, Chapter 42)

Distance horopter, (Foundations Volume 2, Chapter 24) See also Horopter

Distance of task, (Clinical Volume 5, Chapter 47)

Distichiasis, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 40)

in craniofacial syndromes, (Clinical Volume 6, Chapter 110)

Distortion, (Clinical Volume 1, Chapter 30) (Clinical Volume 1, Chapter 51B)

pincushion, (Clinical Volume 1, Chapter 30)

prismatic, (Clinical Volume 1, Chapter 30)

Distributive equity, (Clinical Volume 5, Chapter 69)

Diuretics, for pseudotumor cerebri, (Clinical Volume 2, Chapter 5)

Diurnal rhythm

glucocorticoids, (Foundations Volume 3, Chapter 31)

intraocular pressure, (Foundations Volume 2, Chapter 7)

shedding of rods and cones, (Foundations Volume 2, Chapter 12)

Divergence, (Clinical Volume 1, Chapter 2) (Clinical Volume 1, Chapter 4)

excess, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 7)

exodeviations and, (Clinical Volume 1, Chapter 6)

fusional, (Clinical Volume 1, Chapter 7)

insufficiency, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 7)

paralysis, (Clinical Volume 1, Chapter 12) (Clinical Volume 2, Chapter 10) (Clinical Volume 2, Chapter 12)

saccadic velocity in, (Clinical Volume 1, Chapter 21)

repetitive, (Clinical Volume 2, Chapter 11)

synergistic, (Clinical Volume 2, Chapter 13)

Divergence insufficiency, (Foundations Volume 1, Chapter 38)

"Divergence-retraction” nystagmus, (Foundations Volume 1, Chapter 38)

Divergent wavefronts, (Clinical Volume 1, Chapter 33)

Diverticuli, lacrimal sac, (Foundations Volume 1, Chapter 32)

Diving, eye injuries from, (Clinical Volume 5, Chapter 45)

protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Dizziness, (Clinical Volume 2, Chapter 18 )

acute attack, (Clinical Volume 2, Chapter 18)

in children, (Clinical Volume 2, Chapter 18)

chronic, (Clinical Volume 2, Chapter 18)

clinical assessment, (Clinical Volume 2, Chapter 18)

audiometry in, (Clinical Volume 2, Chapter 18)

brainstem auditory-evoked response in, (Clinical Volume 2, Chapter 18)

circumstances, (Clinical Volume 2, Chapter 18)

electronystagmography in, (Clinical Volume 2, Chapter 18)

eye movements, (Clinical Volume 2, Chapter 18)

history, (Clinical Volume 2, Chapter 18)

medications and, (Clinical Volume 2, Chapter 18)

neuroimaging, (Clinical Volume 2, Chapter 18)

office examination, (Clinical Volume 2, Chapter 18)

posturography, (Clinical Volume 2, Chapter 18)

stance and gait, (Clinical Volume 2, Chapter 18)

symptoms, (Clinical Volume 2, Chapter 18)

tempo of attack, (Clinical Volume 2, Chapter 18)

disequilibrium, (Clinical Volume 2, Chapter 18)

drug-induced, (Clinical Volume 2, Chapter 18)

episodic, (Clinical Volume 2, Chapter 18)

head trauma and, (Clinical Volume 2, Chapter 18)

history, (Clinical Volume 2, Chapter 18)

hyperventilation and, (Clinical Volume 2, Chapter 18)

migraine and, (Clinical Volume 2, Chapter 18)

motion sickness and, (Clinical Volume 2, Chapter 18)

orthostatic hypotension and, (Clinical Volume 2, Chapter 18)

panic attacks and, (Clinical Volume 2, Chapter 18)

perilymphatic fistula and, (Clinical Volume 2, Chapter 18)

seizures and, (Clinical Volume 2, Chapter 18)

symptoms, (Clinical Volume 2, Chapter 18)

disequilibrium, (Clinical Volume 2, Chapter 18)

floating, swimming, rocking, spinning inside of head, (Clinical Volume 2, Chapter 18)

lightheadedness, (Clinical Volume 2, Chapter 18)

oscillopsia, (Clinical Volume 2, Chapter 18)

vertigo, (Clinical Volume 2, Chapter 18) See also Vertigo

transient ischemic attacks and, (Clinical Volume 2, Chapter 18)

vestibular system overview, (Clinical Volume 2, Chapter 18 )

DLS. See Dynamic light scattering

DNA. See Deoxyribonucleic acid

DNA repair mechanisms, impaired, disorders associated with, (Clinical Volume 5, Chapter 41)

Dobesilate, (Foundations Volume 3, Chapter 41)

Dolichoectasia, (Clinical Volume 2, Chapter 17)

carotid, optic neuropathy with, (Clinical Volume 2, Chapter 5)

Doll head maneuver, (Clinical Volume 1, Chapter 4) (Foundations Volume 1, Chapter 38) (Foundations Volume 2, Chapter 23)

Donders, Franciscus, (Clinical Volume 5, Chapter 51)

Dopamine. See also Catecholamine(s)

effect on catecholamine systems, (Foundations Volume 3, Chapter 29)

in retinal neuromodulation, (Foundations Volume 1, Chapter 20)

Doppler shift, (Clinical Volume 1, Chapter 31)

Doppler ultrasound, of capillary hemangioma, (Clinical Volume 2, Chapter 27)

Dorello canal, (Clinical Volume 1, Chapter 3)

Dorsal midbrain syndrome, (Clinical Volume 2, Chapter 10) (Clinical Volume 2, Chapter 15) See also Parinaud’s dorsal midbrain syndrome

eye movements in, (Clinical Volume 2, Chapter 10) (Clinical Volume 2, Chapter 12) (Foundations Volume 2, Chapter 9)

Dorsal nasal artery, (Foundations Volume 1, Chapter 5)

Dorsal pathway, lesions of, (Foundations Volume 2, Chapter 22 )

Dorsal terminal nucleus, ocular motility and, (Foundations Volume 2, Chapter 23)

Dorzolamide (Trusopt); , (Foundations Volume 3, Chapter 30) See also Carbonic anhydrase inhibitors

additivity with other drugs, (Clinical Volume 3, Chapter 56)

contraindications to, (Clinical Volume 3, Chapter 56)

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56)

dosage and administration of, (Clinical Volume 3, Chapter 56)

efficacy of, (Clinical Volume 3, Chapter 56)

malignant, (Clinical Volume 3, Chapter 53)

indications for, (Clinical Volume 3, Chapter 56)

ocular toxicity, (Clinical Volume 3, Chapter 56)

in pars planitis, (Clinical Volume 4, Chapter 43)

sezolamide versus, (Foundations Volume 3, Chapter 30)

systemic toxicity, (Clinical Volume 3, Chapter 56)

Double elevator palsy

congenital fibrosis of inferior rectus muscle versus, (Clinical Volume 1, Chapter 20)

saccadic velocity in, (Clinical Volume 1, Chapter 21)

Double-plate shunt, 3–4, (Clinical Volume 6, Chapter 17)

surgical technique, (Clinical Volume 6, Chapter 17)

Double vision. See Diplopia

Downbeat nystagmus, (Clinical Volume 2, Chapter 11) (Foundations Volume 1, Chapter 38)

Down syndrome, (Foundations Volume 3, Chapter 56) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 41)

anesthesia in child with, 3, 4; , (6) 81

cataract in, (Clinical Volume 5, Chapter 41)

clinical features, (Clinical Volume 4, Chapter 15)

ocular anomalies, (Clinical Volume 4, Chapter 15)

surgery in child with, (Clinical Volume 6, Chapter 80)

Down syndrome (trisomy 21), (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 52)

atropine toxicity and, (Foundations Volume 3, Chapter 43)

cataract in, (Foundations Volume 3, Chapter 12)

and strabismus, (Foundations Volume 3, Chapter 59)

Downward gaze. See under Gaze

Doxepin, for migraine, (Clinical Volume 2, Chapter 16)

Doxorubicin (Adriablastina, Adriamycin), (Foundations Volume 3, Chapter 33) (Foundations Volume 3, Chapter 41)

Doxycycline

in blepharitis

in cicatricial pemphigoid, (Clinical Volume 5, Chapter 27)

in meibomian gland dysfunction, (Clinical Volume 4, Chapter 22) (Clinical Volume 4, Chapter 26)

in chemical injuries, (Clinical Volume 4, Chapter 28)

in inclusion conjunctivitis, (Clinical Volume 4, Chapter 26)

for Lyme disease, (Foundations Volume 2, Chapter 75)

in meibomianitis, in cicatricial pemphigoid, (Clinical Volume 5, Chapter 27)

ocular toxicity, (Clinical Volume 5, Chapter 37)

for rickettsial disease, (Foundations Volume 2, Chapter 58)

for staphylococcal blepharitis, (Foundations Volume 3, Chapter 36)

for toxoplasmosis, (Foundations Volume 2, Chapter 66)

Doyne honeycomb choroiditis, (Clinical Volume 3, Chapter 9)

Dracunculiasis, (Foundations Volume 2, Chapter 79)

Drance hemorrhage, (Clinical Volume 2, Chapter 5)

Drault bundle, embryology of, (Foundations Volume 1, Chapter 2)

Dreschlera, (Foundations Volume 2, Chapter 54)

Driving, multifocal intraocular lenses and, (Clinical Volume 1, Chapter 68A)

Droperidol

intraoperative dosage and administration of, for children, (Clinical Volume 6, Chapter 81)

ocular toxicity, (Clinical Volume 5, Chapter 37)

postoperative administration of, for children, (Clinical Volume 6, Chapter 81)

Drosophila visual system, genetics of, lessons from, (Foundations Volume 1, Chapter 19A)

Drug abuse, as teratogenic, (Clinical Volume 5, Chapter 39)

Drugs. See also See also Pharmacokinetics; Pharmacology; specific drugs; specific drugs and drug types

for Acanthamoeba keratitis, (Clinical Volume 4, Chapter 18A)

administration with therapeutic hydrogel lenses, (Clinical Volume 4, Chapter 11)

affecting blood, (Foundations Volume 3, Chapter 41 )

affecting ocular blood flow, (Foundations Volume 2, Chapter 5)

agonist, (Clinical Volume 3, Chapter 56)

allergy to, immunopathology, (Foundations Volume 2, Chapter 34)

alpha-adrenergic, (Foundations Volume 3, Chapter 29) See also Alpha–agonists; Alpha–antagonists

antagonist, (Clinical Volume 3, Chapter 56)

antibiotic, (Clinical Volume 4, Chapter 26 )

anticholinergic, side effects of, (Foundations Volume 3, Chapter 43)

antifungal, (Foundations Volume 2, Chapter 62 )

anti-inflammatory, nonsteroidal. (See Nonsteroidal anti-inflammatory drugs (NSAIDs))

antimicrobial and antibiotic

in Acanthamoeba keratitis, (Foundations Volume 2, Chapter 80)

in actinomycosis, (Foundations Volume 2, Chapter 60)

for anaerobic infections, (Foundations Volume 2, Chapter 57)

for cellulitis

orbital, (Foundations Volume 3, Chapter 36)

preseptal, (Foundations Volume 3, Chapter 36)

for conjunctivitis, (Foundations Volume 3, Chapter 36) (Foundations Volume 3, Chapter 39)

for endophthalmitis, (Foundations Volume 3, Chapter 36)

fortified, extemporaneously compounded, (Foundations Volume 3, Chapter 39)

intravitreal injection, (Foundations Volume 2, Chapter 61)

for keratitis, (Foundations Volume 3, Chapter 36) (Foundations Volume 3, Chapter 39)

for lacrimal apparatus infections, (Foundations Volume 3, Chapter 36)

for lid infections, (Foundations Volume 3, Chapter 36)

for Lyme disease, (Foundations Volume 2, Chapter 75)

methods of administration of, (Foundations Volume 2, Chapter 61)

in mycobacterial infections, (Foundations Volume 2, Chapter 56)

ocular pharmacology of, (Foundations Volume 2, Chapter 100 )

ocular teratogenicity, (Foundations Volume 1, Chapter 39)

peptides, (Foundations Volume 2, Chapter 101)

periocular injection, (Foundations Volume 2, Chapter 61)

prophylactic use, (Foundations Volume 2, Chapter 43) (Foundations Volume 2, Chapter 64)

in bullous keratopathy, (Foundations Volume 2, Chapter 64)

neonatal conjunctivitis and, (Foundations Volume 2, Chapter 64) (Foundations Volume 3, Chapter 36)

postoperative, (Foundations Volume 2, Chapter 64)

posttraumatic, (Foundations Volume 2, Chapter 64)

tissue transplantation material and, (Foundations Volume 2, Chapter 64)

resistance to, (Foundations Volume 2, Chapter 64)

gram-negative bacilli and, (Foundations Volume 2, Chapter 52)

in rickettsial disease, (Foundations Volume 2, Chapter 58)

routes of administration, (Foundations Volume 3, Chapter 36)

for keratitis, (Foundations Volume 3, Chapter 36)

selection, (Foundations Volume 3, Chapter 39)

side effects, in infants and children, (Foundations Volume 3, Chapter 43)

susceptibility testing, (Foundations Volume 2, Chapter 40)

systemic administration, (Foundations Volume 2, Chapter 61)

in toxoplasmosis, (Foundations Volume 2, Chapter 76)

antithyroid, (Clinical Volume 2, Chapter 36)

antiviral, (Foundations Volume 2, Chapter 92) (Foundations Volume 2, Chapter 100)

acyclovir, (Foundations Volume 2, Chapter 100)

adverse effects, (3) 43: 14

prophylactic, (Foundations Volume 2, Chapter 64)

cidofovir, (Foundations Volume 2, Chapter 100)

effects during herpes simplex virus latency and reactivation, (Foundations Volume 2, Chapter 89)

famciclovir, (Foundations Volume 2, Chapter 100)

Fomivirsen, (Foundations Volume 2, Chapter 100)

foscarnet, (Foundations Volume 2, Chapter 100)

ganciclovir, (Foundations Volume 2, Chapter 100)

prophylactic, (Foundations Volume 2, Chapter 64)

idoxuridine, (Foundations Volume 2, Chapter 100)

indinavir, (Foundations Volume 2, Chapter 64)

lamivudine, (Foundations Volume 2, Chapter 64)

prophylactic, (Foundations Volume 2, Chapter 43) (Foundations Volume 2, Chapter 64)

structural formulas, (Foundations Volume 2, Chapter 100)

systemic, (Foundations Volume 3, Chapter 37)

topical, (Foundations Volume 2, Chapter 61)

trifluridine, (Foundations Volume 2, Chapter 100)

valaciclovir, (Foundations Volume 2, Chapter 100)

Valganciclovir, (Foundations Volume 2, Chapter 100)

in varicella-zoster virus therapy, (Foundations Volume 2, Chapter 94)

vidarabine, (Foundations Volume 2, Chapter 100)

viral replication cycle, (Foundations Volume 2, Chapter 100)

zidovudine

prophylactic, after mucous membrane exposure, (Foundations Volume 2, Chapter 64)

aqueous humor and

formation, (Foundations Volume 2, Chapter 6)

outflow, (Foundations Volume 2, Chapter 6)

aqueous humor formation and, (Clinical Volume 3, Chapter 45)

bioavailability of. ( See Bioavailability)

cardioselective, (Clinical Volume 3, Chapter 56)

cataracts from, (Clinical Volume 1, Chapter 71) (Clinical Volume 1, Chapter 73)

cataracts induced by, (Foundations Volume 2, Chapter 10; 21;(3)12)

cellular binding of, (Foundations Volume 3, Chapter 23)

cholinergic. ( See Cholinergic(s))

choroidal atrophy and, (Clinical Volume 4, Chapter 66)

cicatricial pemphigoid induced by, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 12)

cicatrization induced by, (Foundations Volume 2, Chapter 29)

compliance and, (Foundations Volume 3, Chapter 24)

corneal alterations caused by, pigmentation, (Foundations Volume 3, Chapter 9)

cycloplegics. (See Cycloplegic agents)

derivatives, deposition in conjunctiva, (Foundations Volume 3, Chapter 8)

diabetic retinopathy and, (Clinical Volume 3, Chapter 30)

dizziness and, (Clinical Volume 2, Chapter 18)

dosage of, in infants and children, (Foundations Volume 3, Chapter 43)

excretion of, (Foundations Volume 3, Chapter 23)

fixed dilated pupil, (Clinical Volume 2, Chapter 15)

for genetic diseases, (Foundations Volume 3, Chapter 55)

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56) (Clinical Volume 3, Chapter 57)

interactions in anesthesia, in children, (Clinical Volume 6, Chapter 81)

intraocular pressure and, (Foundations Volume 2, Chapter 7)

non-steady-state alterations of, (Foundations Volume 3, Chapter 25)

steady-state alterations of, (Foundations Volume 3, Chapter 25)

metabolism of, in systemic therapy, (Foundations Volume 3, Chapter 23)

for migraine, (Clinical Volume 2, Chapter 16)

miotics. (See Miotics)

muscarinic, (Foundations Volume 3, Chapter 26)

antagonists, (Foundations Volume 3, Chapter 26 )

direct-acting agonists, (Foundations Volume 3, Chapter 26 )

indirect-acting agonists, (Foundations Volume 3, Chapter 26 )

myasthenia-like syndromes from, (Clinical Volume 2, Chapter 12)

nicotinic, (Foundations Volume 3, Chapter 26 )

nystagmus induced by, (Clinical Volume 2, Chapter 11)

ocular motility and, (Foundations Volume 2, Chapter 23)

ocular side effects, (Foundations Volume 3, Chapter 42)

ocular toxicity. (See Toxicology)

ophthalmic medications, interaction with anesthetics, (Clinical Volume 6, Chapter 1)

optic neuropathies from, (Clinical Volume 2, Chapter 5)

parasympatholytic, side effects, (Foundations Volume 3, Chapter 43)

parasympathomimetic, side effects, (Foundations Volume 3, Chapter 43)

perioperative management of, in children, (Clinical Volume 6, Chapter 81)

polyarteritis nodosa and, (Foundations Volume 2, Chapter 33)

preanesthetic review, (Clinical Volume 6, Chapter 1)

preoperative

in children, (Clinical Volume 6, Chapter 81)

before penetrating keratoplasty, (Clinical Volume 6, Chapter 26)

preservatives, hydrogel lenses and, (Clinical Volume 4, Chapter 11)

pseudotumor cerebri and, (Clinical Volume 2, Chapter 5)

pupil and, (Foundations Volume 2, Chapter 9 )

retinopathy caused by, 3, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 42)

retinopathy due to, (Clinical Volume 3, Chapter 33 )

in scleritis, (Clinical Volume 4, Chapter 23)

sympathomimetic, (3) 43: 46

in HIV infection, (Foundations Volume 2, Chapter 36)

in infants and children, (Foundations Volume 3, Chapter 43 )

tear secretion and, (Foundations Volume 2, Chapter 3)

teratogenicity, (Foundations Volume 1, Chapter 39)

therapeutic uses, side effects, (Foundations Volume 3, Chapter 42)

topical

access to retina, (Clinical Volume 3, Chapter 57)

combinations, (Foundations Volume 3, Chapter 23)

common dosage, (Foundations Volume 3, Chapter 43)

side effects, in infants and children, (Foundations Volume 3, Chapter 43 )

toxic epidermal necrolysis due to, (Clinical Volume 5, Chapter 27)

toxicology, (Clinical Volume 5, Chapter 37 )

uveitis due to, (Clinical Volume 4, Chapter 37) (Clinical Volume 4, Chapter 54)

visual hallucinations due to, (Clinical Volume 2, Chapter 7)

vortex keratopathy and, (Clinical Volume 4, Chapter 17)

Drusen, (Clinical Volume 2, Chapter 24) (Clinical Volume 3, Chapter 7) (Clinical Volume 5, Chapter 25) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 16) (Clinical Volume 3, Chapter 23) (Clinical Volume 4, Chapter 31)

dominant, (Clinical Volume 3, Chapter 9) (Clinical Volume 3, Chapter 23)

of Bruch’s membrane, (Foundations Volume 3, Chapter 60)

fluorescein angiography, (Foundations Volume 2, Chapter 113B)

familial, (Clinical Volume 3, Chapter 9)

fluorescein angiography in, (Clinical Volume 3, Chapter 4)

in foveomacular vitelliform dystrophy, (Clinical Volume 3, Chapter 9)

“giant, ”, (2) 5: 21

macular, (Clinical Volume 3, Chapter 7)

in membranoproliferative glomerulonephritis, (Clinical Volume 5, Chapter 31)

nevi causing, (Foundations Volume 3, Chapter 20)

in North Carolina macular dystrophy, (Clinical Volume 3, Chapter 9)

optic disc, (Clinical Volume 2, Chapter 5)

optic nerve head, (Clinical Volume 3, Chapter 7)

pigmented epithelium, (Clinical Volume 3, Chapter 7)

in Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9)

in tuberous sclerosis, (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 58) (Foundations Volume 3, Chapter 16)

Dry eye, (Foundations Volume 2, Chapter 3) (Clinical Volume 6, Chapter 48)

corneal sensation, (Clinical Volume 6, Chapter 49)

evaporative dry eye, (Foundations Volume 2, Chapter 3)

blepharitis, (Foundations Volume 2, Chapter 3)

blink disorders, (Foundations Volume 2, Chapter 3)

inflammatory dry eye, (Foundations Volume 2, Chapter 3)

lid aperture, lid/globe congruity, (Foundations Volume 2, Chapter 3)

meibomian gland disease, (Foundations Volume 2, Chapter 3)

tear-deficient dry eye, (Foundations Volume 2, Chapter 3)

non-Sjogren syndromes, (Foundations Volume 2, Chapter 3)

Sjogren syndrome, (Foundations Volume 2, Chapter 3)

Dry eye syndrome(s). See also Keratoconjunctivitis sicca

blepharitis and, (Clinical Volume 4, Chapter 22)

contact lens causing, (Clinical Volume 4, Chapter 27)

test for, (Clinical Volume 4, Chapter 13)

DSCI. See Deep sclerectomy with collagen implant

DSVC. See Deep sclerectomy with viscocanalostomy

D1trisomy. (See Patau’s syndrome)

D-15 test, (Clinical Volume 2, Chapter 7) (Clinical Volume 3, Chapter 6)

D1trisomy, (Clinical Volume 4, Chapter 15)

Duane retraction syndrome, (Clinical Volume 1, Chapter 20) (Clinical Volume 2, Chapter 13) (Foundations Volume 3, Chapter 59)

acquired, (Clinical Volume 1, Chapter 20)

bilateral, (Clinical Volume 1, Chapter 20)

classification of, (Clinical Volume 1, Chapter 20)

clinical presentation of, (Clinical Volume 1, Chapter 20)

combined horizontal and vertical, (Clinical Volume 1, Chapter 20)

congenital labyrinthine deafness with, (Clinical Volume 1, Chapter 20)

differential diagnosis, (Clinical Volume 1, Chapter 12)

epidemiology of, (Clinical Volume 1, Chapter 20)

genetics of, (Clinical Volume 1, Chapter 20)

Goldenhar’s syndrome and, (Clinical Volume 1, Chapter 20)

inverse, (Clinical Volume 1, Chapter 20)

Klippel-Feil anomaly with, (Clinical Volume 1, Chapter 20)

nonocular abnormalities associated with, (Clinical Volume 1, Chapter 20)

progressive, (Clinical Volume 1, Chapter 20)

pseudo-, (Clinical Volume 1, Chapter 20)

saccadic velocity in, (Clinical Volume 1, Chapter 21)

surgery for, (Clinical Volume 1, Chapter 20) (Clinical Volume 6, Chapter 96 )

complications, (Clinical Volume 6, Chapter 96)

contraindications, (Clinical Volume 6, Chapter 96)

Fadenoperation, (Clinical Volume 6, Chapter 91)

indications, (Clinical Volume 6, Chapter 96)

lateral rectus muscle recession, (Clinical Volume 6, Chapter 96)

medial rectus muscle recession, (Clinical Volume 6, Chapter 96)

posterior fixation suture, (Clinical Volume 6, Chapter 96)

procedures, 5, (Clinical Volume 6, Chapter 96)

results, (Clinical Volume 6, Chapter 96)

vertical rectus and inferior oblique weakening procedures, (Clinical Volume 6, Chapter 96)

vertical rectus muscle transposition, (Clinical Volume 6, Chapter 96)

Y-splitting procedure, 5, (Clinical Volume 6, Chapter 96)

type I, (Clinical Volume 1, Chapter 20)

type II, (Clinical Volume 1, Chapter 20)

type III, (Clinical Volume 1, Chapter 20)

unilateral, (Clinical Volume 1, Chapter 20)

variant, (Clinical Volume 1, Chapter 20)

Duane syndrome, surgery to correct, (Clinical Volume 6, Chapter 96)

complications, (Clinical Volume 6, Chapter 96)

lateral rectus muscle posterior fixation suture, (Clinical Volume 6, Chapter 96)

rectus muscles, ipsilateral recessions, (Clinical Volume 6, Chapter 96)

results, (Clinical Volume 6, Chapter 96)

vertical rectus, inferior oblique muscle weakening procedures, (Clinical Volume 6, Chapter 96)

Y-splitting procedure, (Clinical Volume 6, Chapter 96)

Duchenne dystrophy, (Clinical Volume 5, Chapter 29)

genetics, (Clinical Volume 3, Chapter 2)

Duchenne muscular dystrophy, (Foundations Volume 1, Chapter 38) (Foundations Volume 1, Chapter 38)

Ductal eccrine carcinoma, (Foundations Volume 3, Chapter 7)

Duction, (Clinical Volume 1, Chapter 2)

Duction test, forced. See Forced duction test

Ductopapillary apocrine carcinoma, (Foundations Volume 3, Chapter 7)

Duplex retina, (Foundations Volume 2, Chapter 16)

Dural arteriovenous fistula, (Clinical Volume 2, Chapter 37)

Dural arteriovenous malformations, endovascular interventions, (Clinical Volume 2, Chapter 17)

Dural cavernous fistula, (Foundations Volume 3, Chapter 17)

Dural-cavernous sinus fistula, (Clinical Volume 2, Chapter 24) (Clinical Volume 2, Chapter 29)

Dural-sinus fistula, (Foundations Volume 1, Chapter 32)

Dural venous sinus thrombosis, (Clinical Volume 2, Chapter 5)

Dura mater, (Foundations Volume 1, Chapter 25)

development, (Foundations Volume 1, Chapter 25)

Duration and frequency of light stimulus, (Clinical Volume 1, Chapter 5)

Durham tonometer, (Clinical Volume 3, Chapter 47)

Dwarf eye. See Nanophthalmos

Dwarfism, polydystrophic. See Maroteaux-Lamy syndrome

D-wave, (Foundations Volume 2, Chapter 13)

Dyad synapses, (Foundations Volume 1, Chapter 19)

Dyclonine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Dye disappearance test, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

Dyes

fluorescein. (See Fluorescein)

in lacrimal drainage evaluation, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

ophthalmic, systemic toxicity, (Clinical Volume 5, Chapter 37)

in test for toxoplasmosis, (Clinical Volume 4, Chapter 46)

Dynamic light scattering (DLS), (Clinical Volume 3, Chapter 38)

Dynamic lines, lid, (Foundations Volume 1, Chapter 5)

Dysbetalipoproteinemia, (Clinical Volume 4, Chapter 15)

Dyschromatopsia, (Clinical Volume 2, Chapter 2) See also Color vision defects

cerebral, (Clinical Volume 2, Chapter 7)

with fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

Dyscrasias

blood. (See Blood dyscrasias; Retinopathy of blood dyscrasias)

carbonic anhydrase inhibitor-induced, (Foundations Volume 3, Chapter 30)

plasma cell, (Clinical Volume 3, Chapter 18)

Dysgeneses. See also Congenital anomalies

corneal, (Clinical Volume 3, Chapter 51) (Clinical Volume 4, Chapter 16 )

glaucoma and, (Clinical Volume 3, Chapter 51) See also Glaucoma, developmental

iridocorneal mesodermal, (Clinical Volume 3, Chapter 55)

of iris, (Clinical Volume 3, Chapter 51)

mesenchymal, (Clinical Volume 4, Chapter 16)

trabecular meshwork, 3, (Clinical Volume 3, Chapter 51)

Dysgerminomas, chiasmal syndromes, (Clinical Volume 2, Chapter 6)

Dyskeratoma, warty, (Foundations Volume 3, Chapter 7)

Dyskeratosis, (Foundations Volume 3, Chapter 7 hereditary benign intraepithelial,) (Clinical Volume 4, Chapter 10)

acantholytic, with corps ronds, (Foundations Volume 3, Chapter 7)

Dyskeratosis palmoplantaris. See Schafer’s syndrome

Dyslexia, (Clinical Volume 2, Chapter 13) (Clinical Volume 5, Chapter 46)

attentional, (Clinical Volume 2, Chapter 7) (Foundations Volume 2, Chapter 22)

central, (Clinical Volume 2, Chapter 7) (Foundations Volume 2, Chapter 22)

hemianopic, (Clinical Volume 2, Chapter 7)

neglect, (Clinical Volume 2, Chapter 7) (Foundations Volume 2, Chapter 22)

Dysmetria, (Clinical Volume 1, Chapter 4) (Clinical Volume 2, Chapter 11)

flutter, (Clinical Volume 2, Chapter 11)

in internuclear ophthalmoplegia, (Clinical Volume 2, Chapter 10)

Dysmetropsia, (Clinical Volume 2, Chapter 7)

macropsia, metamorphopsia, (Clinical Volume 2, Chapter 7)

micropsia, (Clinical Volume 2, Chapter 7)

Dysmorphic sialidosis, (Foundations Volume 3, Chapter 54B)

Dysostoses, craniofacial, (Foundations Volume 1, Chapter 41) (Foundations Volume 3, Chapter 58) (Foundations Volume 3, Chapter 59)

Dysostosis

Crouzon’s craniofacial, (Clinical Volume 5, Chapter 29)

mandibulofacial, (Clinical Volume 5, Chapter 29) (Clinical Volume 2, Chapter 30)

Dysphasia, color, (Foundations Volume 2, Chapter 22)

Dysplasia

arteriohepatic, (Clinical Volume 5, Chapter 30)

chiasmal, congenital, (Clinical Volume 2, Chapter 6)

ectodermal

anhidrotic, (Clinical Volume 5, Chapter 27)

cataract in, (Clinical Volume 5, Chapter 41)

cataract in, (Clinical Volume 1, Chapter 73) (Clinical Volume 5, Chapter 41)

fibromuscular, retinal ischemia in, (Clinical Volume 2, Chapter 5)

fibrous, (Clinical Volume 2, Chapter 30)

hereditary mucoepithelial, cataract in, (Clinical Volume 5, Chapter 41)

oculoauricular, (Clinical Volume 2, Chapter 30) See also Goldenhar’s syndrome

oculovertebral, (Clinical Volume 5, Chapter 29)

optic nerve, (Foundations Volume 3, Chapter 16)

retinal, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 21) (Foundations Volume 3, Chapter 53)

glaucoma and, (Clinical Volume 3, Chapter 54E)

pediatric, (Clinical Volume 6, Chapter 72)

skeletal, (Foundations Volume 3, Chapter 61)

Dysplastic nevus, (Foundations Volume 3, Chapter 7)

Dysplastic nevus syndrome, (Foundations Volume 3, Chapter 20)

Dysthyroidism. See also Graves’ disease; Thyroid disorders

chemodenervation in, (Clinical Volume 6, Chapter 89)

Dystonia

blepharospasm-oromandibular, (Foundations Volume 1, Chapter 37)

cranial, (Foundations Volume 1, Chapter 36)

Dystopia

canthal

after eyelid surgery, (Clinical Volume 5, Chapter 75)

in craniofacial syndromes, (Clinical Volume 6, Chapter 110)

orbital, (Clinical Volume 2, Chapter 30)

Dystrophies

Bietti’s, (Foundations Volume 3, Chapter 13)

Bowman Type I, (Foundations Volume 3, Chapter 9)

central areolar

choroidal, (Foundations Volume 3, Chapter 60)

pigment epithelial, (Foundations Volume 3, Chapter 60)

chorioretinal, (Foundations Volume 2, Chapter 12)

generalized, fluorescein angiography, (Foundations Volume 2, Chapter 113B )

hereditary. (See also specific type)

fluorescein angiography, (Foundations Volume 2, Chapter 113B )

choroidal, (Foundations Volume 1, Chapter 13) (Foundations Volume 3, Chapter 11)

central areolar, (Foundations Volume 2, Chapter 113B) (Foundations Volume 3, Chapter 60)

fluorescein angiography, (Foundations Volume 2, Chapter 113B)

generalized, (Foundations Volume 2, Chapter 113B)

regional, (Foundations Volume 3, Chapter 11)

cone

ERG, (Foundations Volume 2, Chapter 103)

fluorescein angiography, (Foundations Volume 2, Chapter 113B)

congenital hereditary endothelial, (Foundations Volume 3, Chapter 53) (Foundations Volume 3, Chapter 9)

corneal, (3) 9: 21–39. See also Cornea, dystrophies

inheritance, (Foundations Volume 3, Chapter 63 )

deep, hereditary, (Foundations Volume 3, Chapter 9)

foveomacular, adult type, (Foundations Volume 3, Chapter 60)

Fuchs’, (1)63: 3, 15–16

granular, (Foundations Volume 3, Chapter 9)

macular. (See Macular dystrophy(ies))

map-dot-fingerprint, (Foundations Volume 3, Chapter 9)

Meesmann’s, (Foundations Volume 3, Chapter 9)

microcystic, band-shaped and whorled, (Foundations Volume 3, Chapter 9)

muscular, Duchenne’s, (Foundations Volume 1, Chapter 38)

myotonic, (Foundations Volume 2, Chapter 105) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 17) (Foundations Volume 3, Chapter 58)

pattern, retinal pigment epithelium, (Foundations Volume 2, Chapter 104) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 60)

pigment

butterfly-shaped, molecular genetics, (Foundations Volume 3, Chapter 55)

pattern, (Foundations Volume 3, Chapter 60)

fluorescein angiography, (Foundations Volume 2, Chapter 113B)

posterior

amorphous, (Foundations Volume 3, Chapter 63)

polymorphous, (Foundations Volume 1, Chapter 9) (Foundations Volume 3, Chapter 63) (Foundations Volume 3, Chapter 9)

differential diagnosis, (Foundations Volume 3, Chapter 19)

progressive, of Waardenburg and Jonkers, (Foundations Volume 3, Chapter 63)

Reis-Buckler’s, (Foundations Volume 3, Chapter 9)

retinal

hereditary, (Foundations Volume 3, Chapter 13 )

vitreoretinal, (Foundations Volume 3, Chapter 61 )

Sorsby, (Foundations Volume 3, Chapter 11)

stromal, (3) 9: 24, 32

vascular, fluorescein angiography, (Foundations Volume 2, Chapter 113B)

vitelliform, (Foundations Volume 3, Chapter 13) See also Best’s vitelliform macular dystrophy

vitreoretinal, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 61)

vitreotapetoretinal, fluorescein angiography, (Foundations Volume 2, Chapter 113B)

Dystrophy

Best’s vitelliform macular, (Clinical Volume 4, Chapter 53)

central areolar pigment epithelial, (Clinical Volume 3, Chapter 9)

choroidal, (Clinical Volume 4, Chapter 66)

central areolar, (Clinical Volume 4, Chapter 66)

primary, (Clinical Volume 4, Chapter 66)

secondary, (Clinical Volume 4, Chapter 66)

cone, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 4) (Clinical Volume 3, Chapter 9) (Clinical Volume 3, Chapter 24 )

choroidal atrophy in, (Clinical Volume 4, Chapter 66)

progressive, (Clinical Volume 3, Chapter 9)

cone-rod, (Clinical Volume 2, Chapter 5)

choroidal atrophy in, (Clinical Volume 4, Chapter 66)

genetics, (Clinical Volume 3, Chapter 2)

progressive, (Clinical Volume 3, Chapter 9 )

congenital hereditary endothelial, (Clinical Volume 4, Chapter 16A)

corneal, (Clinical Volume 4, Chapter 16 )

anterior, (Clinical Volume 4, Chapter 16)

hereditary, (Clinical Volume 4, Chapter 16)

anterior mosaic crocodile shagreen, (Clinical Volume 4, Chapter 16)

central cloudy, (Clinical Volume 4, Chapter 16)

central crystalline, (Clinical Volume 4, Chapter 16)

Chandler’s syndrome, (Clinical Volume 4, Chapter 16)

congenital hereditary endothelial, (Clinical Volume 4, Chapter 16)

congenital hereditary stromal, (Clinical Volume 4, Chapter 16)

deep filiform, (Clinical Volume 4, Chapter 16)

endothelial, (Clinical Volume 4, Chapter 16)

fleck, (Clinical Volume 4, Chapter 16)

Fuchs’, (Clinical Volume 3, Chapter 54F) (Clinical Volume 4, Chapter 16)

gelatinous droplike, (Clinical Volume 4, Chapter 16)

granular, (Clinical Volume 1, Chapter 30) (Clinical Volume 4, Chapter 16)

superficial keratectomy in, (Clinical Volume 6, Chapter 28)

Grayson-Wilbrandt, (Clinical Volume 4, Chapter 16)

guttata, (Clinical Volume 4, Chapter 16)

idiopathic band keratopathy, (Clinical Volume 4, Chapter 16)

kertoglobus, (Clinical Volume 4, Chapter 16)

lattice, (Clinical Volume 4, Chapter 15) (Clinical Volume 4, Chapter 16)

macular, (Clinical Volume 4, Chapter 16)

map-dot-fingerprint, (Clinical Volume 4, Chapter 16)

superficial keratectomy in, (Clinical Volume 6, Chapter 28)

marginal crystalline, (Clinical Volume 4, Chapter 16)

Meesman’s, (Clinical Volume 4, Chapter 16)

noninflammatory ectasias, (Clinical Volume 4, Chapter 16)

pellucid marginal degeneration, (Clinical Volume 4, Chapter 16)

polymorphic stromal, (Clinical Volume 4, Chapter 16)

posterior amorphous stromal, (Clinical Volume 4, Chapter 16)

posterior mosaic crocodile shagreen, (Clinical Volume 4, Chapter 16)

posterior polymorphous, (Clinical Volume 3, Chapter 54F) (Clinical Volume 4, Chapter 16)

pre-Descemet’s membrane, (Clinical Volume 4, Chapter 16)

Reis-Bucklers’, (Clinical Volume 4, Chapter 16)

superficial keratectomy in, (Clinical Volume 6, Chapter 28)

Schnyder’s crystalline, (Clinical Volume 4, Chapter 15) (Clinical Volume 4, Chapter 16)

stromal, (Clinical Volume 4, Chapter 16)

vortex, (Clinical Volume 4, Chapter 16)

corneoretinal, Biett’s crystalline, (Clinical Volume 4, Chapter 66)

crystalline, Bietti’s corneoretinal, (Clinical Volume 4, Chapter 66)

Duchenne’s, (Clinical Volume 5, Chapter 29)

fovea

butterfly-shaped pigment of, (Clinical Volume 3, Chapter 9)

dominant progressive, (Clinical Volume 3, Chapter 9)

foveomacular pigment epithelial, adult-onset, (Clinical Volume 3, Chapter 9)

Fuchs’, (Clinical Volume 4, Chapter 16A)

fundus, Sorsby’s, (Clinical Volume 4, Chapter 66)

genetics, (Clinical Volume 3, Chapter 2)

hereditary. (See Hereditary macular dystrophies)

hereditary hemorrhagic, (Clinical Volume 3, Chapter 9)

Lefler-Wadsworth-Sidbury, (Clinical Volume 3, Chapter 9)

macroreticular, (Clinical Volume 3, Chapter 9)

macular, (Clinical Volume 4, Chapter 16)

benign concentric annular, (Clinical Volume 3, Chapter 9)

cystoid, dominant, (Clinical Volume 3, Chapter 9)

dominant slowly progressive, (Clinical Volume 3, Chapter 9)

end-stage, (Clinical Volume 4, Chapter 66)

fenestrated sheen, (Clinical Volume 3, Chapter 9)

muscular, (Clinical Volume 5, Chapter 29)

Duchenne’s, (Clinical Volume 3, Chapter 2)

myotonic. (See Myotonic dystrophy)

North Carolina, (Clinical Volume 3, Chapter 9) (Clinical Volume 4, Chapter 66)

genetics, (Clinical Volume 3, Chapter 2)

ocular muscle, (Clinical Volume 5, Chapter 29)

oculopharyngeal, (Clinical Volume 2, Chapter 12) (Clinical Volume 5, Chapter 29)

pattern, (Clinical Volume 3, Chapter 9)

posterior polymorphous, (Clinical Volume 4, Chapter 16A)

pseudoinflammatory, (Clinical Volume 3, Chapter 9)

retinal, (Clinical Volume 5, Chapter 31) See also Choroideremia

acquired, (Clinical Volume 3, Chapter 2)

hereditary, (Clinical Volume 3, Chapter 2)

retinal pigment epithelium, (Clinical Volume 3, Chapter 9 )

macroreticular, (Clinical Volume 3, Chapter 9)

rod-cone, pericentral, (Clinical Volume 3, Chapter 9)

Sjorgren’s reticular, (Clinical Volume 3, Chapter 9)

spider, (Clinical Volume 3, Chapter 9)

tapetochoroidal, (Clinical Volume 4, Chapter 66)

vitelliform, (Clinical Volume 3, Chapter 9)

foveomacular, (Clinical Volume 3, Chapter 9)

vitelliruptive macular, (Clinical Volume 3, Chapter 9)

Subject Index E

Eagle minimal essential medium, (Foundations Volume 2, Chapter 40)

Eale disease, (Foundations Volume 2, Chapter 113E) (Foundations Volume 3, Chapter 13)

Eales’ disease, (Clinical Volume 2, Chapter 5) (Clinical Volume 4, Chapter 57) (Clinical Volume 4, Chapter 58) (Clinical Volume 3, Chapter 16) (Clinical Volume 4, Chapter 44)

clinical features, (Clinical Volume 3, Chapter 16)

epidemiology, (Clinical Volume 3, Chapter 16)

pathogenesis, (Clinical Volume 3, Chapter 16)

photocoagulation in, (Clinical Volume 3, Chapter 16) (Clinical Volume 3, Chapter 6)

prognosis, (Clinical Volume 3, Chapter 16)

treatment, (Clinical Volume 3, Chapter 16)

and tuberculosis, (Clinical Volume 3, Chapter 16) (Clinical Volume 4, Chapter 57)

uveitis in, (Clinical Volume 4, Chapter 37)

Ear infection

anesthesia in child with, (Clinical Volume 6, Chapter 81)

facial nerve and, (Clinical Volume 2, Chapter 8)

Early receptor potential (ERP), (Foundations Volume 2, Chapter 13)

Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart, (Foundations Volume 2, Chapter 17) (Clinical Volume 5, Chapter 51)

Eaton-Lambert syndrome, (Clinical Volume 2, Chapter 12)

EBV. See Epstein-Barr virus (EBV)

“E” card, in visual acuity testing, (Clinical Volume 2, Chapter 2)

Eccentric gaze-holding mechanism, nystagmus, disturbance of, (Foundations Volume 1, Chapter 38)

Ecchymosis

conjunctival, in herpes simplex keratitis, (Clinical Volume 4, Chapter 19)

eyelid, pediatric orbital disorders causing, (Clinical Volume 2, Chapter 27)

Eccrine acrospiroma, (Foundations Volume 3, Chapter 7)

Eccrine carcinoma, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 7)

Eccrine glands, of lids, tumors of

benign, (Foundations Volume 3, Chapter 7)

malignant, (Foundations Volume 3, Chapter 7)

Eccrine hidrocystoma, (Clinical Volume 4, Chapter 3) (Foundations Volume 3, Chapter 7)

Eccrine poroma, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 7)

Eccrine spiradenoma, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 7)

Eccrine tumors, (Foundations Volume 3, Chapter 7)

ECF-A. See Eosinophil chemotactic factor of anaphylaxis

Echinococcosis, (Foundations Volume 2, Chapter 79) (Foundations Volume 3, Chapter 4)

orbital cysts in, (Clinical Volume 2, Chapter 31)

Echinococcus, (Clinical Volume 5, Chapter 33)

Echinococcus granulosus, (Foundations Volume 2, Chapter 79) (Foundations Volume 3, Chapter 4)

Echography. See also Ultrasonography

of capillary hemangioma, (Clinical Volume 2, Chapter 27)

for ocular measurements, (Clinical Volume 1, Chapter 33)

optic nerve, (Clinical Volume 2, Chapter 5)

orbital, (Clinical Volume 2, Chapter 14)

preoperative, (Clinical Volume 5, Chapter 86)

Echothiophate iodide (Phospholine Iodide), (Clinical Volume 3, Chapter 56)

in accommodative esodeviations, (Clinical Volume 1, Chapter 12)

additivity with ocular hypotensives, (Clinical Volume 3, Chapter 56)

for glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56)

dosage and administration of, (Clinical Volume 3, Chapter 56)

efficacy of, (Clinical Volume 3, Chapter 56)

indications for, (Clinical Volume 3, Chapter 56)

interaction with anesthetics, (Clinical Volume 6, Chapter 1)

lacrimal canaliculi and, (Clinical Volume 4, Chapter 13)

ocular toxicity, (Clinical Volume 3, Chapter 56) (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 37)

perioperative management of, in children, (Clinical Volume 6, Chapter 81)

systemic toxicity, (Clinical Volume 3, Chapter 56) (Clinical Volume 5, Chapter 37)

Echothiophate (Phospholine iodide), side effects of, in infants and children, (Foundations Volume 3, Chapter 43)

Eclampsia, (Clinical Volume 2, Chapter 7) (Clinical Volume 5, Chapter 32) (Clinical Volume 5, Chapter 32)

choroidopathy in, (Clinical Volume 5, Chapter 32)

cortical vision loss in, (Clinical Volume 5, Chapter 32)

retinopathy in, (Clinical Volume 5, Chapter 32)

Economic issues, in ocular trauma, (Clinical Volume 5, Chapter 56)

Ectasia

corneal, noninflammatory, (Clinical Volume 4, Chapter 16)

congenital, (Foundations Volume 3, Chapter 9)

nasal fundus, (Clinical Volume 3, Chapter 8)

scleral, (Clinical Volume 4, Chapter 23)

Ectatic dilation. See Aneurysms, fusiform

Ecthyma, (Foundations Volume 2, Chapter 49)

Ecthyma contagiosum, lids in, (Clinical Volume 4, Chapter 22)

Ecthyma gangrenosum, (Clinical Volume 4, Chapter 22)

Ectoderm, neural and surface, (Foundations Volume 1, Chapter 2)

Ectodermal dysplasia

anhidrotic, (Clinical Volume 5, Chapter 27)

cataract in, (Clinical Volume 5, Chapter 41)

cataract in, (Clinical Volume 1, Chapter 73) (Clinical Volume 5, Chapter 41)

Ectomesenchyme, (Foundations Volume 1, Chapter 32)

Ectoparasite, (Foundations Volume 2, Chapter 79)

Ectoparasiticides, (Foundations Volume 2, Chapter 66)

Ectopia lentis, (Foundations Volume 1, Chapter 15) (Foundations Volume 3, Chapter 53) (Foundations Volume 3, Chapter 54A) (Clinical Volume 1, Chapter 73) See Lens of eye, (Clinical Volume 5, Chapter 41)

cataract in, (Clinical Volume 1, Chapter 73)

conditions associated with, (Clinical Volume 3, Chapter 54A)

congenital, (Foundations Volume 3, Chapter 12) (Foundations Volume 3, Chapter 58)

in Ehlers-Danlos syndrome, (Clinical Volume 5, Chapter 41)

glaucoma from, (Clinical Volume 3, Chapter 54A)

in homocystinuria, (Clinical Volume 3, Chapter 54A) (Clinical Volume 5, Chapter 19) (Clinical Volume 5, Chapter 41)

in Marfan’s syndrome, (Clinical Volume 3, Chapter 51) (Clinical Volume 3, Chapter 54A) (Clinical Volume 5, Chapter 29) (Clinical Volume 5, Chapter 41)

molecular genetics, (Foundations Volume 3, Chapter 55)

traumatic, (Clinical Volume 3, Chapter 31) (Clinical Volume 6, Chapter 66)

in Weill-Marchesani syndrome, (Clinical Volume 3, Chapter 54A) (Clinical Volume 5, Chapter 29) (Clinical Volume 5, Chapter 41)

Ectopia lentis et pupillae, (Foundations Volume 3, Chapter 12)

Ectopic lacrimal gland, (Foundations Volume 3, Chapter 8)

Ectropion, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 73 )

aging and, (Foundations Volume 3, Chapter 7)

cicatricial, (Clinical Volume 5, Chapter 73)

congenital, (Clinical Volume 5, Chapter 73)

in craniofacial syndromes, (Clinical Volume 6, Chapter 110)

in epidermolysis bullosa, (Clinical Volume 5, Chapter 27)

involutional, (Clinical Volume 5, Chapter 73)

iris, congenital, (Foundations Volume 3, Chapter 53)

lid, congenital, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 40)

in neurofibromatosis, (Clinical Volume 3, Chapter 51)

paralytic, (Clinical Volume 5, Chapter 73)

postoperative, (Clinical Volume 5, Chapter 75) (Clinical Volume 5, Chapter 87)

tarsal, (Clinical Volume 5, Chapter 73)

Ectropion uveae, (Foundations Volume 3, Chapter 18)

Eczema

atopic, (Clinical Volume 4, Chapter 9) (Clinical Volume 5, Chapter 27) See also Atopic dermatitis

of eyelids, (Clinical Volume 4, Chapter 22)

Eczematoid dermatitis, infectious, (Foundations Volume 2, Chapter 49)

Edema. See also Angioedema; Disc swelling

Berlin’s, (Foundations Volume 3, Chapter 6) (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 31)

choroidal. (See Effusions, ciliochoroidal)

corneal, (Clinical Volume 4, Chapter 16A )

with bandage lens use, (Clinical Volume 4, Chapter 11)

Bowman’s layer cautery in, (Clinical Volume 4, Chapter 16A)

cataract surgery and, (Clinical Volume 4, Chapter 16A)

clinical entities, (Clinical Volume 4, Chapter 16A )

in congenital hereditary endothelial dystrophy, (Clinical Volume 4, Chapter 16A)

conjunctival flap in, (Clinical Volume 4, Chapter 16A)

from contact lens, (Clinical Volume 4, Chapter 16A)

contrast sensitivity and, (Clinical Volume 1, Chapter 35)

control of contributing factors, (Clinical Volume 4, Chapter 16A)

in diabetes mellitus, (Foundations Volume 3, Chapter 18)

diabetic vitrectomy and, (Clinical Volume 6, Chapter 57)

in Down’s syndrome, (Clinical Volume 4, Chapter 15)

in endothelial disease, primary, (Clinical Volume 4, Chapter 16A)

epithelial, (Clinical Volume 1, Chapter 31)

in herpes simplex keratitis, (Clinical Volume 4, Chapter 19)

foreign bodies and, (Clinical Volume 4, Chapter 16A)

in Fuch’s dystrophy, (Clinical Volume 4, Chapter 16A)

glare sensitivity and, (Clinical Volume 1, Chapter 35)

graft rejection versus, (Clinical Volume 4, Chapter 2)

intraocular pressure and, (Clinical Volume 4, Chapter 16A)

in iridocorneal endothelial syndrome, (Clinical Volume 4, Chapter 16A)

with normal endothelial function, (Clinical Volume 4, Chapter 16A)

penetrating keratoplasty for, (Clinical Volume 4, Chapter 16A) See also Keratoplasty, penetrating

persistent epithelial defect and, (Clinical Volume 4, Chapter 16A)

in posterior polymorphous dystrophy, (Clinical Volume 4, Chapter 16A)

stromal, (Clinical Volume 4, Chapter 16A)

trauma and, mechanical, (Clinical Volume 4, Chapter 16A)

treatment, (Clinical Volume 4, Chapter 16A)

ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106)

disciform, in herpetic keratitis, (Clinical Volume 4, Chapter 39)

lid, (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 36) (Foundations Volume 2, Chapter 49)

macular

corticosteroids in, (Foundations Volume 3, Chapter 31)

cystoid, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 18)

after blunt trauma, (Foundations Volume 3, Chapter 6)

after cataract extraction, (Foundations Volume 3, Chapter 6)

dominantly inherited, (Foundations Volume 3, Chapter 60)

fluorescein angiography, (Foundations Volume 2, Chapter 113F)

optical coherence tomography, (Foundations Volume 2, Chapter 107)

in diabetic retinopathy, (Foundations Volume 3, Chapter 18)

fluorescein angiography, (Foundations Volume 2, Chapter 113D)

pseudophakia versus, (Foundations Volume 2, Chapter 113D)

optical coherence tomography, (Foundations Volume 2, Chapter 107)

postoperative, NSAIDs and, (Foundations Volume 3, Chapter 38)

macular. (See Cystoid macular edema; Macula, edema)

optic disc, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 14) (Clinical Volume 3, Chapter 18) See also Papilledema

in diabetic retinopathy, (Clinical Volume 3, Chapter 30)

optic nerve, (Foundations Volume 3, Chapter 16) See also Disc swelling; Papilledema

optic nerve head, in malignant hypertension, (Clinical Volume 3, Chapter 13)

papilledema. (See Papilledema)

residues, in hypertensive retinopathy, (Clinical Volume 3, Chapter 13)

retinal, (Clinical Volume 3, Chapter 18)

in hypertension, (Clinical Volume 3, Chapter 13)

in retinal migraine, (Clinical Volume 2, Chapter 5)

subconjunctival, scleral rupture and, (Clinical Volume 3, Chapter 31)

Edema, corneal, (Foundations Volume 2, Chapter 4)

Edinger-Westphal nucleus, (Clinical Volume 1, Chapter 3) (Clinical Volume 2, Chapter 15) (Foundations Volume 2, Chapter 9) (Clinical Volume 2, Chapter 21 pupillary light reflex integration at)

Edrophonium (Tensilon) test

in myasthenia, (Clinical Volume 2, Chapter 12) (Clinical Volume 5, Chapter 29)

in myasthenia gravis, (Clinical Volume 1, Chapter 20)

in ptosis of lids, (Clinical Volume 2, Chapter 3)

EDTA. See Ethylene diamine tetraacetic acid

Edwards’ syndrome, (Clinical Volume 4, Chapter 15)

cataract, (Clinical Volume 3, Chapter 55) (Clinical Volume 5, Chapter 41)

glaucoma in, (Clinical Volume 3, Chapter 55)

Edwards’ syndrome. See Trisomy 18

Edward syndrome, (Clinical Volume 5, Chapter 41)

Effectivity principle, spectacle lenses and, (Clinical Volume 1, Chapter 36)

Efference copy, eye movements and, (Foundations Volume 2, Chapter 23)

Efferent system

abnormalities, (Clinical Volume 2, Chapter 29)

anatomy, (Clinical Volume 2, Chapter 29)

Efficiency

allocative, (Clinical Volume 5, Chapter 69)

in health economics, (Clinical Volume 5, Chapter 69)

technical, (Clinical Volume 5, Chapter 69)

Effusions

ciliochoroidal, (Clinical Volume 4, Chapter 52)

anatomic features, (Clinical Volume 4, Chapter 52)

annular, (Clinical Volume 4, Chapter 52)

clinical features, 3, (Clinical Volume 4, Chapter 52)

differential diagnosis, 4, (Clinical Volume 4, Chapter 52)

etiology, (Clinical Volume 4, Chapter 52)

flat, 3, (Clinical Volume 4, Chapter 52)

idiopathic, (Clinical Volume 4, Chapter 52)

inflammatory, (Clinical Volume 4, Chapter 52)

treatment, (Clinical Volume 4, Chapter 52)

intraoperative, expulsive, (Clinical Volume 4, Chapter 52)

lobular, 3, (Clinical Volume 4, Chapter 52)

in nanophthalmos, (Clinical Volume 4, Chapter 52)

surgery for, (Clinical Volume 3, Chapter 53)

pathophysiology, (Clinical Volume 4, Chapter 52)

postoperative, (Clinical Volume 4, Chapter 52)

scleral buckling and, (Clinical Volume 6, Chapter 59)

surgery for, (Clinical Volume 3, Chapter 53) (Clinical Volume 4, Chapter 52)

traumatic, (Clinical Volume 4, Chapter 52)

treatment, (Clinical Volume 4, Chapter 52)

in uveal effusion syndrome, (Clinical Volume 4, Chapter 52)

in Vogt-Koyanagi-Harada syndrome, (Clinical Volume 4, Chapter 52)

uveal, (Clinical Volume 4, Chapter 52)

in nanophthalmos, surgery for, (Clinical Volume 3, Chapter 53)

EFI. See Epithelial-fiber interface

Ehlers-Danlos syndrome, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 27) (Clinical Volume 3, Chapter 39) (Clinical Volume 5, Chapter 27) (Foundations Volume 1, Chapter 16) (Foundations Volume 3, Chapter 58) (Foundations Volume 3, Chapter 58)

defined, (Clinical Volume 5, Chapter 27)

diagnosis, (Clinical Volume 5, Chapter 27)

ectopia lentis in, (Clinical Volume 5, Chapter 41)

epidemiology, (Clinical Volume 5, Chapter 27)

ocular findings, (Clinical Volume 5, Chapter 27) (Clinical Volume 5, Chapter 41)

ocular manifestations, (Foundations Volume 3, Chapter 58)

pathogenesis, (Clinical Volume 5, Chapter 27)

systemic manifestations, (Foundations Volume 3, Chapter 58)

treatment, (Clinical Volume 5, Chapter 27)

types, (Clinical Volume 5, Chapter 27)

Ehlers-Danlos’ syndrome, (Clinical Volume 5, Chapter 41)

Eigengrau, (Foundations Volume 2, Chapter 16) (Foundations Volume 2, Chapter 20)

Eighth cranial nerve, neuroma. See Acoustic neuroma

Einephrine

corneal alterations caused by, pigmentation, (Foundations Volume 3, Chapter 9)

side effects, in infants and children, (Foundations Volume 3, Chapter 43)

Einstein, Albert, (Clinical Volume 1, Chapter 31)

Eisler pocket, (Foundations Volume 1, Chapter 5)

Elastic fibers, scleral, (Foundations Volume 1, Chapter 23)

Elasticity of skin, disorders, (Clinical Volume 5, Chapter 27)

Elastin, (Foundations Volume 1, Chapter 23)

in zonular microfibrillar system, (Foundations Volume 1, Chapter 14)

Elastin, sclera, (Foundations Volume 1, Chapter 23)

Elastorrhexis. See Pseudoxanthoma elasticum

Elastotic degeneration, corneal, (Foundations Volume 3, Chapter 9) (Clinical Volume 6, Chapter 35)

Elderly. See also Age/aging

blindness in, (Clinical Volume 5, Chapter 53)

Electrical injury, cataract with, (Clinical Volume 5, Chapter 41)

Electrical shock, cataract due to, (Foundations Volume 3, Chapter 12)

Electrical signals, of retina and visual cortex, (Foundations Volume 2, Chapter 13 )

Electrical stimulation, phosphenes created by, (Foundations Volume 2, Chapter 20)

Electrical synapses, (Foundations Volume 1, Chapter 20)

dopamine and, (Foundations Volume 1, Chapter 20)

Electric shock, cataract from, (Clinical Volume 1, Chapter 73) (Clinical Volume 1, Chapter 73)

Electroencephalography. See also Visual evoked potential (VEP)

Electromagnetic energy, (Clinical Volume 3, Chapter 6)

in gyrate atrophy, (Clinical Volume 3, Chapter 25)

in migraine, (Clinical Volume 2, Chapter 16)

Electrolytes, in lens, (Foundations Volume 2, Chapter 10)

Electrolyte secretion, mechanism of water and, (Foundations Volume 2, Chapter 2A)

Electromagnetic scleral search coil, (Clinical Volume 2, Chapter 9)

Electromagnetic spectrum, (Foundations Volume 2, Chapter 19)

Electromyography

in Duane retraction syndrome, (Clinical Volume 1, Chapter 20)

in myasthenia gravis, (Clinical Volume 1, Chapter 20) (Clinical Volume 2, Chapter 12)

ocular, (Clinical Volume 2, Chapter 9)

in progressive external ophthalmoplegia, (Clinical Volume 1, Chapter 20)

Electronic cap monitor, in compliance evaluation, (Foundations Volume 3, Chapter 24)

Electron microscopy, (Foundations Volume 2, Chapter 40)

of amyloid, (Clinical Volume 2, Chapter 35)

cell preparation for, (Clinical Volume 4, Chapter 35)

of extraocular muscle fibers, (Foundations Volume 1, Chapter 31)

in Hunter syndrome, (Foundations Volume 3, Chapter 54B)

of iris, (Foundations Volume 1, Chapter 11 )

of oligodendrocytes, optic nerve, (Foundations Volume 1, Chapter 25)

of rods and cones, (Clinical Volume 3, Chapter 1)

in viral infections, (Foundations Volume 2, Chapter 88)

Electronystagmography

in dizzy patient, (Clinical Volume 2, Chapter 18)

vestibular system assessment, (Clinical Volume 2, Chapter 18)

Electro-oculogram (EOG), (Foundations Volume 2, Chapter 13) (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 104)

recording, (Foundations Volume 2, Chapter 13)

Electro-oculography (EOG), (Clinical Volume 2, Chapter 9) (Clinical Volume 3, Chapter 5)

in autosomal dominant fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

in benign concentric annular macular dystrophy, (Clinical Volume 3, Chapter 9)

in dominant cystoid macular dystrophy, (Clinical Volume 3, Chapter 9)

in familial drusen, (Clinical Volume 3, Chapter 9)

in familial foveal retinoschisis, (Clinical Volume 3, Chapter 9)

in fenestrated sheen macular dystrophy, (Clinical Volume 3, Chapter 9)

in fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

normal values, (Clinical Volume 1, Chapter 21)

optokinetic nystagmus

normal, (Clinical Volume 1, Chapter 21)

sixth nerve palsy, (Clinical Volume 1, Chapter 21)

in pattern dystrophy of pigment epithelium, (Clinical Volume 3, Chapter 9)

in progressive cone-rod dystrophies, (Clinical Volume 3, Chapter 9)

in rod monochromaticism, (Clinical Volume 3, Chapter 9)

saccadic velocity measurements, (Clinical Volume 1, Chapter 21)

in Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9)

in Stargardt’s disease, (Clinical Volume 3, Chapter 9)

technique, (Clinical Volume 1, Chapter 21)

in X-linked juvenile retinoschisis, (Clinical Volume 3, Chapter 9)

Electrophoresis, (Foundations Volume 2, Chapter 40) (Foundations Volume 3, Chapter 55)

Electrophysiology

of retina, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 2) (Clinical Volume 3, Chapter 5 )

in choroideremia, (Clinical Volume 3, Chapter 25A)

in diabetic retinopathy, (Clinical Volume 3, Chapter 30)

testing, (Clinical Volume 2, Chapter 2 )

Electrophysiology tests, (Clinical Volume 2, Chapter 10)

electroretinography, (Clinical Volume 2, Chapter 10)

focal electroretinography, (Clinical Volume 2, Chapter 10)

multifocal electroretinography, (Clinical Volume 2, Chapter 10)

multifocal visual evoked potentials, (Clinical Volume 2, Chapter 10)

pattern electroretinography, (Clinical Volume 2, Chapter 10)

standard (full-field) electroretinography, (Clinical Volume 2, Chapter 10)

visual evoked potentials, (Clinical Volume 2, Chapter 10)

Electroretinogram (ERG), (Foundations Volume 2, Chapter 13) (Foundations Volume 2, Chapter 103)

a-wave, (Foundations Volume 2, Chapter 13)

“bright flash, ”, (2) 103: 9

b-wave, (Foundations Volume 2, Chapter 13)

in cases of decreased vision and nystagmus since birth, (Foundations Volume 2, Chapter 103)

in central retinal artery obstruction, (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 113C)

clinical use, (Foundations Volume 2, Chapter 103)

corneal recordings, (Foundations Volume 2, Chapter 13)

c-wave, (Foundations Volume 2, Chapter 13)

d-wave, (Foundations Volume 2, Chapter 13)

early receptor potential, (Foundations Volume 2, Chapter 13)

examination methods, (Foundations Volume 2, Chapter 103)

extracellular intraretinal recordings, (Foundations Volume 2, Chapter 13)

focal, (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 103)

foveal cone, (Foundations Volume 2, Chapter 14)

full-field, (Foundations Volume 2, Chapter 14)

in generalized degeneration of retina, (Foundations Volume 2, Chapter 103)

intracellular recordings, (Foundations Volume 2, Chapter 13)

in known hereditary degeneration, (Foundations Volume 2, Chapter 103)

methods of localizing components, (Foundations Volume 2, Chapter 13)

multifocal, (Foundations Volume 2, Chapter 14)

opaque media, (Foundations Volume 2, Chapter 103)

in ophthalmic artery obstruction, (Foundations Volume 2, Chapter 103) (Foundations Volume 2, Chapter 113C)

oscillatory potentials, (Foundations Volume 2, Chapter 14)

parameters, 2, (Foundations Volume 2, Chapter 103)

pattern, (Foundations Volume 2, Chapter 13) (Foundations Volume 2, Chapter 103)

recording configurations, (Foundations Volume 2, Chapter 13)

in retinal disease assessment, (Foundations Volume 2, Chapter 14)

scotopic threshold response, (Foundations Volume 2, Chapter 13)

standardized protocol, (Foundations Volume 2, Chapter 103)

stimulus conditions, (Foundations Volume 2, Chapter 103)

stray light effect, (Foundations Volume 2, Chapter 103)

subjective complaints outweighing findings, (Foundations Volume 2, Chapter 103)

in vascular occlusions, (Foundations Volume 2, Chapter 103)

Electroretinography, (Clinical Volume 2, Chapter 10) (Clinical Volume 4, Chapter 38)

Electroretinography (ERG), (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 5) (Clinical Volume 3, Chapter 24 )

in acute retinal necrosis syndrome, (Clinical Volume 3, Chapter 28)

in amblyopia, (Clinical Volume 1, Chapter 10)

with autosomal dominant fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

in Bardet-Biedl syndrome, (Clinical Volume 5, Chapter 31)

in benign concentric annular macular dystrophy, (Clinical Volume 3, Chapter 9)

in central retinal vein occlusion, (Clinical Volume 3, Chapter 15)

in choroideremia, (Clinical Volume 3, Chapter 25A)

chromatic, (Clinical Volume 3, Chapter 5)

clinical applications, (Clinical Volume 3, Chapter 5 )

in dominant optic atrophy, (Clinical Volume 2, Chapter 5)

early receptor response, (Clinical Volume 3, Chapter 2)

in familial foveal retinoschisis, (Clinical Volume 3, Chapter 9)

in fenestrated sheen macular dystrophy, (Clinical Volume 3, Chapter 9)

flash, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 2) (Clinical Volume 3, Chapter 5)

focal, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 2)

frequency-based, (Clinical Volume 3, Chapter 5)

in fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

in hypoperfusion retinopathy, (Clinical Volume 3, Chapter 14)

implicit time, (Clinical Volume 3, Chapter 5)

intensity response functions, (Clinical Volume 3, Chapter 5)

international standards, (Clinical Volume 3, Chapter 5)

in Leber’s congenital amaurosis, (Clinical Volume 3, Chapter 8)

long-duration flashes, (Clinical Volume 3, Chapter 5)

multifocal, (Clinical Volume 3, Chapter 5)

ISCEV guidelines, (Clinical Volume 3, Chapter 5)

in multiple evanescent white dot syndrome, (Clinical Volume 4, Chapter 49)

in ocular ischemic syndrome, (Clinical Volume 3, Chapter 12)

pattern (PERG), (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 2) (Clinical Volume 3, Chapter 5)

photopic negative response, (Clinical Volume 3, Chapter 5)

photoreceptor current, (Clinical Volume 3, Chapter 5)

photoresponse model, (Clinical Volume 3, Chapter 2)

preoperative, (Clinical Volume 6, Chapter 56)

in progressive cone-rod dystrophies, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 9)

pulse, (Clinical Volume 3, Chapter 2)

in retinal artery obstruction, central, (Clinical Volume 3, Chapter 14)

in retinal disease diagnosis, (Clinical Volume 3, Chapter 5)

in rod monochromaticism, (Clinical Volume 3, Chapter 9)

scotopic threshold response, (Clinical Volume 3, Chapter 2)

standard (full-field), (Clinical Volume 2, Chapter 2)

in Stargardt’s disease, (Clinical Volume 3, Chapter 9)

swept, (Clinical Volume 3, Chapter 5)

time series-based, (Clinical Volume 3, Chapter 5)

in visual loss, organic vs. functional, (Clinical Volume 3, Chapter 5)

in X-linked juvenile retinoschisis, (Clinical Volume 3, Chapter 9)

Elejalde syndrome, (Clinical Volume 4, Chapter 38)

Elephantiasis neuromatosa, (Clinical Volume 2, Chapter 41) (Foundations Volume 3, Chapter 2)

Eletriptan for migraine, (Clinical Volume 2, Chapter 16)

Elevator deficiencies, 27–29

Elevator palsy, congenital, (Clinical Volume 2, Chapter 13)

ELISA. See Enzyme-linked immunosorbent assay (ELISA)

Ellingson (UGH) syndrome, (Clinical Volume 3, Chapter 54G)

intraocular lenses and, (Clinical Volume 6, Chapter 11)

Elliptic nystagmus, (Clinical Volume 2, Chapter 11)

Ellis-van Creveld syndrome, (Foundations Volume 3, Chapter 59)

Elschnig

border tissue of, (Foundations Volume 1, Chapter 25)

inner limiting membrane of, (Foundations Volume 1, Chapter 16) (Foundations Volume 1, Chapter 25)

Elschnig pearls, postoperative, (Foundations Volume 3, Chapter 6)

Elschnig spots, (Clinical Volume 3, Chapter 14) (Foundations Volume 2, Chapter 113C)

in hypertensive choroidopathy, (Clinical Volume 3, Chapter 13)

in kidney disease, 2, (Clinical Volume 5, Chapter 31)

Emboli

amniotic fluid, (Clinical Volume 5, Chapter 32)

in carotid artery disease, (Clinical Volume 2, Chapter 1) (Clinical Volume 3, Chapter 14)

fat, retinal, (Foundations Volume 3, Chapter 6)

retinal, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 14)

atrial fibrillation and, (Clinical Volume 2, Chapter 5)

microemboli, (Clinical Volume 2, Chapter 5)

retinal artery occlusion and, central, (Clinical Volume 3, Chapter 14)

sources of, (Clinical Volume 2, Chapter 5)

talc and cornstarch, (Foundations Volume 3, Chapter 6)

Embolization, cavernous sinus tumor, (Clinical Volume 2, Chapter 17)

EMBP. See Eosinophil granule major basic protein

Embryology, (Foundations Volume 1, Chapter 2) (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 53)

aqueous outflow pathways, (Foundations Volume 1, Chapter 2)

Bowman’s membrane, (Foundations Volume 1, Chapter 2)

Bruch’s membrane, (Foundations Volume 1, Chapter 2)

choroidal, (Foundations Volume 1, Chapter 2)

ciliary body

epithelium, (Foundations Volume 1, Chapter 2)

fine structure of epithelia, (Foundations Volume 1, Chapter 2)

muscle, (Foundations Volume 1, Chapter 2)

stromal and vascular components, (Foundations Volume 1, Chapter 2)

conjunctival and lid glands, (Foundations Volume 1, Chapter 2)

connective tissue coats

corneal, (Foundations Volume 1, Chapter 2)

scleral, (Foundations Volume 1, Chapter 2)

corneal, (Foundations Volume 1, Chapter 2) (Foundations Volume 2, Chapter 4) (Foundations Volume 3, Chapter 53) (Foundations Volume 3, Chapter 3)

craniofacial anomalies, (Foundations Volume 1, Chapter 41 )

Descemet’s membrane, (Foundations Volume 1, Chapter 2) (Foundations Volume 3, Chapter 53)

early morphogenesis, (Foundations Volume 1, Chapter 2)

extraocular muscles, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 31) (Foundations Volume 1, Chapter 32)

eye, 2; (Clinical Volume 5, Chapter 72) (Clinical Volume 3, Chapter 8)

facial nerve, (Foundations Volume 1, Chapter 37) (Clinical Volume 2, Chapter 8)

iridocorneal angle, (Foundations Volume 1, Chapter 2) (Foundations Volume 3, Chapter 53)

iris, (Foundations Volume 1, Chapter 11)

melanogenesis, (Foundations Volume 1, Chapter 2)

neuroectodermal constituents, (Foundations Volume 1, Chapter 2)

tunica vasculosa lentis, pupillary membrane, and stroma, (Foundations Volume 1, Chapter 2)

lacrimal gland, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 32) (Clinical Volume 2, Chapter 40)

lashes, (Foundations Volume 1, Chapter 2)

lens, (Foundations Volume 1, Chapter 15) (Foundations Volume 2, Chapter 10)f (Clinical Volume 1, Chapter 71)

induction and differentiation, (Foundations Volume 1, Chapter 2) (Foundations Volume 3, Chapter 53)

maturation, (Foundations Volume 1, Chapter 2)

nuclei, (Foundations Volume 1, Chapter 2)

primary fibers, (Foundations Volume 1, Chapter 2)

secondary fibers, (Foundations Volume 1, Chapter 2)

sutures, (Foundations Volume 1, Chapter 2)

lids, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 5) (Foundations Volume 3, Chapter 53)

macular, (Foundations Volume 1, Chapter 2)

malformations. (See Developmental anomalies; specific type)

nasolacrimal drainage apparatus, (Foundations Volume 1, Chapter 2)

neuroectodermal layers

pigment epithelium, (Foundations Volume 1, Chapter 2)

retina, (Foundations Volume 1, Chapter 2)

optic nerve, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 25)

lamina cribrosa, (Foundations Volume 1, Chapter 2)

myelination, (Foundations Volume 1, Chapter 2)

optic nerve head, (Foundations Volume 1, Chapter 25)

optic stalk, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 25)

migration of nerve fibers into inner layer, (Foundations Volume 1, Chapter 2)

sheaths, (Foundations Volume 1, Chapter 25)

orbit, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 32)

origins of ocular tissue, (Foundations Volume 1, Chapter 2)

periocular mesenchyme and, (Foundations Volume 1, Chapter 3 )

pupillary membrane, (Foundations Volume 1, Chapter 2)

retinal, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 19) (Foundations Volume 2, Chapter 5) (Foundations Volume 3, Chapter 53)

Schlemm’s canal, (Foundations Volume 1, Chapter 2)

scleral, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 3) (Foundations Volume 1, Chapter 23) (Foundations Volume 3, Chapter 53)

sequence of ocular development, (Foundations Volume 1, Chapter 2)

teratology and, (Foundations Volume 1, Chapter 39)

trabecular meshwork, (Foundations Volume 1, Chapter 2)

uveal, (Foundations Volume 1, Chapter 2)

visual sensory system, (Foundations Volume 1, Chapter 34) (Clinical Volume 2, Chapter 4)

vitreous and hyaloid system, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 16) (Foundations Volume 3, Chapter 53)

primary vitreous, (Foundations Volume 1, Chapter 2)

secondary vitreous, (Foundations Volume 1, Chapter 2)

tertiary vitreous and zonular fibers, (Foundations Volume 1, Chapter 2)

Embryonal rhabdomyosarcoma. See Rhabdomyosarcoma

Embryonic cataract, anterior axial, (Foundations Volume 1, Chapter 15)

Embryonic plate, (Clinical Volume 3, Chapter 8)

Embryopathy, infectious, (Foundations Volume 3, Chapter 2)

Embryotoxon, posterior, (Clinical Volume 4, Chapter 16)

anterior, (Foundations Volume 3, Chapter 9)

glaucoma, (Clinical Volume 3, Chapter 51) (Clinical Volume 3, Chapter 55)

posterior, (Foundations Volume 3, Chapter 9) (Foundations Volume 3, Chapter 53) (Foundations Volume 3, Chapter 64)

Emergent light, in retinoscopy, (Clinical Volume 1, Chapter 37 )

Emiocytosis, (Foundations Volume 1, Chapter 30)

Emissaria, scleral, (Foundations Volume 1, Chapter 1) (Foundations Volume 1, Chapter 23)

Emissary canals, sclera, (Foundations Volume 1, Chapter 23)

Emmetropia, (Foundations Volume 1, Chapter 1) (Clinical Volume 1, Chapter 33)

amblyopia and, (Clinical Volume 1, Chapter 10)

chromatic blur, (Clinical Volume 1, Chapter 33)

far-point plane, (Clinical Volume 1, Chapter 36)

Emmetropization, (Clinical Volume 1, Chapter 42)

Emphysema, orbital, proptosis in, (Clinical Volume 2, Chapter 28)

Empirical horopter, (Foundations Volume 2, Chapter 24) See also Horopter

Employees, occupational ophthalmology and, (Clinical Volume 5, Chapter 47)

Empty sella syndrome, (Clinical Volume 2, Chapter 6)

Encephalocele

optic disc, (Clinical Volume 2, Chapter 5)

orbital, (Clinical Volume 2, Chapter 31)

Encephalocraniocutaneous lipomatosis, (Foundations Volume 1, Chapter 40)

Encephalomyelitis, acute disseminated, optic neuritis and, (Clinical Volume 2, Chapter 5)

Encephalopathy

in Lyme disease, (Foundations Volume 2, Chapter 75)

subacute necrotizing, (Foundations Volume 3, Chapter 59)

Encephalopathy, Wernicke, (Clinical Volume 5, Chapter 29) (Clinical Volume 5, Chapter 30)

Encephalotrigeminal angiomatosis, (Clinical Volume 2, Chapter 17) (Foundations Volume 3, Chapter 2) (Foundations Volume 3, Chapter 58)

Encephalotrigeminal angiomatosis. See Sturge-Weber syndrome

Endarterectomy, carotid, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 14)

in ocular ischemic syndrome, (Clinical Volume 3, Chapter 12)

Endocapsular posterior chamber lens, (Clinical Volume 6, Chapter 8)

Endocardiosis, verrucal, degenerative, (Clinical Volume 5, Chapter 22)

Endocarditis

infective, (Clinical Volume 5, Chapter 22)

prophylaxis

in children, 4, (Clinical Volume 6, Chapter 81)

surgery in children and, (Clinical Volume 6, Chapter 80)

infective, ocular abnormalities, (Clinical Volume 5, Chapter 22)

nonbacterial thrombotic, ocular abnormalities, (Clinical Volume 5, Chapter 22)

thrombotic, nonbacterial, (Clinical Volume 5, Chapter 22)

thrombotic, nonbacterial, ocular abnormalities, (Clinical Volume 5, Chapter 22)

Endocrine diseases. See also specific disease

immunology, (Foundations Volume 2, Chapter 35 )

Endocrine disorders, (Clinical Volume 5, Chapter 21)

adrenal, (Clinical Volume 5, Chapter 21)

cornea, (Clinical Volume 4, Chapter 15)

hypothalamic gliomas and, (Clinical Volume 2, Chapter 6)

multiple endocrine neoplasia, (Clinical Volume 5, Chapter 21)

parathyroid, (Clinical Volume 5, Chapter 21) See also Parathyroid disorders

pituitary, (Clinical Volume 5, Chapter 21) See also Pituitary gland

thyroid, (Clinical Volume 5, Chapter 21) See also Thyroid disorders

Endocrine neoplasia, multiple. See Multiple endocrine neoplasia

Endocytosis, P. aeruginosa, (Foundations Volume 2, Chapter 52)

Endodiathermy. See Diathermy

Endogenous endophthalmitis, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 24)

diagnosis, (Clinical Volume 4, Chapter 24)

therapy, (Clinical Volume 4, Chapter 24)

Endolaser cyclophotocoagulation, (Clinical Volume 6, Chapter 19)

Endoneurium, (Clinical Volume 2, Chapter 41)

Endoparasite, (Foundations Volume 2, Chapter 79)

Endophthalmitis, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 40) (Clinical Volume 6, Chapter 64) (Foundations Volume 3, Chapter 3) (Clinical Volume 6, Chapter 11) (Clinical Volume 6, Chapter 64)

Acremonium, (Volume 4, Chapter 55 )

after intravitreal injections, (Clinical Volume 6, Chapter 64)

antibiotic therapy, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 26) (Clinical Volume 6, Chapter 64)

initial regimen, (Clinical Volume 4, Chapter 24)

modification, (Clinical Volume 4, Chapter 24)

periocular, (Clinical Volume 6, Chapter 64)

prophylactic, (Clinical Volume 4, Chapter 24)

guidelines, (Clinical Volume 4, Chapter 24)

systemic, (Clinical Volume 6, Chapter 64)

topical, (Clinical Volume 6, Chapter 64)

vitrectomy plus, (Clinical Volume 6, Chapter 64)

anti-inflammatory therapy, (Clinical Volume 4, Chapter 55)

Aspergillus, (Clinical Volume 3, Chapter 11) (Clinical Volume 4, Chapter 55)

bacterial, (Clinical Volume 6, Chapter 64)

antibiotics in, (Clinical Volume 4, Chapter 26) See also Endophthalmitis, antibiotic therapy

endogenous, (Clinical Volume 5, Chapter 33)

listerial, (Foundations Volume 2, Chapter 51)

postoperative, (Foundations Volume 3, Chapter 6)

treatment, (Foundations Volume 3, Chapter 36)

Blastomyces dermatitidis, (Clinical Volume 3, Chapter 11)

bleb-associated, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 64)

clinical features of, (Clinical Volume 4, Chapter 55)

prognosis for, (Clinical Volume 4, Chapter 55)

risk factors for, (Clinical Volume 4, Chapter 55)

treatment of, (Clinical Volume 4, Chapter 55)

Candida, (Clinical Volume 3, Chapter 11) (Clinical Volume 4, Chapter 55) (Clinical Volume 4, Chapter 57)

cataract surgery and, (Clinical Volume 3, Chapter 54G)

pediatric, (Clinical Volume 6, Chapter 100)

categories, (Clinical Volume 6, Chapter 64)

chronic postoperative, (Clinical Volume 6, Chapter 64)

classification, (Foundations Volume 3, Chapter 3) (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64) (Clinical Volume 6, Chapter 64)

clinical features of, (Clinical Volume 4, Chapter 55)

clinical presentation, (Clinical Volume 4, Chapter 24)

conjunctival filtering bleb-associated, (Foundations Volume 3, Chapter 3) (Foundations Volume 3, Chapter 6)

corticosteroids in, (Foundations Volume 2, Chapter 101)

corticosteroid therapy, (Clinical Volume 6, Chapter 64) (Clinical Volume 6, Chapter 64)

Cryptococcus, (Clinical Volume 3, Chapter 11)

crystalline lens management, (Clinical Volume 6, Chapter 64)

culture, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64)

delayed bacterial, (Clinical Volume 4, Chapter 55)

clinical features of, (Clinical Volume 4, Chapter 55)

definition of, (Clinical Volume 4, Chapter 55)

diagnosis of, (Clinical Volume 4, Chapter 55)

epidemiology of, (Clinical Volume 4, Chapter 55)

etiology of, (Clinical Volume 4, Chapter 55)

treatment of, (Clinical Volume 4, Chapter 55)

visual prognosis for, (Clinical Volume 4, Chapter 55)

delayed-onset, (Foundations Volume 3, Chapter 3)

diagnosis, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64) (Clinical Volume 6, Chapter 64)

causative organisms and, (Clinical Volume 4, Chapter 24)

differential diagnosis, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64)

early bacterial, postoperative, (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 64)

clinical features, (Clinical Volume 4, Chapter 55)

diagnosis, (Clinical Volume 4, Chapter 55)

epidemiology of, (Clinical Volume 4, Chapter 55)

etiology, (Clinical Volume 4, Chapter 55)

prevention, (Clinical Volume 4, Chapter 55)

prognosis, (Clinical Volume 4, Chapter 55)

risk factors for, (Clinical Volume 4, Chapter 55)

source, (Clinical Volume 4, Chapter 55)

treatment, (Clinical Volume 4, Chapter 55)

endogenous, (Foundations Volume 2, Chapter 49) (Foundations Volume 3, Chapter 3) (Clinical Volume 6, Chapter 64) (Clinical Volume 4, Chapter 24)

bacterial, (Clinical Volume 5, Chapter 33)

uveitis in, (Clinical Volume 4, Chapter 37)

endophthalmitis vitrectomy study, (Clinical Volume 6, Chapter 64)

fungal, (Foundations Volume 2, Chapter 54) (Foundations Volume 3, Chapter 14) (Clinical Volume 3, Chapter 11 )

after cataract extraction, (Foundations Volume 3, Chapter 6)

in AIDS, (Foundations Volume 2, Chapter 82)

amphotericin B for, (Foundations Volume 2, Chapter 62)

Fusarium, (Clinical Volume 4, Chapter 55)

histology, (Foundations Volume 3, Chapter 3)

histoplasmic, (Clinical Volume 4, Chapter 48)

incidence, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64) (Clinical Volume 6, Chapter 64)

infectious

delayed, uveitis versus, (Clinical Volume 4, Chapter 54)

pathogenesis of, (Foundations Volume 2, Chapter 48)

intraocular lens-related inflammations and, (Clinical Volume 4, Chapter 41)

intravitreal antibiotics, (Clinical Volume 6, Chapter 64)

iridocyclitis and, (Clinical Volume 4, Chapter 42)

localized, (Clinical Volume 4, Chapter 41 )

malignant-like glaucoma in, (Clinical Volume 3, Chapter 53)

management, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64 )

antibiotics, (Clinical Volume 4, Chapter 24) See also Endophthalmitis, antibiotic therapy

anti-inflammatory agents, (Clinical Volume 4, Chapter 24)

antimycotics, (Clinical Volume 4, Chapter 24)

corticosteroid therapy, (Clinical Volume 6, Chapter 64)

lens management during, (Clinical Volume 6, Chapter 64)

results, (Clinical Volume 4, Chapter 24)

tissue plasminogen activator in, (Clinical Volume 6, Chapter 64)

visual outcome and, (Clinical Volume 6, Chapter 64)

vitrectomy, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 56) (Clinical Volume 6, Chapter 64 )

microbial

epidemics and outbreaks, (Foundations Volume 2, Chapter 43)

epidemiology, (Foundations Volume 2, Chapter 43)

Paecilomyces, (Clinical Volume 4, Chapter 55)

pathogenic mechanisms of, (Foundations Volume 2, Chapter 48)

periocular antibiotic therapy, (Clinical Volume 6, Chapter 64)

phacoanaphylactic, (Foundations Volume 3, Chapter 4) (Foundations Volume 3, Chapter 12) (Clinical Volume 4, Chapter 41) (Clinical Volume 4, Chapter 42) (Clinical Volume 4, Chapter 54) (Clinical Volume 4, Chapter 55) (Clinical Volume 4, Chapter 64)

after cataract extraction, (Foundations Volume 3, Chapter 6)

postoperative, 2; (Clinical Volume 4, Chapter 55) (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 55)

acute, (Clinical Volume 6, Chapter 64)

acute infectious, (Foundations Volume 3, Chapter 3)

after cataract extraction, (Foundations Volume 3, Chapter 6)

after refractive surgery, (Foundations Volume 3, Chapter 6)

after retinal reattachment, (Foundations Volume 3, Chapter 6)

antimicrobial prophylaxis, (Foundations Volume 2, Chapter 64)

penetrating keratoplasty and, (Foundations Volume 2, Chapter 64)

delayed-onset, (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 64)

diabetic vitrectomy and, (Clinical Volume 6, Chapter 57)

early-onset, (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 64)

glaucoma and, (Clinical Volume 3, Chapter 54G)

incidence, preoperative antibiotic effects on, (Foundations Volume 2, Chapter 64)

radial keratotomy and, (Clinical Volume 6, Chapter 41)

sources, preoperative culture testing and, (Foundations Volume 2, Chapter 64)

postpartum, (Clinical Volume 5, Chapter 32)

post-traumatic, (Foundations Volume 2, Chapter 49) (Foundations Volume 3, Chapter 3)

prevention, (Foundations Volume 2, Chapter 64)

prevention, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 64) (Clinical Volume 6, Chapter 64)

Propionibacterium acnes, (Clinical Volume 4, Chapter 43) (Clinical Volume 4, Chapter 55)

retained lens fragments and, (Clinical Volume 6, Chapter 65)

sequelae, (Foundations Volume 3, Chapter 3 )

sequestered, (Foundations Volume 3, Chapter 14)

shunt extrusion and, (Clinical Volume 6, Chapter 17)

Sporothrix schenckii, (Clinical Volume 3, Chapter 11)

staphylococcal, (Foundations Volume 2, Chapter 49)

sterile, (Foundations Volume 2, Chapter 49)

streptococcal, (Foundations Volume 2, Chapter 49)

surgical asepsis in prevention, (Clinical Volume 4, Chapter 24)

sympathetic ophthalmia and, (Clinical Volume 4, Chapter 51) (Clinical Volume 4, Chapter 55)

therapeutic challenges of, (Foundations Volume 2, Chapter 48)

tissue plasminogen activator, (Clinical Volume 6, Chapter 64)

tissue plasminogen activator in, (Clinical Volume 6, Chapter 64)

tissue transplantation material and, (Foundations Volume 2, Chapter 64)

topical antibiotic therapy, (Clinical Volume 6, Chapter 64)

Torulopsis, (Clinical Volume 4, Chapter 55)

trauma-associated, (Clinical Volume 4, Chapter 24) (Clinical Volume 6, Chapter 56) (Clinical Volume 6, Chapter 64)

epidemiology, (Clinical Volume 6, Chapter 66)

treatment, (Clinical Volume 6, Chapter 66)

treatment, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 55)

treatment modalities, (Clinical Volume 6, Chapter 64)

ultrasonography, (Clinical Volume 3, Chapter 3)

uveal melanoma and, (Foundations Volume 3, Chapter 20)

visual outcome after treatment, (Clinical Volume 4, Chapter 55) (Clinical Volume 6, Chapter 64)

vitrectomy, (Clinical Volume 6, Chapter 64)

vitrectomy causing, (Clinical Volume 6, Chapter 56)

Endophythalmitis, infectious, (Clinical Volume 4, Chapter 24)

acute postoperative endophthalmitis, (Clinical Volume 4, Chapter 24)

acute postoperative infection, (Clinical Volume 4, Chapter 24)

antimicrobial therapy, (Clinical Volume 4, Chapter 24)

choice of antimicrobial agent, (Clinical Volume 4, Chapter 24)

intraocular injections, (Clinical Volume 4, Chapter 24)

subconjunctival injections, (Clinical Volume 4, Chapter 24)

systemic antimicrobials, (Clinical Volume 4, Chapter 24)

topical antimicrobials, (Clinical Volume 4, Chapter 24)

bacilli, (Clinical Volume 4, Chapter 24)

blebitis, (Clinical Volume 4, Chapter 24)

bleb-related endophthalmitis, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 24)

clinical presentation, (Clinical Volume 4, Chapter 24)

coagulase-negative staphylococci, (Clinical Volume 4, Chapter 24)

delayed-onset postoperative endophthalmitis, (Clinical Volume 4, Chapter 24)

delayed-onset postoperative infection, (Clinical Volume 4, Chapter 24)

endogenous endophthalmitis, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 24)

diagnosis, (Clinical Volume 4, Chapter 24)

therapy, (Clinical Volume 4, Chapter 24)

fungi, (Clinical Volume 4, Chapter 24)

incidence, (Clinical Volume 4, Chapter 24)

management strategies, (Clinical Volume 4, Chapter 24)

organism, outcome by, (Clinical Volume 4, Chapter 24)

propionibacterium acnes, (Clinical Volume 4, Chapter 24)

pseudomonas, (Clinical Volume 4, Chapter 24)

staphylococcus aureus, (Clinical Volume 4, Chapter 24)

streptococcus, (Clinical Volume 4, Chapter 24)

surgical procedures, (Clinical Volume 4, Chapter 24)

pars plana vitrectomy, (Clinical Volume 4, Chapter 24)

complications, (Clinical Volume 4, Chapter 24)

corticosteroids, (Clinical Volume 4, Chapter 24)

indications, (Clinical Volume 4, Chapter 24)

tap, inject, (Clinical Volume 4, Chapter 24)

traumatic endophthalmitis, (Clinical Volume 4, Chapter 24) (Clinical Volume 4, Chapter 24)

Endophytic retinoblastoma, 3, (Foundations Volume 3, Chapter 14) (Foundations Volume 3, Chapter 21)

Endoretinal biopsy, (Clinical Volume 4, Chapter 45)

Endothelial blebs, contact lenses and, (Clinical Volume 1, Chapter 55)

Endothelial cell count, (Clinical Volume 6, Chapter 6)

Endothelial cell damage, (Clinical Volume 6, Chapter 11)

Endothelial cells, contact lenses and, (Clinical Volume 1, Chapter 55)

Endothelial rejection line, in corneal graft rejection, (Clinical Volume 4, Chapter 2) (Clinical Volume 6, Chapter 26)

Endothelium, (Foundations Volume 1, Chapter 8)

innervation, (Foundations Volume 1, Chapter 8)

trigeminal nerve, (Foundations Volume 1, Chapter 8)

Endothelium, corneal, (Foundations Volume 1, Chapter 1) (Foundations Volume 1, Chapter 8) (Foundations Volume 2, Chapter 4) See Cornea, endothelium

barrier function, (Foundations Volume 2, Chapter 4)

decompensation, (Foundations Volume 2, Chapter 4) (Foundations Volume 3, Chapter 6)

dystrophies, (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 9) (Foundations Volume 3, Chapter 63)

embryology, (Foundations Volume 1, Chapter 2)

function, (Foundations Volume 2, Chapter 4)

injury during cataract extraction, (Foundations Volume 3, Chapter 6)

ion and fluid transport, (Foundations Volume 2, Chapter 4)

metabolism, (Foundations Volume 2, Chapter 4)

microscopic anatomy, (Foundations Volume 2, Chapter 4)

wound healing, (Foundations Volume 2, Chapter 4)

Endotoxin, gram-negative bacilli, (Foundations Volume 2, Chapter 52)

Endovascular interventional procedures, (Clinical Volume 2, Chapter 17)

End-point (physiologic) nystagmus, (Clinical Volume 2, Chapter 11)

Energy, in light, (Foundations Volume 2, Chapter 15)

Enophthalmos, (Foundations Volume 3, Chapter 17)

differential diagnosis of, (Clinical Volume 2, Chapter 14)

in Horner’s syndrome, (Clinical Volume 2, Chapter 15)

Entamoeba histolytica, (Foundations Volume 2, Chapter 79)

Enteritis, regional. See Crohn’s disease

Enterobacter aerogenes, corneal ulcers, (Clinical Volume 4, Chapter 18)

Enterococci

endophthalmitis from, (Clinical Volume 4, Chapter 55)

vancomycin-resistant, (Foundations Volume 2, Chapter 64)

Enterococcus, (Foundations Volume 2, Chapter 49)

Enterococcus faecalis, (2) 41: 8; 49: 4, 7

infectious endophthalmitis and, (Foundations Volume 2, Chapter 48)

Enterococcus faecium, (Foundations Volume 2, Chapter 49)

Entero-Vioform. See Iodochlorhydroxyquin (clioquinol)

Enterovirus, (Foundations Volume 2, Chapter 85) (Foundations Volume 2, Chapter 92)

antigenic relationships, (Foundations Volume 2, Chapter 92)

biological properties, (Foundations Volume 2, Chapter 92)

control, (Foundations Volume 2, Chapter 92)

diagnosis, (Foundations Volume 2, Chapter 92)

diagnostic tests, (Foundations Volume 2, Chapter 40) (Foundations Volume 2, Chapter 88)

epidemics and outbreaks, (Foundations Volume 2, Chapter 43) (Foundations Volume 2, Chapter 92)

epidemiology, (Foundations Volume 2, Chapter 43) (Foundations Volume 2, Chapter 92)

evolution, (Foundations Volume 2, Chapter 92)

morphology, (Foundations Volume 2, Chapter 92)

pathogenicity, (Foundations Volume 2, Chapter 92)

physicochemical properties, (Foundations Volume 2, Chapter 92)

serotypes, (Foundations Volume 2, Chapter 92)

typing, (Foundations Volume 2, Chapter 92)

Enterovirus 70, eye movements with, (Clinical Volume 2, Chapter 12)

Entomoplasma, (Foundations Volume 2, Chapter 59)

Entoptic imagery, (Foundations Volume 2, Chapter 20 )

afterimages, (Foundations Volume 2, Chapter 20)

blue arcs of the retina, (Foundations Volume 2, Chapter 20)

description of, (Foundations Volume 2, Chapter 20)

halos, (Foundations Volume 2, Chapter 20)

neural adaptation and, (Foundations Volume 2, Chapter 20)

ocular media and, (Foundations Volume 2, Chapter 20)

phosphenes, (Foundations Volume 2, Chapter 20)

photoreceptor directional sensitivity and, (Foundations Volume 2, Chapter 20)

polarized light, (Foundations Volume 2, Chapter 20)

retinal circulation and, (Foundations Volume 2, Chapter 20)

retinal pigmentation effects on, (Foundations Volume 2, Chapter 20)

shadows, (Foundations Volume 2, Chapter 20)

Entoptic perimetry, (Foundations Volume 2, Chapter 20)

Entoptic visualization, (Foundations Volume 2, Chapter 20)

Entrance pupil, aperture and, (Clinical Volume 1, Chapter 30)

Entropion, (Clinical Volume 5, Chapter 73 )

aging and, (Foundations Volume 3, Chapter 7)

cicatricial, (Clinical Volume 5, Chapter 73)

in chemical injuries, (Clinical Volume 4, Chapter 28)

postoperative, (Clinical Volume 5, Chapter 75)

surgical correction, (Clinical Volume 5, Chapter 83)

congenital, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 40)

in craniofacial syndromes, (Clinical Volume 6, Chapter 110)

surgery, (Clinical Volume 5, Chapter 78) (Clinical Volume 6, Chapter 110)

complications, (Clinical Volume 6, Chapter 110)

contraindications, (Clinical Volume 6, Chapter 110)

indications, (Clinical Volume 6, Chapter 110)

results, (Clinical Volume 6, Chapter 110)

Enucleation, (Clinical Volume 5, Chapter 82 )

anophthalmic socket, (Clinical Volume 5, Chapter 83 )

basic technique, (Clinical Volume 5, Chapter 83)

complications, (Clinical Volume 5, Chapter 83) (Clinical Volume 6, Chapter 109)

dermal fat graft and, (Clinical Volume 5, Chapter 83)

hydroxyapatite implant and, (Clinical Volume 5, Chapter 83)

nonvascularized implant and, (Clinical Volume 5, Chapter 83)

congenital, (Clinical Volume 5, Chapter 73)

dermal fat graft in, (Clinical Volume 5, Chapter 83)

complications, (Clinical Volume 5, Chapter 83)

historical development, (Clinical Volume 5, Chapter 83)

implant, (Clinical Volume 5, Chapter 83)

extrusion, surgical management, (Clinical Volume 5, Chapter 83)

insertion

hydroxyapatite implant, (Clinical Volume 5, Chapter 83)

nonvascularized implant, (Clinical Volume 5, Chapter 83)

nonvascularized, (Clinical Volume 5, Chapter 83)

selection. (See also Implants, orbital)

indications, (Clinical Volume 6, Chapter 109)

involutional, (Clinical Volume 5, Chapter 73)

for melanoma, posterior uveal, (Clinical Volume 6, Chapter 70 )

complications, (Clinical Volume 6, Chapter 70)

hydroxyapatite integrated orbital implant in, (Clinical Volume 6, Chapter 70)

“no touch” method, (Clinical Volume 6, Chapter 70)

relative indications, (Clinical Volume 6, Chapter 70)

results, (Clinical Volume 6, Chapter 70)

standard method, (Clinical Volume 6, Chapter 70)

techniques, (Clinical Volume 6, Chapter 70)

modified, for conjunctival tumors, (Clinical Volume 4, Chapter 10)

surgical techniques, (Clinical Volume 5, Chapter 83 )

in sympathetic ophthalmia, (Clinical Volume 4, Chapter 51)

Environment, retinal blood flow and, (Foundations Volume 2, Chapter 5)

Environmental factors, ocular teratogenicity, (Foundations Volume 1, Chapter 39)

Environmental surveillance, occupational ophthalmology and, (Clinical Volume 5, Chapter 47)

Enzyme-conjugated stains, (Foundations Volume 2, Chapter 40)

Enzyme detection, (Foundations Volume 2, Chapter 40)

Enzyme immunoassay, in follicular conjunctivitis, (Clinical Volume 4, Chapter 7)

Enzyme inhibitors, in corneal ulcers, bacterial, (Clinical Volume 4, Chapter 18)

Enzyme-linked immunosorbent assay (ELISA), (Foundations Volume 2, Chapter 40)

in Lyme disease, (Clinical Volume 2, Chapter 5) (Foundations Volume 2, Chapter 75)

for Toxoplasma gondii, (Clinical Volume 4, Chapter 46)

in uveitis, (Clinical Volume 4, Chapter 35)

in viral infections, (Foundations Volume 2, Chapter 88)

Enzymes

antioxidant

cataract risk reduction and, (Clinical Volume 1, Chapter 72C)

in eye, (Clinical Volume 1, Chapter 72C)

replacement therapy in gyrate atrophy, (Clinical Volume 3, Chapter 25)

Enzyme(s)

matrix-degrading, scleral, (Foundations Volume 1, Chapter 23)

in Pseudomonas infections, (Foundations Volume 2, Chapter 42) (Foundations Volume 2, Chapter 52)

restriction, (Foundations Volume 1, Chapter 19A)

in prenatal diagnosis, (Foundations Volume 3, Chapter 56)

in tears, (Foundations Volume 2, Chapter 3)

vitreous reactions, (Foundations Volume 1, Chapter 16)

EOG. See Electro-oculography/oculogram (EOG)

Eosinophil chemotactic factor of anaphylaxis (ECF-A), in inflammation, (Foundations Volume 2, Chapter 27)

Eosinophil granule major basic protein (EMBP), in inflammation, (Foundations Volume 2, Chapter 27)

Eosinophilia

angiolymphoid hyperplasia with. (See Kimura’s disease)

in Churg-Strauss syndrome, (Clinical Volume 2, Chapter 35)

Eosinophilic granuloma, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 17) (Foundations Volume 3, Chapter 31) See also Histiocytosis X

of lacrimal fossa, (Clinical Volume 2, Chapter 24)

Eosinophils, (Foundations Volume 2, Chapter 25) (Foundations Volume 2, Chapter 40)

inflammation and, (Foundations Volume 2, Chapter 27) (Foundations Volume 3, Chapter 1)

Eosinophil(s)

in conjunctival scrapings, in vernal keratoconjunctivitis, (Clinical Volume 4, Chapter 9)

in immune response, (Clinical Volume 4, Chapter 2)

Ephaptic transmission, in facial nerve, (Foundations Volume 1, Chapter 37)

Ephedrine

ocular toxicity, (Clinical Volume 5, Chapter 37)

systemic toxicity, (Clinical Volume 5, Chapter 37)

Epiblepharon, (Foundations Volume 1, Chapter 5)

Epibulbar osseous choristoma, (Clinical Volume 4, Chapter 10)

Epibulbar tumors

choristoma, (Foundations Volume 1, Chapter 40) (Foundations Volume 3, Chapter 8) (Foundations Volume 3, Chapter 9)

ultrasound biomicroscopy, (Foundations Volume 2, Chapter 106)

Epicanthal folds, repair, (Clinical Volume 5, Chapter 88)

Epicanthus, (Foundations Volume 1, Chapter 5) (Foundations Volume 3, Chapter 53)

Epidemic keratoconjunctivitis, (Clinical Volume 4, Chapter 17) (Foundations Volume 2, Chapter 96)

Epidemic ocular infection, (Foundations Volume 2, Chapter 43)

adenovirus conjunctivitis, (Foundations Volume 2, Chapter 43)

Epidemic typhus, 2, (Foundations Volume 2, Chapter 58)

Epidemiology

of ocular infections, (Foundations Volume 2, Chapter 43) (Foundations Volume 2, Chapter 65) See also specific infections

analytic studies, (Foundations Volume 2, Chapter 43)

anecdotal studies, (Foundations Volume 2, Chapter 43)

blindness and, 2, (Foundations Volume 2, Chapter 43)

burden of disease and, (Foundations Volume 2, Chapter 43)

case-comparison studies, (Foundations Volume 2, Chapter 43)

case definition, (Foundations Volume 2, Chapter 43)

case reports, (Foundations Volume 2, Chapter 43)

case series, (Foundations Volume 2, Chapter 43)

causality, (Foundations Volume 2, Chapter 43)

cohort studies, (Foundations Volume 2, Chapter 43)

correlational studies, (Foundations Volume 2, Chapter 43)

descriptive studies, (Foundations Volume 2, Chapter 43)

disease frequency and, (Foundations Volume 2, Chapter 43)

emergence of ophthalmic epidemiology, (Foundations Volume 2, Chapter 43)

epidemics and outbreaks, (Foundations Volume 2, Chapter 43)

experimental studies, (Foundations Volume 2, Chapter 43)

features and determinants of common infections, (Foundations Volume 2, Chapter 43)

infectivity, (Foundations Volume 2, Chapter 43)

laboratory criteria, (Foundations Volume 2, Chapter 43)

pathogenicity, (Foundations Volume 2, Chapter 43)

population sampling, (Foundations Volume 2, Chapter 43)

precision and, (Foundations Volume 2, Chapter 43)

prevention and, (Foundations Volume 2, Chapter 43)

screening, (Foundations Volume 2, Chapter 43)

sources, (Foundations Volume 2, Chapter 43)

strategies, (Foundations Volume 2, Chapter 43)

surveillance, (Foundations Volume 2, Chapter 43)

surveys, (Foundations Volume 2, Chapter 43)

transmission of disease and, (Foundations Volume 2, Chapter 43)

validity and, (Foundations Volume 2, Chapter 43)

in teratology, (Foundations Volume 1, Chapter 39)

Epidermal cysts, (Foundations Volume 3, Chapter 7)

Epidermal growth factor, and lens of eye, (Clinical Volume 1, Chapter 72A)

Epidermal inclusion cyst, of eyelid, (Clinical Volume 4, Chapter 3)

Epidermal inclusion cysts, milia, (Foundations Volume 3, Chapter 7)

Epidermal necrolysis, toxic, (Foundations Volume 2, Chapter 29) (Clinical Volume 5, Chapter 27)

histology, (Clinical Volume 5, Chapter 27)

immunology, (Clinical Volume 5, Chapter 27)

Epidermal nevus, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 7)

Epidermoid cholesteatoma, (Clinical Volume 2, Chapter 37) (Clinical Volume 2, Chapter 37)

clinical features, (Clinical Volume 2, Chapter 37)

histopathology, (Clinical Volume 2, Chapter 37)

investigations, (Clinical Volume 2, Chapter 37)

treatment, (Clinical Volume 2, Chapter 37)

Epidermoid cyst, (Foundations Volume 3, Chapter 17)

Epidermoid cysts, of orbit, (Clinical Volume 2, Chapter 31)

Epidermolysis bullosa, (Foundations Volume 3, Chapter 7) (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27) (Foundations Volume 3, Chapter 7)

acquired, (Clinical Volume 5, Chapter 27)

atrophic, (Clinical Volume 5, Chapter 27)

cornea in, (Clinical Volume 5, Chapter 27)

defined, (Clinical Volume 5, Chapter 27)

diagnosis, (Clinical Volume 5, Chapter 27)

epidemiology, (Clinical Volume 5, Chapter 27)

forms, (Clinical Volume 5, Chapter 27)

histology, (Clinical Volume 5, Chapter 27)

immunology, (Clinical Volume 5, Chapter 27)

junctional, (Clinical Volume 5, Chapter 27)

ocular involvement, (Clinical Volume 5, Chapter 27)

pathogenesis, (Clinical Volume 5, Chapter 27)

treatment, (Clinical Volume 5, Chapter 27)

Epidermolysis bullosa dystrophica, (Clinical Volume 5, Chapter 27)

Epidermolysis bullosa simplex, (Clinical Volume 5, Chapter 27)

Epidermolytic hyperkeratosis, (Clinical Volume 5, Chapter 27) See also Ichthyosis

Epifrin. See Epinephrine (adrenaline)

Epikeratophakia, (Clinical Volume 1, Chapter 64) (Clinical Volume 6, Chapter 103) See also Keratoplasty

complications, (Foundations Volume 3, Chapter 6)

contraindications, (Clinical Volume 6, Chapter 103)

epithelial healing after, (Clinical Volume 6, Chapter 103)

indications, (Clinical Volume 6, Chapter 103)

infections from, (Clinical Volume 6, Chapter 103)

interface cysts after, (Clinical Volume 6, Chapter 103)

lens dehiscence after, (Clinical Volume 6, Chapter 103)

postoperative care, (Clinical Volume 6, Chapter 103)

power calculation, (Clinical Volume 6, Chapter 103)

inaccuracies, (Clinical Volume 6, Chapter 103)

procedure, (Clinical Volume 6, Chapter 103)

results, (Clinical Volume 6, Chapter 103)

surgical technique, (Clinical Volume 6, Chapter 103)

tissue preparation, (Clinical Volume 6, Chapter 103)

Epikeratoplasty, (Clinical Volume 6, Chapter 45) (Clinical Volume 6, Chapter 100)

history, (Clinical Volume 6, Chapter 45)

indications, (Clinical Volume 6, Chapter 45)

surgical technique, (Clinical Volume 6, Chapter 45)

Epi-lasek, (Clinical Volume 6, Chapter 48)

Epilepsy. See Seizures

Epimyoepithelial island, (Clinical Volume 2, Chapter 35) (Foundations Volume 3, Chapter 17)

Epinephrine (adrenaline), (Clinical Volume 3, Chapter 56) (Foundations Volume 3, Chapter 29) See also Catecholamine(s)

for acute anaphylactic reaction, in allergic rhinoconjunctivitis, (Clinical Volume 4, Chapter 2)

aqueous humor drainage, (Clinical Volume 3, Chapter 45)

aqueous humor formation, (Clinical Volume 3, Chapter 45)

aqueous humor outflow and, (Foundations Volume 3, Chapter 25)

dosage forms, (Clinical Volume 3, Chapter 56)

effect on catecholamine systems, (Foundations Volume 3, Chapter 29)

in glaucoma, (Clinical Volume 3, Chapter 52) (Clinical Volume 3, Chapter 56) (Clinical Volume 3, Chapter 60)

in combination therapy, (Clinical Volume 3, Chapter 56)

efficacy, (Clinical Volume 3, Chapter 56)

indications for, (Clinical Volume 3, Chapter 56)

interaction with anesthetics, (Clinical Volume 6, Chapter 1)

in lacrimal fluid, (Foundations Volume 3, Chapter 29)

with local anesthetics, (Foundations Volume 3, Chapter 35)

ocular teratogenicity, (Foundations Volume 1, Chapter 39)

ocular toxicity, (Clinical Volume 3, Chapter 56) (Clinical Volume 5, Chapter 37)

side effects of, in infants and children, (Foundations Volume 3, Chapter 43)

systemic toxicity, (Clinical Volume 3, Chapter 56) (Clinical Volume 5, Chapter 37)

uveitis due to, (Clinical Volume 3, Chapter 56) (Clinical Volume 4, Chapter 54)

Epiphora, (Clinical Volume 4, Chapter 13)

acute versus chronic, treatment, (Clinical Volume 4, Chapter 13)

baseline tear production and, (Clinical Volume 5, Chapter 79)

causes, (Clinical Volume 4, Chapter 13)

conventional x-ray films and, (Clinical Volume 4, Chapter 13)

dacryocystography in, (Clinical Volume 5, Chapter 79)

diagnostic techniques for, (Clinical Volume 4, Chapter 13)

dye disappearance test and, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

dye tests and, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

evaluation, (Clinical Volume 5, Chapter 79)

examination, (Clinical Volume 4, Chapter 13)

history, (Clinical Volume 4, Chapter 13)

irrigation of canaliculus and, (Clinical Volume 4, Chapter 13) (Clinical Volume 5, Chapter 79)

in lacrimal drainage system disorders, (Clinical Volume 4, Chapter 13 )

lacrimal sac pressure, application, (Clinical Volume 4, Chapter 13)

lacrimal scintigraphy in, (Clinical Volume 5, Chapter 79)

observation, (Clinical Volume 5, Chapter 79)

open nasal space syndrome with, (Clinical Volume 4, Chapter 13)

probing, (Clinical Volume 4, Chapter 13)

irrigation and, (Clinical Volume 5, Chapter 79)

Epiretinal membranes, (Foundations Volume 2, Chapter 11) (Foundations Volume 2, Chapter 113F)

delamination, (Clinical Volume 6, Chapter 56)

in diabetic retinopathy, (Clinical Volume 6, Chapter 56)

etiology of, (Clinical Volume 6, Chapter 56)

in hypertensive retinopathy, (Clinical Volume 3, Chapter 13)

macular, (Clinical Volume 6, Chapter 61 )

clinical features, (Clinical Volume 6, Chapter 61)

pathology, (Clinical Volume 6, Chapter 61)

treatment, (Clinical Volume 6, Chapter 61)

complications, (Clinical Volume 6, Chapter 61)

results, (Clinical Volume 6, Chapter 61)

optical coherence tomography, (Foundations Volume 2, Chapter 107)

peeler cutter scissors for, (Clinical Volume 6, Chapter 56)

peeling, (Clinical Volume 6, Chapter 56)

segmentation, (Clinical Volume 6, Chapter 56)

in sickle cell disease, (Clinical Volume 3, Chapter 17)

in uveitis, (Clinical Volume 4, Chapter 32)

viscodelamination, (Clinical Volume 6, Chapter 56)

vitrectomy and, 4, 6; (Clinical Volume 6, Chapter 61) (Clinical Volume 6, Chapter 56) (Clinical Volume 6, Chapter 57)

Episclera. See Sclera and episclera

anatomy, (Foundations Volume 1, Chapter 23)

melanocytes, (Foundations Volume 3, Chapter 20)

melanosis, differential diagnosis, (Foundations Volume 3, Chapter 20)

Episclera, sclera, (Foundations Volume 1, Chapter 23)

Episcleral venous pressure, (Foundations Volume 3, Chapter 25) (Foundations Volume 3, Chapter 25)

agents changing, (Foundations Volume 3, Chapter 25)

intraocular pressure and, (Foundations Volume 2, Chapter 7)

muscarinic agonists and, (Foundations Volume 3, Chapter 26)

Episcleritis, (Clinical Volume 4, Chapter 23) See also Scleritis; (Foundations Volume 3, Chapter 9)

Episodic headache, (Clinical Volume 2, Chapter 16)

clinical manifestations, (Clinical Volume 4, Chapter 23)

corneal changes in, (Clinical Volume 4, Chapter 23)

course, (Clinical Volume 4, Chapter 23)

etiology, (Clinical Volume 4, Chapter 23)

glaucoma and, (Clinical Volume 3, Chapter 54D)

in gout, (Clinical Volume 4, Chapter 15)

history of patient with, (Clinical Volume 4, Chapter 23)

inflammatory pseudotumor and, (Clinical Volume 2, Chapter 27)

in leprosy, (Clinical Volume 5, Chapter 63)

nodular, (Clinical Volume 4, Chapter 23)

phlyctenular keratoconjunctivitis versus, (Clinical Volume 4, Chapter 8)

pathology, (Clinical Volume 4, Chapter 23)

prognosis, (Clinical Volume 4, Chapter 23)

treatment, (Clinical Volume 4, Chapter 23)

tuberculosis, (Clinical Volume 4, Chapter 58)

Epitarsus, coloboma and, (Foundations Volume 3, Chapter 8)

Epithelial basement membrane dystrophy. See Map-dot-fingerprint dystrophy

Epithelial cells

in cytologic examination, (Foundations Volume 2, Chapter 40)

in wound healing, 2, (Foundations Volume 3, Chapter 6)

Epithelial cysts, (Clinical Volume 2, Chapter 6)

Epithelial dystrophy

basement membrane, 2–3, (Foundations Volume 3, Chapter 63)

juvenile, Meesmann’s, 3–5, (Foundations Volume 3, Chapter 63)

Epithelial edema, from contact lens, (Clinical Volume 1, Chapter 55)

Epithelial erosions

bandage lenses and, (Clinical Volume 1, Chapter 56)

punctate, (Clinical Volume 4, Chapter 17)

Epithelial facet, (Foundations Volume 3, Chapter 6)

Epithelial-fiber interface (EFI), (Clinical Volume 1, Chapter 71A)

Epithelial inclusion cyst, (Clinical Volume 6, Chapter 33)

Epithelial inclusion cyst, conjunctival, (Foundations Volume 3, Chapter 8)

Epithelial keratitis, (Foundations Volume 2, Chapter 97)

herpes simplex, (Clinical Volume 4, Chapter 19 )

punctate, in herpes simplex keratitis, (Clinical Volume 4, Chapter 19)

in staphylococcal lid infection, (Clinical Volume 4, Chapter 22)

Epithelial keratopathy

punctate, (Clinical Volume 4, Chapter 17)

contact lens-associated, (Clinical Volume 4, Chapter 27)

subepithelial keratopathy combined with, (Clinical Volume 4, Chapter 17)

Epithelial lesions, (Clinical Volume 4, Chapter 17)

Epithelial microcysts, punctate, (Clinical Volume 4, Chapter 17)

Epithelial rejection line, in corneal graft rejection, (Clinical Volume 4, Chapter 2) (Clinical Volume 6, Chapter 26)

Epithelial tumors, (Foundations Volume 3, Chapter 7) (Foundations Volume 3, Chapter 7)

Epitheliitis, retinal pigment, (Clinical Volume 4, Chapter 37) (Clinical Volume 4, Chapter 49) (Clinical Volume 4, Chapter 57)

ancillary testing, (Clinical Volume 4, Chapter 49)

differential diagnosis, (Clinical Volume 4, Chapter 49)

history, (Clinical Volume 4, Chapter 49)

symptoms, (Clinical Volume 4, Chapter 49)

Epithelioid cells, (Foundations Volume 3, Chapter 20)

Epithelioid hemangioma, (Clinical Volume 2, Chapter 37)

clinical features, (Clinical Volume 2, Chapter 37)

differential diagnosis, (Clinical Volume 2, Chapter 37)

histopathology, (Clinical Volume 2, Chapter 37)

treatment, (Clinical Volume 2, Chapter 37)

Epithelioid histiocytes, inflammation and, (Foundations Volume 3, Chapter 1)

Epithelioid melanoma, (Foundations Volume 3, Chapter 20)

Epithelioma

calcifying, Malherbe’s, (Foundations Volume 3, Chapter 7)

Epithelium, (Foundations Volume 1, Chapter 8)

anchoring fibrils, plaques, (Foundations Volume 1, Chapter 8)

anchoring structures, (Foundations Volume 1, Chapter 8)

apical cells, (Foundations Volume 1, Chapter 8)

basal cells, (Foundations Volume 1, Chapter 8)

basal lamina, (Foundations Volume 1, Chapter 8)

basement membrane controversy, (Foundations Volume 1, Chapter 8)

hemidesmosomes, (Foundations Volume 1, Chapter 8)

wing cells, (Foundations Volume 1, Chapter 8)

Epithelium. See also Pigment epithelium

ciliary

embryology, (Foundations Volume 1, Chapter 2)

junction of nonpigmented and pigmented, (Foundations Volume 1, Chapter 13)

nonpigmented, (Foundations Volume 1, Chapter 13)

pigmented, (Foundations Volume 1, Chapter 13)

conjunctival, (Foundations Volume 1, Chapter 29)

benign tumors, (Clinical Volume 4, Chapter 10)

cysts, (Foundations Volume 1, Chapter 29)

goblet cells, (Foundations Volume 1, Chapter 29)

lesions, (Foundations Volume 3, Chapter 8)

limbal, (Foundations Volume 1, Chapter 29)

malignant lesions, (Clinical Volume 4, Chapter 10)

nonpigmented, tumors of, (Clinical Volume 4, Chapter 68)

tarsal, (Foundations Volume 1, Chapter 29)

corneal, (Foundations Volume 1, Chapter 8) (Foundations Volume 2, Chapter 4)

apical cells, (Foundations Volume 1, Chapter 8)

barrier function, (Foundations Volume 2, Chapter 4) (Foundations Volume 2, Chapter 61)

basal cells, (Foundations Volume 1, Chapter 8)

basement membrane, (Foundations Volume 1, Chapter 8)

controversy, (Foundations Volume 1, Chapter 8)

defect, in bacterial adherence, (Foundations Volume 2, Chapter 42)

dystrophy, (Foundations Volume 1, Chapter 63)

electrophysiology, (Foundations Volume 2, Chapter 4)

embryology, (Foundations Volume 1, Chapter 2)

folds in, (Foundations Volume 2, Chapter 20)

function, (Foundations Volume 2, Chapter 4)

inflammation, nonulcerative, (Foundations Volume 3, Chapter 9)

injury, (Foundations Volume 2, Chapter 4)

ion transport, (Foundations Volume 2, Chapter 4)

metabolism, (Foundations Volume 2, Chapter 4)

microscopic anatomy, (Foundations Volume 2, Chapter 4)

shadows created by, (Foundations Volume 2, Chapter 20)

wing cells, (Foundations Volume 1, Chapter 8)

wound healing, 2, (Foundations Volume 2, Chapter 4) (Foundations Volume 3, Chapter 6)

corneal. (See Cornea, epithelium)

cutaneous, benign tumors of, (Foundations Volume 3, Chapter 7)

downgrowth, (Foundations Volume 3, Chapter 19)

after cataract extraction, (Foundations Volume 3, Chapter 6)

ingrowth, after LASIK, (Foundations Volume 3, Chapter 6)

lacrimal system, tumors, (Foundations Volume 3, Chapter 7)

lens, (Foundations Volume 1, Chapter 15) (Foundations Volume 2, Chapter 10) (Foundations Volume 3, Chapter 12)

of lens, (Clinical Volume 1, Chapter 71)

decompensation, in age-related cataract, (Clinical Volume 1, Chapter 73)

healing, after epikeratophakia, (Clinical Volume 6, Chapter 103)

ocular surface, host defense against bacterial and fungal disease and, (Foundations Volume 2, Chapter 45)

Epitrate. See Epinephrine (adrenaline)

Epitrichial cells, (Foundations Volume 1, Chapter 15)

Eppy/N. See Epinephrine (adrenaline)

Epsilon-Aminocaproic acid, (Foundations Volume 3, Chapter 41)

Epstein-Barr virus (EBV), (Clinical Volume 2, Chapter 6) (Clinical Volume 4, Chapter 7) (Clinical Volume 4, Chapter 45) (Clinical Volume 5, Chapter 33) (Foundations Volume 2, Chapter 28) (Foundations Volume 2, Chapter 85) (Foundations Volume 2, Chapter 91)

acyclovir for, (Foundations Volume 3, Chapter 37)

in conjunctivitis, (Clinical Volume 4, Chapter 4)

diagnosis, (Foundations Volume 2, Chapter 40) (Foundations Volume 2, Chapter 88) (Foundations Volume 2, Chapter 91)

immunopathogenesis, (Foundations Volume 2, Chapter 85)

life cycle, molecular genetics, (Foundations Volume 2, Chapter 91)

multiple sclerosis and, (Foundations Volume 2, Chapter 35)

as normal inhabitant of eye, (Foundations Volume 2, Chapter 41)

ocular disease due to, (Foundations Volume 2, Chapter 91)

epidemiology, (Foundations Volume 2, Chapter 43)

treatment of, (Foundations Volume 2, Chapter 91)

serology, (Foundations Volume 2, Chapter 40)

in Sjorgren’s syndrome, (Clinical Volume 4, Chapter 2)

EPTFE. See Polytetrafluoroethylene (PTFE)

Equestrian sports, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Equidistance horopter, (Foundations Volume 2, Chapter 24) See also Horopter

Equity

distributive, (Clinical Volume 5, Chapter 69)

in health economics, (Clinical Volume 5, Chapter 69)

horizontal, (Clinical Volume 5, Chapter 69)

vertical, (Clinical Volume 5, Chapter 69)

Equivalent background, adaptation and, (Foundations Volume 2, Chapter 16)

Equivalent light hypothesis, (Clinical Volume 3, Chapter 2)

Erdheim-Chester disease, (Clinical Volume 2, Chapter 35) (Clinical Volume 2, Chapter 39) (Foundations Volume 3, Chapter 17)

Erectile agent, ocular toxicity, (Clinical Volume 5, Chapter 37)

ERG. See Electroretinography/Electroretinogram

Erggelet space, (Clinical Volume 6, Chapter 51) (Foundations Volume 1, Chapter 16)

Ergonomic tactics to prevent visual fatigue, (Clinical Volume 5, Chapter 47)

Ergonovine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Ergotamine, for cluster headache, (Clinical Volume 2, Chapter 16)

Ergotamine tartrate, for migraine, (Clinical Volume 2, Chapter 16) (Clinical Volume 2, Chapter 19)

Ergot derivatives

for migraine, (Clinical Volume 2, Chapter 16)

for prolactinomas, (Clinical Volume 2, Chapter 6)

Erosions, corneal

in Acanthamoeba keratitis, (Clinical Volume 4, Chapter 18A)

contact lens-associated, (Clinical Volume 4, Chapter 27)

ERP (early receptor potential), (Foundations Volume 2, Chapter 13)

Eruptive syringomas, (Foundations Volume 3, Chapter 7)

Erysipelas, (Clinical Volume 4, Chapter 22)

cellulitis in, (Clinical Volume 4, Chapter 25) (Foundations Volume 2, Chapter 49) (Foundations Volume 3, Chapter 7)

Erythema migrans, in Lyme disease, (Foundations Volume 2, Chapter 75)

Erythema multiforme, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27) (Foundations Volume 2, Chapter 29) (Foundations Volume 3, Chapter 7)

clinical features, (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 12)

conjunctiva and, (Foundations Volume 3, Chapter 8)

cornea in, (Clinical Volume 5, Chapter 27)

defined, (Clinical Volume 5, Chapter 27)

diagnosis, (Clinical Volume 5, Chapter 27)

differential diagnosis, (Clinical Volume 4, Chapter 12)

epidemiology, (Clinical Volume 5, Chapter 27)

histology, (Foundations Volume 2, Chapter 29)

histopathology, (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27)

immunopathology, (Foundations Volume 2, Chapter 29) (Clinical Volume 4, Chapter 2) (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27)

ocular involvement, (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27)

pathogenesis, (Clinical Volume 5, Chapter 27)

precipitating factors, (Clinical Volume 4, Chapter 12)

treatment, (Clinical Volume 4, Chapter 12) (Clinical Volume 5, Chapter 27)

Erythema nodosum, (Foundations Volume 2, Chapter 29)

associated conditions, (Foundations Volume 2, Chapter 29)

histology, (Foundations Volume 2, Chapter 29)

immunopathology, (Foundations Volume 2, Chapter 29)

Erythema nodosum leprosum, (Foundations Volume 2, Chapter 56)

Erythrocytes, (Foundations Volume 2, Chapter 40)

Erythrocyte(s), ghost, (Clinical Volume 3, Chapter 7)

Erythrocyte sedimentation rate

in orbital inflammation, (Clinical Volume 2, Chapter 35)

in temporal arteritis, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 16) (Clinical Volume 2, Chapter 35)

in uveitis, (Clinical Volume 4, Chapter 37)

Erythromycin, (Clinical Volume 4, Chapter 26)

adverse effects, (Foundations Volume 3, Chapter 39)

adverse reactions, (Clinical Volume 4, Chapter 26) (Clinical Volume 5, Chapter 37)

chemistry, (Foundations Volume 3, Chapter 39)

for chlamydial infection, (Clinical Volume 4, Chapter 6)

clinical uses, (Foundations Volume 3, Chapter 39)

for conjunctivitis, (Foundations Volume 3, Chapter 36) (Foundations Volume 3, Chapter 39)

inclusion, (Clinical Volume 4, Chapter 26)

neonatal, (Clinical Volume 4, Chapter 26)

in corneal ulcers, (Clinical Volume 4, Chapter 18)

fortified topical preparation, (Clinical Volume 4, Chapter 18)

in inclusion conjunctivitis

adult, (Clinical Volume 4, Chapter 26)

neonatal, (Clinical Volume 4, Chapter 26)

in infectious eczematoid dermatitis, (Clinical Volume 4, Chapter 22)

for keratitis, (Foundations Volume 3, Chapter 39)

ointments, (Clinical Volume 4, Chapter 26)

for ophthalmia neonatorum, chlamydial, (Clinical Volume 4, Chapter 6)

ophthalmic preparation, (Foundations Volume 3, Chapter 39)

pharmacologic action, (Foundations Volume 3, Chapter 39)

prophylactic, neonatal, (Foundations Volume 2, Chapter 64)

in Ritter’s disease, (Clinical Volume 4, Chapter 22)

subconjunctival dose, (Clinical Volume 4, Chapter 18)

systemic toxicity, (Clinical Volume 5, Chapter 37)

Escherichia coli, corneal ulcers, (Clinical Volume 4, Chapter 18)

Escherichia coli, contact lenses and

Eserine. See Physostigmine

Eserine Sulfate. See Physostigmine

Esodeviations, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 12) See also Esotropia

accommodative, (Clinical Volume 1, Chapter 12) (Clinical Volume 6, Chapter 84)

AC/A ratio in, (Clinical Volume 1, Chapter 12)

characteristics, (Clinical Volume 1, Chapter 12)

clinical course, (Clinical Volume 1, Chapter 12)

clinical investigation, (Clinical Volume 1, Chapter 12)

cycloplegic refraction in, (Clinical Volume 1, Chapter 12)

etiology, (Clinical Volume 1, Chapter 12)

fusional divergence amplitude in, (Clinical Volume 1, Chapter 12)

sensory and motor complications, (Clinical Volume 1, Chapter 12)

treatment, (Clinical Volume 1, Chapter 12)

4 to 8 years, (Clinical Volume 1, Chapter 12)

under 4 years, (Clinical Volume 1, Chapter 12)

8 years and older, (Clinical Volume 1, Chapter 12)

amblyopia and, (Clinical Volume 1, Chapter 10)

Duane retraction syndrome and, (Clinical Volume 1, Chapter 20)

Fresnel lenses, (Clinical Volume 1, Chapter 52)

in hyperopia, (Clinical Volume 1, Chapter 36)

nonaccommodative, (Clinical Volume 1, Chapter 12 )

Esofixation disparity, (Clinical Volume 1, Chapter 5)

Esophoria, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 36)

accommodative, (Clinical Volume 1, Chapter 12) (Clinical Volume 1, Chapter 36)

Fresnel prisms, (Clinical Volume 1, Chapter 52)

fusional convergence amplitudes, (Clinical Volume 1, Chapter 7)

fusional divergence amplitudes, (Clinical Volume 1, Chapter 7)

tonic vergences, (Clinical Volume 1, Chapter 7)

Esotropia, (Clinical Volume 1, Chapter 6)

accommodative, (Clinical Volume 1, Chapter 12) (Clinical Volume 1, Chapter 36)

direct-acting muscarinic agonists in, (Foundations Volume 3, Chapter 26)

indirect-acting muscarinic agonists and, (Foundations Volume 3, Chapter 26)

partial, (Clinical Volume 6, Chapter 84)

with high AC/A ratio, (Clinical Volume 6, Chapter 84)

surgery, (Clinical Volume 6, Chapter 84 )

acquired

acute comitant, (Clinical Volume 2, Chapter 13)

cyclic, (Clinical Volume 2, Chapter 13)

nonaccommodative, (Clinical Volume 1, Chapter 12)

surgery, (Clinical Volume 6, Chapter 84)

progressive, with myopia, (Clinical Volume 2, Chapter 13)

amblyopia and, (Clinical Volume 1, Chapter 10)

Bagolini striated glasses test in, (Clinical Volume 1, Chapter 9)

chromosomal disease and, (Foundations Volume 3, Chapter 59)

congenital, (Clinical Volume 1, Chapter 12) (Clinical Volume 1, Chapter 20)

accommodative estropia and amblyopia in, (Clinical Volume 1, Chapter 12)

diagnosis, (Clinical Volume 1, Chapter 12)

dissociated vertical deviations in, (Clinical Volume 1, Chapter 12)

Fadenoperation in, (Clinical Volume 6, Chapter 91)

management, (Clinical Volume 1, Chapter 12)

surgical approach, (Clinical Volume 1, Chapter 12) (Clinical Volume 6, Chapter 84)

cyclic, (Clinical Volume 1, Chapter 12)

cyclic esotropia, 58–59

dissociated horizontal deviation and, (Clinical Volume 1, Chapter 18)

surgical options, (Clinical Volume 1, Chapter 18)

divergence insufficiency estropia, 58

in Duane retraction syndrome, (Clinical Volume 1, Chapter 20)

early, (Foundations Volume 2, Chapter 24)

with high AC/A ratio, Fadenoperation in, (Clinical Volume 6, Chapter 91)

with impaired sight, (Clinical Volume 1, Chapter 12)

infantile, (Foundations Volume 2, Chapter 24)

surgery, (Clinical Volume 6, Chapter 84 )

late-onset, strabismic amblyopia and, (Clinical Volume 5, Chapter 54)

in Mobius syndrome, (Clinical Volume 1, Chapter 20)

nystagmus blockage syndrome. (See Nystagmus, blockage syndromein)

oblique muscle overaction and, (Clinical Volume 1, Chapter 17)

overcorrection, (Clinical Volume 1, Chapter 12)

in Pierre Robin syndrome, (Clinical Volume 5, Chapter 29)

prism adaptation testing in, (Clinical Volume 1, Chapter 12)

progressive estropia with nyopia, 59

residual, (Clinical Volume 6, Chapter 84)

sensory, surgery, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 1, Chapter 19)

surgery, (Clinical Volume 6, Chapter 84 )

in strabismus fixus, (Clinical Volume 1, Chapter 20)

surgery, (Clinical Volume 6, Chapter 84 )

in accommodative esotropia, (Clinical Volume 6, Chapter 84)

partial, (Clinical Volume 6, Chapter 84)

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

anesthetic considerations, (Clinical Volume 6, Chapter 84)

associated conditions and, (Clinical Volume 6, Chapter 84)

complications, (Clinical Volume 6, Chapter 84)

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

in partial accommodative esotropia with high AC/A ratio, (Clinical Volume 6, Chapter 84)

in partially accommodative esotropia, (Clinical Volume 6, Chapter 84)

in sensory esotropia, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

in congenital esotropia, (Clinical Volume 1, Chapter 12)

sensory results, (Clinical Volume 1, Chapter 12)

contraindications

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

in partial accommodative esotropia with high AC/A ratio, (Clinical Volume 6, Chapter 84)

in partially accommodative esotropia, (Clinical Volume 6, Chapter 84)

in sensory esotropia, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

Fadenoperation, (Clinical Volume 6, Chapter 91)

with impaired sight, (Clinical Volume 1, Chapter 12)

indications

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

in partial accommodative esotropia with high AC/A ratio, (Clinical Volume 6, Chapter 84)

in partially accommodative esotropia, (Clinical Volume 6, Chapter 84)

in sensory esotropia, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

operative considerations, (Clinical Volume 6, Chapter 84)

overcorrection, (Clinical Volume 6, Chapter 84)

postoperative considerations, (Clinical Volume 6, Chapter 84)

preoperative considerations, (Clinical Volume 6, Chapter 84)

procedure

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

in partial accommodative esotropia with high AC/A ratio, (Clinical Volume 6, Chapter 84)

in partially accommodative esotropia, (Clinical Volume 6, Chapter 84)

in sensory esotropia, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

reoperation, (Clinical Volume 6, Chapter 98)

results

in acquired nonaccommodative esotropia, (Clinical Volume 6, Chapter 84)

in infantile esotropia, (Clinical Volume 6, Chapter 84)

in partial accommodative esotropia with high AC/A ratio, (Clinical Volume 6, Chapter 84)

in partially accommodative esotropia, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

in sensory esotropia, (Clinical Volume 6, Chapter 84)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

size of deviation and, (Clinical Volume 6, Chapter 84)

timing, (Clinical Volume 6, Chapter 84)

type of procedure, (Clinical Volume 6, Chapter 84)

undercorrection, (Clinical Volume 6, Chapter 84)

in A and V patterns, (Clinical Volume 6, Chapter 84)

undercorrection, (Clinical Volume 1, Chapter 12)

A and V patterns, surgery, (Clinical Volume 6, Chapter 84)

Worth 4-dot test in, (Clinical Volume 1, Chapter 9)

Espundia, (Foundations Volume 2, Chapter 79)

Essential hypercholesterolemic xanthomatosis, (Clinical Volume 5, Chapter 41)

Esthesioneuroblastoma, orbital, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 24) (Clinical Volume 2, Chapter 46)

Estropia, acute acquired, 57–58

ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity chart, (Foundations Volume 2, Chapter 17)

Ethambutol

ocular toxicity, (Clinical Volume 5, Chapter 37)

ophthalmic side effects, (Clinical Volume 4, Chapter 58)

optic neuropathy from, (Clinical Volume 2, Chapter 5)

in tuberculosis, blepharitis, (Clinical Volume 4, Chapter 22)

Ethanol. See also Alcohol

dependence. (See Alcoholism)

intraocular pressure and, (Foundations Volume 2, Chapter 7) (Foundations Volume 3, Chapter 28)

nystagmus and, (Clinical Volume 2, Chapter 11)

for permanent local anesthesia, (Foundations Volume 3, Chapter 35)

teratogenicity, (Clinical Volume 5, Chapter 39)

Ethchlorvynol

ocular toxicity, (Clinical Volume 5, Chapter 37)

optic neuropathy from, (Clinical Volume 2, Chapter 6)

Ether, discovery of, (Clinical Volume 6, Chapter 1)

Ether theory of light, (Clinical Volume 1, Chapter 31)

Ethics, (Clinical Volume 5, Chapter 68 )

codes, (Clinical Volume 5, Chapter 68)

decision making, (Clinical Volume 5, Chapter 68)

defined, (Clinical Volume 5, Chapter 68)

medicine as moral practice, (Clinical Volume 5, Chapter 68)

of patient’s desire for unnecessary surgery, (Clinical Volume 5, Chapter 68)

of patient’s knowledge of which surgeon will perform surgery, (Clinical Volume 5, Chapter 68)

relation to ophthalmology, (Clinical Volume 5, Chapter 68)

of sight versus life, (Clinical Volume 5, Chapter 68)

of sports medicine, (Clinical Volume 5, Chapter 45)

Ethmoidal arteries, (Foundations Volume 1, Chapter 32)

Ethmoidal foramina, (Foundations Volume 1, Chapter 32)

Ethmoidal mucopyocele, (Foundations Volume 3, Chapter 17)

Ethmoidal sinus, (Clinical Volume 2, Chapter 24)

anatomy, (Foundations Volume 1, Chapter 32)

embryology, (Foundations Volume 1, Chapter 32)

Ethmoid bone, (Clinical Volume 2, Chapter 21) (Foundations Volume 1, Chapter 32)

Ethmoid exenteration, in orbital decompression, (Clinical Volume 2, Chapter 36)

Ethmoiditis, spheno-ethmoiditis, (Clinical Volume 2, Chapter 5)

Ethmoid sinus, (Clinical Volume 2, Chapter 21)

bacterial infection, (Clinical Volume 4, Chapter 25) See also Cellulitis, orbital

mucoceles, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 6)

tumors, (Clinical Volume 2, Chapter 5)

Ethoxzolamide, systemic toxicity, (Clinical Volume 5, Chapter 37)

Ethylene diamine tetraacetic acid (EDTA), (Foundations Volume 3, Chapter 43)

in contact lens care, (Foundations Volume 2, Chapter 80)

Ethylene oxide, in laboratory disinfection, (Foundations Volume 2, Chapter 47)

Ethylenimine derivatives, (Foundations Volume 3, Chapter 33)

Ethylmalonic aciduria, (Clinical Volume 5, Chapter 19 )

clinical features, (Clinical Volume 5, Chapter 19)

infantile, (Clinical Volume 5, Chapter 19)

pathophysiology, (Clinical Volume 5, Chapter 19)

Etoposide, (Foundations Volume 3, Chapter 33)

Etretinate

ocular toxicity, (Clinical Volume 5, Chapter 37)

in psoriasis, (Clinical Volume 5, Chapter 27)

teratogenicity, (Clinical Volume 5, Chapter 39)

Euryblepharon, (Foundations Volume 1, Chapter 5)

Eutonyl. See Pargyline

Evaporation

corneal edema and, (Clinical Volume 4, Chapter 16A)

Evaporative dry eye, (Foundations Volume 2, Chapter 3)

blepharitis, (Foundations Volume 2, Chapter 3)

blink disorders, (Foundations Volume 2, Chapter 3)

inflammatory dry eye, (Foundations Volume 2, Chapter 3)

lid aperture, lid/globe congruity, (Foundations Volume 2, Chapter 3)

meibomian gland disease, (Foundations Volume 2, Chapter 3)

Eversion

of lacrimal puncta, (Clinical Volume 4, Chapter 13)

lid. (See Ectropionof)

Evisceration, (Clinical Volume 5, Chapter 82) See also Enucleation

anophthalmic socket and, (Clinical Volume 5, Chapter 83)

implants, (Clinical Volume 5, Chapter 83) See also Implants, orbital

Evoked potentials. See Visual evoked potential (VEP)

EVP. See Episcleral venous pressure

Ewing sarcoma. See Sarcoma, Ewing’s

Examination

of children, in congenital motor and sensory anomalies, (Clinical Volume 2, Chapter 13 )

neuro-ophthalmologic, (Clinical Volume 2, Chapter 2) (Clinical Volume 2, Chapter 14 )

in acquired visual loss in childhood, (Clinical Volume 2, Chapter 13)

anatomic and physiologic considerations, (Clinical Volume 2, Chapter 2)

field of vision and, (Clinical Volume 2, Chapter 2)

auscultation in, (Clinical Volume 2, Chapter 14)

binocular fusion, (Clinical Volume 2, Chapter 2)

in blind infant, (Clinical Volume 2, Chapter 13)

case history in, (Clinical Volume 2, Chapter 1 )

color vision, (Clinical Volume 2, Chapter 2)

in comatose patients, (Clinical Volume 2, Chapter 3)

confrontation methods, (Clinical Volume 2, Chapter 2)

conjunctiva in, (Clinical Volume 2, Chapter 14)

contrast sensitivity, (Clinical Volume 2, Chapter 2)

in diplopia, (Clinical Volume 2, Chapter 3)

electrophysiologic measurements, (Clinical Volume 2, Chapter 2)

factitious fields, (Clinical Volume 2, Chapter 2)

field defects, (Clinical Volume 2, Chapter 2 )

forced duction test in, (Clinical Volume 2, Chapter 14)

fundus in, (Clinical Volume 2, Chapter 14)

globe in, (Clinical Volume 2, Chapter 14)

of infants, (Clinical Volume 2, Chapter 3)

intraocular tension in, (Clinical Volume 2, Chapter 14)

lids in, (Clinical Volume 2, Chapter 3) (Clinical Volume 2, Chapter 14)

for ocular motility, (Clinical Volume 2, Chapter 3 )

in comatose patients, (Clinical Volume 2, Chapter 3)

in orbital disease, (Clinical Volume 2, Chapter 29 )

pain and, (Clinical Volume 2, Chapter 3 )

palpation in, (Clinical Volume 2, Chapter 14)

pediatric, (Clinical Volume 2, Chapter 13 )

patient encounter in, (Clinical Volume 2, Chapter 13)

perimetry, (Clinical Volume 2, Chapter 2) See also Perimetry

photostress test, (Clinical Volume 2, Chapter 2)

pupillary light response, (Clinical Volume 2, Chapter 2)

stereopsis, (Clinical Volume 2, Chapter 2)

symptoms as diagnostic clues, (Clinical Volume 2, Chapter 2)

tangent screen, (Clinical Volume 2, Chapter 2)

Valsalva maneuver in, (Clinical Volume 2, Chapter 14)

visual acuity, (Clinical Volume 2, Chapter 2)

visual field, (Clinical Volume 2, Chapter 2 )

visual function, (Clinical Volume 2, Chapter 2 )

preoperative

in children, (Clinical Volume 6, Chapter 80)

psychological considerations, (Clinical Volume 6, Chapter 80)

orbital surgery and, (Clinical Volume 5, Chapter 86)

vitrectomy and, (Clinical Volume 6, Chapter 56)

vitreous, (Clinical Volume 6, Chapter 51)

Exanthem subitum, (Foundations Volume 2, Chapter 93)

Excessively leaking blebs, (Clinical Volume 6, Chapter 15)

Excimer laser, (Clinical Volume 6, Chapter 47) (Clinical Volume 6, Chapter 76) See also Argon lasers

photorefractive keratectomy, videokeratography in, (Clinical Volume 1, Chapter 65)

Excimer laser ablation system, (Clinical Volume 6, Chapter 49)

Excimer laser technology, for lamellar keratoplasty, (Clinical Volume 6, Chapter 26)

Excipients

in oral medications

bioavailability and, (Foundations Volume 3, Chapter 32)

bioinequivalence and, (Foundations Volume 3, Chapter 22)

in topical medications

bioinequivalence and, (Foundations Volume 3, Chapter 22)

protein binding sites and, (Foundations Volume 3, Chapter 23)

Excitotoxicity, optic nerve and, (Foundations Volume 2, Chapter 21)

Excycloduction, (Clinical Volume 1, Chapter 2)

Excyclophoria, (Clinical Volume 1, Chapter 6)

Excyclotropia, (Clinical Volume 1, Chapter 6)

Excyclovergence, (Clinical Volume 1, Chapter 2) (Clinical Volume 1, Chapter 7)

Executive bifocals, (Clinical Volume 1, Chapter 44)

Exenteration, (Clinical Volume 5, Chapter 82)

anophthalmic socket, (Clinical Volume 5, Chapter 83)

ethmoid, in orbital decompression, (Clinical Volume 2, Chapter 36)

indications for, (Clinical Volume 5, Chapter 82)

orbital

in conjunctival tumors, (Clinical Volume 4, Chapter 10)

retinoblastoma and, (Clinical Volume 6, Chapter 109)

uveal melanoma and, (Clinical Volume 6, Chapter 70)

orbital reconstruction and, (Clinical Volume 5, Chapter 82)

procedure for, (Clinical Volume 5, Chapter 82)

Exercise

eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

intraocular pressure and, (Foundations Volume 2, Chapter 7)

and pigment dispersion, (Clinical Volume 3, Chapter 54B)

vestibular, for disequilibrium, (Clinical Volume 2, Chapter 18)

Exfoliation syndrome, (Clinical Volume 3, Chapter 54B) (Clinical Volume 3, Chapter 55) (Clinical Volume 3, Chapter 55)

anterior chamber in, (Clinical Volume 3, Chapter 54B)

cataracts and, (Clinical Volume 3, Chapter 54B)

ciliary body and zonules in, (Clinical Volume 3, Chapter 54B)

clinical features, (Clinical Volume 3, Chapter 54B)

conjunctiva in, (Clinical Volume 3, Chapter 54B)

cornea in, (Clinical Volume 3, Chapter 54B)

differential diagnosis, (Clinical Volume 3, Chapter 54B)

epidemiology, (Clinical Volume 3, Chapter 54B)

glaucoma and, (Clinical Volume 3, Chapter 54B)

angle-closure, (Clinical Volume 3, Chapter 54B)

surgical response, (Clinical Volume 3, Chapter 54B)

histopathology, (Clinical Volume 3, Chapter 54B)

historical background, (Clinical Volume 3, Chapter 54B)

iris in, (Clinical Volume 3, Chapter 54B)

laterality, (Clinical Volume 3, Chapter 54B)

lens in, (Clinical Volume 3, Chapter 54B)

nature of exfoliative material, (Clinical Volume 3, Chapter 54B)

nomenclature, (Clinical Volume 3, Chapter 54B)

pupil in, (Clinical Volume 3, Chapter 54B)

trabecular network in, (Clinical Volume 3, Chapter 54B)

Exfolidating apical cells, (Foundations Volume 1, Chapter 8)

Exit pupil, (Clinical Volume 1, Chapter 30)

aperture and, (Clinical Volume 1, Chapter 30)

Exodeviations. See also Exotropia

AC/A ratio and, (Clinical Volume 1, Chapter 7)

amblyopia and, (Clinical Volume 1, Chapter 10)

Fresnel lenses, (Clinical Volume 1, Chapter 52)

management, (Clinical Volume 1, Chapter 13)

Exofixation disparity, (Clinical Volume 1, Chapter 5)

Exogenously derived causes, cataracts associated with, (Clinical Volume 5, Chapter 41)

Exophoria, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 13)

Fresnel prisms, (Clinical Volume 1, Chapter 52)

fusional convergence amplitudes, (Clinical Volume 1, Chapter 7)

fusional divergence amplitudes, (Clinical Volume 1, Chapter 7)

Exophthalmometry, (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 22)

Exophthalmos

craniofacial anomalies, (Foundations Volume 1, Chapter 41)

in craniostenoses, (Clinical Volume 5, Chapter 29)

in Crouzon’s craniofacial dysostosis, (Clinical Volume 5, Chapter 29)

Crouzon’s syndrome, (Foundations Volume 3, Chapter 58)

Graves’ disease, (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 21) See also Graves’ disease; Thyroid disordersin

intermittent, in orbital varices, (Clinical Volume 2, Chapter 17)

in thyroid orbitopathy, (Clinical Volume 2, Chapter 36)

in thyrotoxicosis ophthalmoplegia, (Clinical Volume 1, Chapter 20)

Exophytic retinoblastoma, 3, (Foundations Volume 3, Chapter 21)

Exotropia, (Clinical Volume 1, Chapter 6) (Clinical Volume 1, Chapter 13)

amblyopia and, (Clinical Volume 1, Chapter 10)

Bagolini striated glasses test in, (Clinical Volume 1, Chapter 9)

and chromosomal anomalies, (Foundations Volume 3, Chapter 59)

in Duane retraction syndrome, (Clinical Volume 1, Chapter 20)

with high AC: A ratio, Fadenoperation in, (Clinical Volume 6, Chapter 91)

intermittent

management, (Clinical Volume 1, Chapter 13 )

surgery, (Clinical Volume 6, Chapter 85 )

in progressive external ophthalmoplegia, (Clinical Volume 1, Chapter 20)

surgery, (Clinical Volume 6, Chapter 85 )

tonic vergences, (Clinical Volume 1, Chapter 7)

in vertical retraction syndrome, (Clinical Volume 1, Chapter 20)

Experimental allergic encephalitis, (Foundations Volume 2, Chapter 35)

Exposure keratopathy, (Clinical Volume 5, Chapter 78)

Expressivity, genetic, defined, (Foundations Volume 3, Chapter 51)

Extending the field in indirect ophthalmology, (Clinical Volume 1, Chapter 63)

External carotid artery, (Foundations Volume 1, Chapter 32)

External limiting membrane, (Foundations Volume 1, Chapter 19)

External ophthalmoplegia. See Ophthalmoplegia(s), external

External scleral sulcus, (Foundations Volume 1, Chapter 1)

External tarsal aponeurectomy, (Clinical Volume 5, Chapter 78)

Extirpation, denervation and, inferior oblique, (Clinical Volume 6, Chapter 87)

Extorsion, (Clinical Volume 1, Chapter 2)

Harada-Ito procedure for, (Clinical Volume 6, Chapter 97)

Extracellular components, in wound healing, (Foundations Volume 3, Chapter 6)

Extracellular recordings, intraretinal, (Foundations Volume 2, Chapter 13)

Extracranial-intracranial arterial bypass surgery, in ocular ischemic syndrome, (Clinical Volume 3, Chapter 12)

Extrageniculate visual systems, functional anatomy, (Foundations Volume 1, Chapter 34) (Clinical Volume 2, Chapter 4)

Extramacular binocular fusion reflex, (Clinical Volume 1, Chapter 8)

Extranodal B-cell marginal zone lymphoma, (Clinical Volume 2, Chapter 39)

Extraocular movements, (Clinical Volume 2, Chapter 22)

Extraocular muscles, (1)38: 2–5. See also specific muscles; See Muscles, extraocular

action, (Foundations Volume 1, Chapter 38) (Foundations Volume 2, Chapter 23)

amplitude of rotation of eye and, (Foundations Volume 2, Chapter 23)

cohesiveness of muscle and, (Foundations Volume 2, Chapter 23)

direction of muscle pull and, (Foundations Volume 2, Chapter 23)

field, (Foundations Volume 2, Chapter 23)

geometry, (Foundations Volume 2, Chapter 23)

innervation to horizontal muscles and, (Foundations Volume 2, Chapter 23)

innervation to vertical muscles and, (Foundations Volume 2, Chapter 23)

length and, (Foundations Volume 2, Chapter 23)

muscle stiffness and, (Foundations Volume 2, Chapter 23)

for positions away from primary position, (Foundations Volume 2, Chapter 23)

primary and secondary, (Foundations Volume 2, Chapter 23)

pulleys, (Foundations Volume 2, Chapter 23)

sideslip over globe and, (Foundations Volume 2, Chapter 23)

size and, (Foundations Volume 2, Chapter 23)

stability of muscle planes in orbit and, (Foundations Volume 2, Chapter 23)

blood supply, (Foundations Volume 1, Chapter 31)

coordination, (Foundations Volume 1, Chapter 31)

depolarizing nicotinic antagonists and, (Foundations Volume 3, Chapter 26)

in Duchenne’s muscular dystrophy, (Foundations Volume 1, Chapter 38)

embryology, (Foundations Volume 1, Chapter 2) (Foundations Volume 1, Chapter 3) (Foundations Volume 1, Chapter 31) (Foundations Volume 1, Chapter 32)

energetics, (Foundations Volume 1, Chapter 31)

fine structure, (Foundations Volume 2, Chapter 23 )

blood flow and, (Foundations Volume 2, Chapter 23)

changes with age and disease and, (Foundations Volume 2, Chapter 23)

contraction and, (Foundations Volume 2, Chapter 23)

differences in tension and, (Foundations Volume 2, Chapter 23)

fascia and, (Foundations Volume 2, Chapter 23)

fatigue and, (Foundations Volume 2, Chapter 23)

mitochondria and, (Foundations Volume 2, Chapter 23)

muscle fiber orientation and, (Foundations Volume 2, Chapter 23)

muscle layers and, (Foundations Volume 2, Chapter 23)

single and multiple innervation and, (Foundations Volume 2, Chapter 23)

T system and, (Foundations Volume 2, Chapter 23)

function, (Foundations Volume 1, Chapter 31 )

functional anatomy, (Foundations Volume 1, Chapter 31 )

gross anatomy, (Foundations Volume 1, Chapter 31)

histochemistry, (Foundations Volume 1, Chapter 31)

indirect-acting muscarinic agonists and, (Foundations Volume 3, Chapter 26)

intraocular pressure and, (Foundations Volume 2, Chapter 7)

mechanical properties, (Foundations Volume 1, Chapter 31)

microscopic anatomy, (Foundations Volume 1, Chapter 31 )

molecular anatomy, (Foundations Volume 1, Chapter 31)

muscle fibers, (Foundations Volume 1, Chapter 31 )

electron microscopy, (Foundations Volume 1, Chapter 31)

function, (Foundations Volume 1, Chapter 31)

light microscopy, (Foundations Volume 1, Chapter 31)

types, (Foundations Volume 1, Chapter 31)

muscle spindles, (Foundations Volume 1, Chapter 31)

myotendinous endings, (Foundations Volume 1, Chapter 31)

nerves, (1)32: 15–16; 31: 10, 28–33

central innervation patterns and coordination, (Foundations Volume 1, Chapter 31)

orbital fascial system and, (Foundations Volume 1, Chapter 32)

orbital tissues and, (Foundations Volume 1, Chapter 31 (Foundations Volume 1, Chapter 32)

sensory receptors, (Foundations Volume 1, Chapter 31)

strabismus surgery and. (See Surgery, strabismus)

Extraocular muscles in pregnancy, (Clinical Volume 5, Chapter 32)

Extraperiosteal orbitotomy, (Clinical Volume 2, Chapter 14) See also Orbitotomy

Extrapyramidal system, (Clinical Volume 2, Chapter 8)

Extrastriate cortex. See also Visual cortex

lesions of, (Foundations Volume 2, Chapter 22 )

Extubation, in children, (Clinical Volume 6, Chapter 81)

Exudates, retinal, (Clinical Volume 3, Chapter 7) See also Cottonwool spots, retinal

in autosomal vitreoretinopathy, (Clinical Volume 3, Chapter 2)

in diabetic retinopathy, 3, (Clinical Volume 3, Chapter 30)

in hypertensive retinopathy, (Clinical Volume 3, Chapter 7) (Clinical Volume 3, Chapter 13)

Exudative detachment of retina

central, (Clinical Volume 3, Chapter 9)

in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A)

in kidney disease, 2, (Clinical Volume 5, Chapter 31)

pediatric, (Clinical Volume 6, Chapter 72)

postoperative, (Clinical Volume 5, Chapter 16)

after scleral buckling, (Clinical Volume 6, Chapter 59)

Exudative retinopathy, (Foundations Volume 3, Chapter 13)

Exudative vitreoretinopathy, familial, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 61)

molecular genetics, (Foundations Volume 3, Chapter 55)

Eye. See also Ocular

face safety program and, (Clinical Volume 5, Chapter 47)

growth of, infantile phases, (Clinical Volume 1, Chapter 34)

immunology of skin diseases that affect, (Foundations Volume 2, Chapter 29 )

metastatic cancer to. (See Metastatic cancer to eye and adnexa)

narrow-angled, gonioscopic evaluation of, (Clinical Volume 3, Chapter 44)

onchocerciasis and, (Clinical Volume 5, Chapter 62)

as optical system, (Clinical Volume 1, Chapter 34)

pulmonary disorders and. (See Pulmonary disorders, eye in)

removal of, (Clinical Volume 5, Chapter 82)

alternatives to, (Clinical Volume 5, Chapter 82)

Eye-associated lymphoid tissue, (Foundations Volume 2, Chapter 45)

Eyeball. See also Eye movement(s)

anterior pole, (Foundations Volume 1, Chapter 1)

anterior segment of, (Foundations Volume 1, Chapter 1)

asymmetry of, (Foundations Volume 1, Chapter 1)

circumference of, (Foundations Volume 1, Chapter 1)

craniofacial anomalies and, (Foundations Volume 1, Chapter 41)

embryology, (Foundations Volume 1, Chapter 32)

geometric axis of, (Foundations Volume 1, Chapter 1)

imaging, (Foundations Volume 1, Chapter 35)

orbit and, (Foundations Volume 1, Chapter 1)

palpation, in intraocular pressure estimation, (Foundations Volume 2, Chapter 7)

posterior pole, (Foundations Volume 1, Chapter 1)

posterior segment of, (Foundations Volume 1, Chapter 1)

rupture, traumatic, (Foundations Volume 3, Chapter 6)

sideslip of muscles over, (Foundations Volume 2, Chapter 23)

surface anatomy of, (Foundations Volume 1, Chapter 1)

topography of, (Foundations Volume 1, Chapter 1)

Eyeball axes, ocular motility and, (Foundations Volume 2, Chapter 23)

Eye Bank Association of America, on antimicrobial prophylaxis, (Foundations Volume 2, Chapter 64)

Eye banks, (Clinical Volume 5, Chapter 61 )

function, (Clinical Volume 5, Chapter 61)

government and, (Clinical Volume 5, Chapter 61)

of India, (Clinical Volume 5, Chapter 61)

structure, (Clinical Volume 5, Chapter 61)

tissue distribution, (Clinical Volume 5, Chapter 61)

tissue evaluation, (Clinical Volume 5, Chapter 61)

tissue harvesting, (Clinical Volume 5, Chapter 61)

tissue preservation, (Clinical Volume 5, Chapter 61)

worldwide situation, (Clinical Volume 5, Chapter 61)

Eyebrows, (Clinical Volume 5, Chapter 75) (Foundations Volume 2, Chapter 1 )

aging and disease states, (Foundations Volume 2, Chapter 1)

deformities, telecanthus and, surgery for, (Clinical Volume 6, Chapter 110)

function, (Foundations Volume 2, Chapter 1)

lacerations, (Clinical Volume 5, Chapter 75)

loss

eyelid trauma and, (Clinical Volume 5, Chapter 75)

in leprosy, 4, (Clinical Volume 5, Chapter 63)

movements, neurologic control, (Foundations Volume 2, Chapter 1)

structure, (Foundations Volume 2, Chapter 1)

Eye charts

in contrast sensitivity testing, (Foundations Volume 2, Chapter 17)

in visual acuity evaluation, (Foundations Volume 2, Chapter 17)

Eye colors, (Clinical Volume 1, Chapter 31)

Eye coordination, adjustment in, (Foundations Volume 2, Chapter 23)

alignment and, (Foundations Volume 2, Chapter 23)

concomitance and, (Foundations Volume 2, Chapter 23)

gaze function and, (Foundations Volume 2, Chapter 23)

Eye drops. See also specific type

lacrimal canaliculi and, (Clinical Volume 4, Chapter 13)

mydriatic, (Clinical Volume 5, Chapter 39)

preservatives, side effects, in infants and children, (Foundations Volume 3, Chapter 43)

volume, and bioavailability, (Foundations Volume 3, Chapter 22)

Eye examinations for environmental and medical surveillance, (Clinical Volume 5, Chapter 47)

Eyelashes. See Lashes

Eyelashes, host defenses and, (Foundations Volume 2, Chapter 45)

Eyelid manifestations of gastrointestinal diseases, (Clinical Volume 5, Chapter 30)

Eyelids. See Lid(s)

Eyelids in pregnancy, (Clinical Volume 5, Chapter 32)

Eye medication

topical, adverse effects, (Foundations Volume 3, Chapter 43)

Eye medicine, traditional, blindness and, (Clinical Volume 5, Chapter 53)

Eye-movement hypothesis, (Foundations Volume 2, Chapter 24)

Eye movements, (Foundations Volume 1, Chapter 38)

abducens nucleus, (Foundations Volume 1, Chapter 38)

lesions of, (Foundations Volume 1, Chapter 38)

cerebellar influences, eye movements, (Foundations Volume 1, Chapter 38)

cerebellar lesions, (Foundations Volume 1, Chapter 38)

cerebral control of, (Foundations Volume 1, Chapter 38)

conjugate horizontal movements, motor commands for, (Foundations Volume 1, Chapter 38)

cranial nerves, anatomy of, (Foundations Volume 1, Chapter 38)

Duchenne’s muscular dystrophy, (Foundations Volume 1, Chapter 38)

fixatuon mechanism, (Foundations Volume 1, Chapter 38)

gaze, common disturbances of, with hemispheric lesions, (Foundations Volume 1, Chapter 38)

gaze-evoked nystagmus, (Foundations Volume 1, Chapter 38)

Hering’s law, (Foundations Volume 1, Chapter 38)

horizontal gaze, brainstem control of, (Foundations Volume 1, Chapter 38)

interstitial nucleus of Cajal, (Foundations Volume 1, Chapter 38)

medial longitudina fasciculus, rostral interstitial nucleus of, (Foundations Volume 1, Chapter 38)

medical longitudinal fasciculus, lesions of, (Foundations Volume 1, Chapter 38)

medical vestibular nuclei (MVN), lesions involving, (Foundations Volume 1, Chapter 38)

nystagmus

caused by disturbance of visual fixation mechanism, (Foundations Volume 1, Chapter 38)

caused by vestibular disturbances, (Foundations Volume 1, Chapter 38)

congenital, (Foundations Volume 1, Chapter 38)

eccentric gaze-holding mechanism, disturbance of, (Foundations Volume 1, Chapter 38)

multiple sclerosis, (Foundations Volume 1, Chapter 38)

Pelizaeus-Merzbacher disease, (Foundations Volume 1, Chapter 38)

scheme for interpreting, (Foundations Volume 1, Chapter 38)

toluene intoxication, (Foundations Volume 1, Chapter 38)

of uncertain origin, (Foundations Volume 1, Chapter 38)

ocular motor periphery, extraocular muscles, (Foundations Volume 1, Chapter 38)

one-and-a-half syndrome, (Foundations Volume 1, Chapter 38)

optokinetic eye movements, (Foundations Volume 1, Chapter 38)

orbital contents, anatomy of, rotations of eyes, (Foundations Volume 1, Chapter 38)

periodic alternating nystagmus, (Foundations Volume 1, Chapter 38)

pons and medulla on horizontal gaze, lesions of, (Foundations Volume 1, Chapter 38)

properties of, (Foundations Volume 1, Chapter 38)

pursuit system, (Foundations Volume 1, Chapter 38)

saccadic intrusions, (Foundations Volume 1, Chapter 38)

ocular flutter, (Foundations Volume 1, Chapter 38)

saccadic system, (Foundations Volume 1, Chapter 38)

seesaw nystagmus, (Foundations Volume 1, Chapter 38)

skew deviation, (Foundations Volume 1, Chapter 38)

smooth pursuit eye movements, (Foundations Volume 1, Chapter 38)

vertical vestibular and, (Foundations Volume 1, Chapter 38)

superior colliculus, (Foundations Volume 1, Chapter 38)

upbeat nystagmus, (Foundations Volume 1, Chapter 38)

vergence eye movements, (Foundations Volume 1, Chapter 38)

brainstem control, (Foundations Volume 1, Chapter 38)

disorders of vergence, (Foundations Volume 1, Chapter 38)

vergence movements, motor commands for, (Foundations Volume 1, Chapter 38)

vertical gaze

brainstem control of, (Foundations Volume 1, Chapter 38)

effects of midbrain lesions on, (Foundations Volume 1, Chapter 38)

visually elicited, (Clinical Volume 2, Chapter 10)

full-threshold static perimetry, (Clinical Volume 2, Chapter 10)

short wavelength automated perimetry, (Clinical Volume 2, Chapter 10)

Swedish interactive threshold algorithm, (Clinical Volume 2, Chapter 10)

Wallenberg’s syndrome, (Foundations Volume 1, Chapter 38)

Eye movement(s), (Foundations Volume 1, Chapter 38. See also Muscle(s); Ocular motility;) See Movements of eye

brain stem control of, (Foundations Volume 1, Chapter 38)

cerebellar control of, (Foundations Volume 1, Chapter 38)

cerebral control of, (Foundations Volume 1, Chapter 38)

cranial nerves and

abducens, (Foundations Volume 1, Chapter 38)

oculomotor, (Foundations Volume 1, Chapter 38)

trochlear, (Foundations Volume 1, Chapter 38)

functional classes, (Foundations Volume 1, Chapter 38)

gaze-holding, (Foundations Volume 1, Chapter 38)

gaze-shifting, (Foundations Volume 1, Chapter 38)

horizontal gaze, (Foundations Volume 1, Chapter 38)

light adaptation and, (Foundations Volume 2, Chapter 16)

miniature, psychophysics of, (Foundations Volume 2, Chapter 23)

purpose and types of, (Foundations Volume 2, Chapter 23)

sensors, (Foundations Volume 2, Chapter 109)

vergence, (Foundations Volume 1, Chapter 38)

vertical gaze, (Foundations Volume 1, Chapter 38)

Eye-opening apraxia, (Clinical Volume 2, Chapter 10)

Eyepiece, (Clinical Volume 1, Chapter 30)

Eye position

basic geometry of. (See Ocular motility, basic geometry of eye positions and)

sense of, (Clinical Volume 1, Chapter 4)

Eye protection

after penetrating keratoplasty, (Clinical Volume 6, Chapter 26)

in blunt trauma prevention, (Clinical Volume 3, Chapter 31)

ptosis surgery and, (Clinical Volume 5, Chapter 78)

sunglasses in. (See Sunglasses)

Eye safety practitioners, essential duties of, (Clinical Volume 5, Chapter 47)

Eye surgery anesthesia, (Clinical Volume 6, Chapter 1)

anatomic perspectives, (Clinical Volume 6, Chapter 1)

for cataract surgery, (Clinical Volume 6, Chapter 1)

complications of ocular anesthesia, (Clinical Volume 6, Chapter 1)

for corneal surgery, (Clinical Volume 6, Chapter 1)

facial nerve blocks, (Clinical Volume 6, Chapter 1)

general anesthesia, (Clinical Volume 6, Chapter 1)

for glaucoma surgery, (Clinical Volume 6, Chapter 1)

historical perspectives, (Clinical Volume 6, Chapter 1)

for oculoplastic surgery, (Clinical Volume 6, Chapter 1)

parabulbar (sub-Tenon’s) anesthesia, (Clinical Volume 6, Chapter 1)

peribulbar anesthesia, (Clinical Volume 6, Chapter 1)

for refractive surgery, (Clinical Volume 6, Chapter 1)

retrobulbar anesthesia, (Clinical Volume 6, Chapter 1)

for strabismus surgery, (Clinical Volume 6, Chapter 1)

topical anesthesia, (Clinical Volume 6, Chapter 1)

for vitreoretinal surgery, (Clinical Volume 6, Chapter 1)

Eye wall biopsy, diagnostic, (Clinical Volume 4, Chapter 36)

Eyeworm, (Foundations Volume 2, Chapter 79)

Eyeworm, African, (Clinical Volume 4, Chapter 22)

Subject Index F

Fabry disease, (Foundations Volume 1, Chapter 9) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B) (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19) (Clinical Volume 5, Chapter 41)

carriers, (Clinical Volume 5, Chapter 19)

cataract, (Clinical Volume 1, Chapter 73) (Clinical Volume 3, Chapter 29) (Clinical Volume 5, Chapter 41)

cataract from, (Clinical Volume 1, Chapter 73)

clinical features, (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

conjunctiva in, (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

cornea in, (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19) (Clinical Volume 5, Chapter 31)

diagnosis, (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

differential diagnosis, (Clinical Volume 4, Chapter 15)

genetics, (Clinical Volume 3, Chapter 29)

lens in, (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

management, (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15)

metabolic defect, (Clinical Volume 3, Chapter 29)

neuropathology, (Clinical Volume 3, Chapter 29)

ocular findings in, (Clinical Volume 3, Chapter 29) (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

retina in, (Clinical Volume 4, Chapter 15) (Clinical Volume 5, Chapter 19)

vortex keratopathy in, (Clinical Volume 4, Chapter 17) (Clinical Volume 5, Chapter 19)

Face

aging and disease states, (Foundations Volume 2, Chapter 1)

angiomas, in Sturge-Weber syndrome, (Clinical Volume 3, Chapter 51)

carcinoma, (Clinical Volume 2, Chapter 3)

cellulitis, in infancy, (Clinical Volume 4, Chapter 25)

clefts, (Clinical Volume 2, Chapter 30 )

congenital diplegia. (See Mobius syndrome)

deformity syndromes, (Clinical Volume 5, Chapter 29)

eye safety program and, (Clinical Volume 5, Chapter 47)

function, (Foundations Volume 2, Chapter 1)

hemiatrophy. (See Parry-Romberg syndrome)

in mandibulofacial dysostosis, (Clinical Volume 5, Chapter 29)

midface, trauma, nasolacrimal drainage and, (Clinical Volume 5, Chapter 79)

in oculoauriculovertebral dysplasia, (Clinical Volume 5, Chapter 29)

in oculomandibulofacial dyscephaly, (Clinical Volume 5, Chapter 29)

in oculovertebral dysplasia, (Clinical Volume 5, Chapter 29)

in Pierre Robin syndrome, (Clinical Volume 5, Chapter 29)

structure, (Foundations Volume 2, Chapter 1)

and perimetric testing, (Clinical Volume 3, Chapter 49)

Face-down position, and retinochoroidal infarction, (Clinical Volume 2, Chapter 5)

Face perception, disorders, (Clinical Volume 2, Chapter 7)

Face perception, disorders of, (Clinical Volume 2, Chapter 7)

Face protectors. See also Sports medicine, protective devices

Facial artery, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 30)

Facial cleft syndromes, (Foundations Volume 1, Chapter 41) (Foundations Volume 3, Chapter 61)

Facial-digital-genital syndrome, (Foundations Volume 3, Chapter 59)

Facial dysmorphism, cataract associated with, (Clinical Volume 5, Chapter 41)

Facial fissure, minimal, (Foundations Volume 3, Chapter 7)

Facial microsomia, (6)110: 10. See also Craniofacial anomalies

Facial myokymia, (Foundations Volume 1, Chapter 37)

Facial nerve, (Clinical Volume 2, Chapter 8) (Foundations Volume 1, Chapter 30) (Foundations Volume 1, Chapter 32) (Foundations Volume 1, Chapter 37)

acoustic neuromas and, (Clinical Volume 2, Chapter 8)

in AIDS, (Foundations Volume 1, Chapter 37)

anatomy, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 37) (Clinical Volume 2, Chapter 8 )

blood supply, (Clinical Volume 2, Chapter 8)

cerebellopontine angle, (Clinical Volume 2, Chapter 8)

cortex, (Clinical Volume 2, Chapter 8)

extracranial segment, (Clinical Volume 2, Chapter 8)

extrapyramidal system, (Clinical Volume 2, Chapter 8)

pons, (Clinical Volume 2, Chapter 8)

supranuclear pathway, (Clinical Volume 2, Chapter 8)

temporal bone, (Clinical Volume 2, Chapter 8)

anesthetic blocks. (See Anesthesia, facial nerve blocks)

anomalies, (Clinical Volume 2, Chapter 8)

autonomic function, (Foundations Volume 1, Chapter 37)

birth trauma, (Clinical Volume 2, Chapter 8)

blink reflex and, (Clinical Volume 2, Chapter 8)

blood supply, (Clinical Volume 2, Chapter 8)

botulism and, (Clinical Volume 2, Chapter 8)

childhood disorders, (Clinical Volume 2, Chapter 8)

embryology, (Foundations Volume 1, Chapter 37) (Clinical Volume 2, Chapter 8)

extramedullary segment, (Clinical Volume 2, Chapter 8)

eyelid opening disorders and, (Clinical Volume 2, Chapter 8)

facial neuromas and, (Clinical Volume 2, Chapter 8)

function, assessment, (Clinical Volume 2, Chapter 8)

hyperkinetic disorders, (Clinical Volume 2, Chapter 8)

infranuclear segment, (Foundations Volume 1, Chapter 37)

intramedullary segment, (Clinical Volume 2, Chapter 8)

intratemporal segment, (Clinical Volume 2, Chapter 8)

in leprosy, 4, (Clinical Volume 5, Chapter 63)

lesions

extracranial, (Clinical Volume 2, Chapter 8)

infranuclear intracranial, (Clinical Volume 2, Chapter 8)

metastatic, (Clinical Volume 2, Chapter 8)

pseudobulbar palsy, (Clinical Volume 2, Chapter 8)

supranuclear, (Clinical Volume 2, Chapter 8)

topical diagnoses of, (Clinical Volume 2, Chapter 8)

transtemporal bone, (Clinical Volume 2, Chapter 8)

variable sites, (Clinical Volume 2, Chapter 8)

metastatic lesions, (Clinical Volume 2, Chapter 8)

microscopic anatomy, (Foundations Volume 1, Chapter 37)

motor evaluation, (Clinical Volume 2, Chapter 8)

motor function, (Foundations Volume 1, Chapter 37)

myasthenia gravis and, (Clinical Volume 2, Chapter 8)

myotonic dystrophy and, (Clinical Volume 2, Chapter 8)

nervus intermedius of Wrisberg, (Foundations Volume 1, Chapter 37)

neuromas and, (Clinical Volume 2, Chapter 8)

neuropathies, (Clinical Volume 2, Chapter 18)

ear infections, (Clinical Volume 2, Chapter 8)

herpes zoster cephalicus, (Clinical Volume 2, Chapter 8)

infectious mononucleosis, (Clinical Volume 2, Chapter 8)

Lyme disease, (Clinical Volume 2, Chapter 8)

polyradiculopathy, (Clinical Volume 2, Chapter 8)

postimmunization, (Clinical Volume 2, Chapter 8)

nuclear segment, (Foundations Volume 1, Chapter 37)

in orbital disease, (Clinical Volume 2, Chapter 29)

overactivity disorders, (Foundations Volume 1, Chapter 37)

infranuclear, (Foundations Volume 1, Chapter 37)

nuclear, (Foundations Volume 1, Chapter 37)

reflex blepharospasm, (Foundations Volume 1, Chapter 37)

supranuclear, (Foundations Volume 1, Chapter 37)

synkinetic movements, (Foundations Volume 1, Chapter 37)

in Paget’s disease, (Clinical Volume 5, Chapter 29)

palsy

bilateral, (Clinical Volume 1, Chapter 20)

congenital, (Clinical Volume 1, Chapter 20)

paralysis, (Clinical Volume 2, Chapter 8) See also Bell’s palsy

acute porphyrias and, (Clinical Volume 2, Chapter 8)

botulism and, (Clinical Volume 2, Chapter 8)

causes, (Clinical Volume 2, Chapter 8)

in children, (Clinical Volume 2, Chapter 8)

eyelid surgery in, (Clinical Volume 5, Chapter 88)

facial neuromas and, (Clinical Volume 2, Chapter 8)

HIV infection and, (Clinical Volume 2, Chapter 8)

Lyme disease and, (Clinical Volume 2, Chapter 8)

management, (Clinical Volume 2, Chapter 8)

in Mobius syndrome, (Clinical Volume 1, Chapter 20)

paresis, (Clinical Volume 2, Chapter 8)

taste test in, (Clinical Volume 2, Chapter 8)

physiologic facial synkineses and, (Clinical Volume 2, Chapter 8)

porphyrias and, (Clinical Volume 2, Chapter 8)

progressive hemifacial atrophy and, (Clinical Volume 2, Chapter 8)

sarcoidosis and, (Clinical Volume 2, Chapter 8)

sensory function, (Foundations Volume 1, Chapter 37)

supranuclear segment, (Foundations Volume 1, Chapter 37)

taste and, (Clinical Volume 2, Chapter 8)

tear function and, (Clinical Volume 2, Chapter 8)

trauma, (Clinical Volume 2, Chapter 8)

tumors, (Clinical Volume 2, Chapter 8)

underactivity disorders, (Foundations Volume 1, Chapter 37)

infranuclear, (Foundations Volume 1, Chapter 37)

nuclear, (Foundations Volume 1, Chapter 37)

supranuclear, (Foundations Volume 1, Chapter 37)

vascular supply, (Foundations Volume 1, Chapter 37)

in Wegener’s granulomatosis, (Clinical Volume 2, Chapter 35)

Facial nerve blocks, (Clinical Volume 6, Chapter 1)

Facial nerve palsy, traumatic, (Foundations Volume 1, Chapter 37)

Facial nuclear reorganization, (Foundations Volume 1, Chapter 37)

Facial numbness, in trigeminal nerve dysfunction, (Foundations Volume 1, Chapter 36)

Facial pain, (Foundations Volume 1, Chapter 36) (Foundations Volume 1, Chapter 36)

atypical, (Foundations Volume 1, Chapter 36) (Foundations Volume 1, Chapter 36) (Clinical Volume 2, Chapter 1) (Clinical Volume 2, Chapter 3) (Clinical Volume 2, Chapter 16)

cluster headache, (Foundations Volume 1, Chapter 36)

trigeminal neuralgia, (Foundations Volume 1, Chapter 36)

in cluster headache, (Foundations Volume 1, Chapter 36)

constant, paraoxysmal, (Foundations Volume 1, Chapter 36)

in multiple sclerosis, (Foundations Volume 1, Chapter 36)

in Raeder’s paratrigeminal neuralgia, (Foundations Volume 1, Chapter 36)

in temporomandibular joint disease, (Foundations Volume 1, Chapter 36)

trigeminal neuralgia, (Foundations Volume 1, Chapter 36)

in trigeminal neuralgia, (Foundations Volume 1, Chapter 36) (Clinical Volume 2, Chapter 16)

Facial Recognition Test, (Clinical Volume 2, Chapter 7)

Facial tic, (Foundations Volume 1, Chapter 37)

Facial vein, anterior, (Foundations Volume 1, Chapter 5)

Facio-auriculovertebral spectrum. See Goldenhar’s syndrome

Factor V Leiden (activated protein C), functional resistance to, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 23)

detection, (Clinical Volume 5, Chapter 23)

Facultative parasite, (Foundations Volume 2, Chapter 79)

Fadenoperation, (Clinical Volume 6, Chapter 91 )

complications, (Clinical Volume 6, Chapter 91)

in congenital esotropia, (Clinical Volume 6, Chapter 91)

in dissociated vertical deviation, 5, (Clinical Volume 6, Chapter 91)

in esotropia with high AC:A ratio, (Clinical Volume 6, Chapter 91)

exotropia with high AC:A ratio, (6)91: 6in

in high myopia, (Clinical Volume 6, Chapter 91)

indications, (Clinical Volume 6, Chapter 91)

in nystagmus blockage syndrome, (Clinical Volume 6, Chapter 91)

results, (Clinical Volume 6, Chapter 91)

in strabismus, (Clinical Volume 6, Chapter 91)

technique, (Clinical Volume 6, Chapter 91)

theory, (Clinical Volume 6, Chapter 91)

Failed bleb, (Foundations Volume 1, Chapter 29)

Faisceau isthmique, (Foundations Volume 1, Chapter 2)

False-negative responses, (Clinical Volume 2, Chapter 10)

False-positive responses, (Clinical Volume 2, Chapter 10)

Famciclovir

efficacy, (Foundations Volume 2, Chapter 100)

in herpes zoster keratouveitis, (Clinical Volume 4, Chapter 39)

for herpes zoster ophthalmicus, (Foundations Volume 2, Chapter 94)

in herpes zoster ophthalmicus, (Clinical Volume 4, Chapter 20)

mechanism of action, (Foundations Volume 2, Chapter 100)

ophthalmic uses, (Foundations Volume 3, Chapter 37)

penetration and pharmacokinetics, (Foundations Volume 2, Chapter 100)

pharmacology, (Foundations Volume 3, Chapter 37)

resistance to, (Foundations Volume 2, Chapter 100)

structure, (Foundations Volume 2, Chapter 100)

systemic uses, (Foundations Volume 3, Chapter 37)

toxicity, (Foundations Volume 3, Chapter 37)

for zoster uveitis, (Clinical Volume 3, Chapter 54D)

Familial adenomatous polyposis coli, (Clinical Volume 5, Chapter 30)

Familial chronic granulomatous disease of childhood, (Foundations Volume 3, Chapter 4)

Familial exudative vitreoretinopathy, (Foundations Volume 1, Chapter 16) (Clinical Volume 5, Chapter 23) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 61)

molecular genetics, (Foundations Volume 3, Chapter 55)

Familial fibrosis syndrome, congenital, (Clinical Volume 2, Chapter 13)

Familial foveal retinoschisis, (Clinical Volume 3, Chapter 9)

Familial hemiplegic migraine, (Clinical Volume 2, Chapter 16)

Familial Mediterranean fever, (Clinical Volume 2, Chapter 5)

Familial nephrophthisis, juvenile, (Foundations Volume 3, Chapter 13)

Family history, ophthalmic, (Foundations Volume 3, Chapter 51 )

Fanconi syndrome, (Clinical Volume 4, Chapter 15)

in cystinosis, (Clinical Volume 5, Chapter 19)

Faraday, Michael, (Clinical Volume 1, Chapter 31)

Farber disease, (Clinical Volume 3, Chapter 29) (Clinical Volume 5, Chapter 19)

retinal changes, (Clinical Volume 3, Chapter 29) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B)

Farnsworth D-15 test, (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 19)

Farnsworth-Munsell 100-hue test, (Foundations Volume 2, Chapter 19) (Foundations Volume 2, Chapter 22)

Farnsworth-Munsell tests, in color vision testing, (2)2: 15; (3) 6: 15–20

cerebral dyschromatopsia, (2)7: 25in

in optic neuropathy, (Clinical Volume 2, Chapter 36)

Far point, (Clinical Volume 1, Chapter 33)

in ametropia, (Clinical Volume 1, Chapter 33)

in aphakic eye, (Clinical Volume 1, Chapter 33)

in astigmatism, correction with spectacle lenses, (Clinical Volume 1, Chapter 36)

correction with spectacle lenses, (Clinical Volume 1, Chapter 36)

in emmetropia, (Clinical Volume 1, Chapter 36)

in hyperopia, (Clinical Volume 1, Chapter 33)

correction with spectacle lenses, (Clinical Volume 1, Chapter 36)

in myopia, (Clinical Volume 1, Chapter 33) (Clinical Volume 1, Chapter 36) (Clinical Volume 1, Chapter 42)

Farsightedness. See Hyperopia

Fasanella-Servat, (Clinical Volume 5, Chapter 78)

Fascia

capsulopalpebral, (Foundations Volume 1, Chapter 5)

lacrimal, (Foundations Volume 1, Chapter 30)

in lid reconstruction, (Clinical Volume 5, Chapter 88)

of muscles, fine structure of, (Foundations Volume 2, Chapter 23)

orbital, (Foundations Volume 1, Chapter 32) (Clinical Volume 2, Chapter 21)

Tenon’s. (See Tenon’s capsule)

Fascia bulbi. See Tenon’s capsule

Fascial sling/silicone procedures, in ptosis correction, (Clinical Volume 5, Chapter 83)

Fascicular cataract, (Foundations Volume 1, Chapter 15)

Fascicular melanoma, (Foundations Volume 3, Chapter 20)

Fasciitis

histopathology, (Clinical Volume 2, Chapter 35)

nodular, (Clinical Volume 2, Chapter 21) (Clinical Volume 2, Chapter 35) (Clinical Volume 4, Chapter 10)

treatment, (Clinical Volume 2, Chapter 35)

Fas-Fas ligand, in uveitis, (Clinical Volume 4, Chapter 34)

Fasting, preoperative, in children, (6)81: 6

FASTPAC full threshold strategy, in automated perimetry, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 49)

Fat, retinal emboli of, (Foundations Volume 3, Chapter 6)

eyelid, (Clinical Volume 5, Chapter 72)

orbital, (Clinical Volume 2, Chapter 21) (Clinical Volume 5, Chapter 75)

in thyroid orbitopathy, (Clinical Volume 2, Chapter 36)

Fat embolism retinopathy, (Clinical Volume 3, Chapter 32)

Fatigue

color perception and, (Clinical Volume 3, Chapter 6)

perimetric testing and, (Clinical Volume 3, Chapter 49)

Fatigue nystagmus, (Clinical Volume 2, Chapter 11)

Fat pads, of lids, (Foundations Volume 1, Chapter 5)

lower, (Foundations Volume 1, Chapter 5)

upper, (Foundations Volume 1, Chapter 5)

Fatty acids, in rod disc membranes, (Foundations Volume 2, Chapter 12)

Fechtner syndrome, (Clinical Volume 5, Chapter 41)

Feeder vessels, (Foundations Volume 2, Chapter 110A)

Felderstruktur, (Foundations Volume 1, Chapter 32) (Foundations Volume 2, Chapter 23)

Fencing, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Fenestrated sheen macular dystrophy, (Clinical Volume 3, Chapter 9) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 60)

Fenoprofen. See Nonsteroidal anti-inflammatory drugs (NSAIDs)

Fentanyl, dosage and administration of, for children, (Clinical Volume 6, Chapter 81)

FERG (focal electroretinogram), (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 103)

Fermat principle, refraction and reflection and, (Clinical Volume 1, Chapter 30)

Ferrocholinate, ocular toxicity, (Clinical Volume 5, Chapter 37)

Ferrous fumarate, ocular toxicity, (Clinical Volume 5, Chapter 37)

Ferrous gluconate, ocular toxicity, (Clinical Volume 5, Chapter 37)

Ferrous succinate, ocular toxicity, (Clinical Volume 5, Chapter 37)

Ferrous sulfate, ocular toxicity, (Clinical Volume 5, Chapter 37)

Fetal alcohol syndrome, (Clinical Volume 1, Chapter 20) (Foundations Volume 1, Chapter 39) (Foundations Volume 3, Chapter 12 Duane retraction syndrome and)

ophthalmic manifestations, (Foundations Volume 1, Chapter 39)

Fetal (choroidal) fissure, (Foundations Volume 3, Chapter 53)

Fetal development. See Embryology; specific aspect

Fetal visualization, (Foundations Volume 3, Chapter 56 )

fetoscopy, (Foundations Volume 3, Chapter 56)

radiology, (Foundations Volume 3, Chapter 56)

ultrasound, (Foundations Volume 3, Chapter 56)

Fetus

ocular teratology, (Foundations Volume 1, Chapter 39) See also Congenital abnormalities; Teratology

optic nerve in, (Foundations Volume 1, Chapter 25)

Fever

in children, anesthesia and, (Clinical Volume 6, Chapter 81)

pharyngoconjunctival, (Clinical Volume 4, Chapter 7)

purpuric, Brazilian, (Clinical Volume 4, Chapter 26)

Fiber cells, lens, (Foundations Volume 2, Chapter 10)

Fiber layer of Henle. See Outer plexiform layer (OPL)

Fibers

elongation of, in lens, (Clinical Volume 1, Chapter 71A)

lens and, (Clinical Volume 1, Chapter 71A)

primary, formation of, in lens, (Clinical Volume 1, Chapter 71A)

secondary, formation of, in lens, (Clinical Volume 1, Chapter 71A)

shape of, lens and, (Clinical Volume 1, Chapter 71A)

Fibrillary astrocytoma, optic nerve, (Foundations Volume 3, Chapter 16)

Fibrillenstruktur, (Foundations Volume 1, Chapter 32) (Foundations Volume 2, Chapter 23)

Fibrillenstruktur fiber, (Clinical Volume 1, Chapter 1)

Fibrillins, (Clinical Volume 3, Chapter 38) (Foundations Volume 1, Chapter 14)

Fibrillopathia epitheliocapsularis, (Clinical Volume 3, Chapter 54B)

Fibrils, (Foundations Volume 1, Chapter 8)

Fibrils. See also Zonular apparatus

anchoring, corneal, (Foundations Volume 1, Chapter 8)

collagen, (Foundations Volume 1, Chapter 16)

ciliary, (Foundations Volume 1, Chapter 13)

zonular microfibrils, (Foundations Volume 1, Chapter 14)

Fibrin, formation

after diabetic vitrectomy, (Clinical Volume 6, Chapter 57)

after vitreous surgery, for proliferative vitreoretinopathy, (Clinical Volume 6, Chapter 58)

Fibrinogen, serum, and ischemic optic neuropathy, (Clinical Volume 2, Chapter 5)

Fibrinolysis, (Clinical Volume 5, Chapter 23)

Fibroblast growth factor

in aqueous humor, (Clinical Volume 1, Chapter 72A)

lens of eye and, (Clinical Volume 1, Chapter 72A)

Fibroblast growth factor (FGF), in glaucoma, (Clinical Volume 3, Chapter 57)

Fibroblast growth factor receptor, in craniofacial syndromes, (Clinical Volume 6, Chapter 110)

Fibroblasts. See also Keratocytes

ciliary, (Foundations Volume 1, Chapter 13)

in iris, (Foundations Volume 1, Chapter 11)

in nodular fasciitis, (Clinical Volume 2, Chapter 35)

scleral, (Foundations Volume 1, Chapter 23)

vitreous cortex, (Clinical Volume 3, Chapter 38) (Clinical Volume 6, Chapter 51)

Fibrocystic disease of pancreas, (Clinical Volume 5, Chapter 24)

Fibrocytes, choroidal, anatomy of, (Foundations Volume 1, Chapter 22)

Fibroepithelial papilloma, (Foundations Volume 3, Chapter 7)

Fibroepithelial papilloma (acrochordon), (Foundations Volume 3, Chapter 7)

Fibroma, in tuberous sclerosis, (Clinical Volume 5, Chapter 36)

conjunctival, (Clinical Volume 4, Chapter 10)

Fibroma molluscum, (Foundations Volume 3, Chapter 2)

Fibromuscular dysplasia, retinal ischemia in, (Clinical Volume 2, Chapter 5)

Fibronectin, in lens of eye, (Clinical Volume 1, Chapter 72A)

Fibro-osseous tumors, craniofacial, (Clinical Volume 2, Chapter 44) See also specific tumors

Fibroplasia, retrolental. See Retinopathy of prematurity (retrolental fibroplasia)

Fibrosclerosis, multifocal, (Clinical Volume 2, Chapter 35)

Fibrosis

around internal tube opening, tube shunts and, (Clinical Volume 6, Chapter 17)

congenital, (Foundations Volume 3, Chapter 59)

diffuse subretinal, (Clinical Volume 4, Chapter 49)

ophthalmoscopy in, (Clinical Volume 3, Chapter 7)

subconjunctival, tube shunts and, (6)17: 13

subepithelial

in cicatricial pemphigoid, (Clinical Volume 5, Chapter 27)

in erythema multiforme, (Clinical Volume 5, Chapter 27)

in thyroid orbitopathy, (Clinical Volume 2, Chapter 36)

Fibrosis syndromes, (Clinical Volume 1, Chapter 20)

congenital

familial, (Clinical Volume 2, Chapter 13)

of inferior rectus muscle, (Clinical Volume 1, Chapter 20)

generalized, (Clinical Volume 1, Chapter 20)

strabismus fixus and, (Clinical Volume 1, Chapter 20)

in thyrotoxicosis ophthalmoplegia, (Clinical Volume 1, Chapter 20)

vertical retraction, (Clinical Volume 1, Chapter 20)

Fibrous dysplasia

of bone, (Clinical Volume 5, Chapter 29)

orbital, (Clinical Volume 2, Chapter 30)

craniofacial, (Clinical Volume 2, Chapter 44 )

Fibrous histiocytoma, (Foundations Volume 3, Chapter 17) See Histiocytoma, fibrous

Fibrovascular detachment, retinal pigment epithelium, optical coherence tomography, (Foundations Volume 2, Chapter 107)

Fibrovascular proliferation, hyaloidal, anterior, (Foundations Volume 3, Chapter 18)

Fibroxanthoma, atypical, (Foundations Volume 3, Chapter 7)

FIC (fractional inhibitory concentration), (Foundations Volume 2, Chapter 40)

Field curvature, (Clinical Volume 1, Chapter 30)

Field defects

after glaucoma surgery, (Clinical Volume 6, Chapter 24)

alexia associated with, (Clinical Volume 2, Chapter 7)

in amblyopia, (Clinical Volume 1, Chapter 10)

anatomic considerations, (Clinical Volume 2, Chapter 2)

in chiasmal syndromes, 2, (Clinical Volume 2, Chapter 6)

in choroideremia, (Clinical Volume 4, Chapter 66)

in craniopharyngioma, (Clinical Volume 2, Chapter 6)

crescents of optic disc and, (Clinical Volume 2, Chapter 5)

drugs causing, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 37)

Fresnel prisms, (Clinical Volume 1, Chapter 52)

in glaucoma, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 49) See also Field of vision, in glaucoma

automated perimetry, (Clinical Volume 3, Chapter 49)

blind spot changes, (Clinical Volume 3, Chapter 49)

diffuse depression, (Clinical Volume 3, Chapter 49)

Doppler effect and, (Clinical Volume 1, Chapter 31)

early, (Clinical Volume 3, Chapter 49)

end-stage, (Clinical Volume 3, Chapter 49)

identification, (Clinical Volume 3, Chapter 49)

localized nerve fiber bundle defects, (Clinical Volume 3, Chapter 49)

differential diagnosis, (Clinical Volume 3, Chapter 49)

open-angle, (Clinical Volume 3, Chapter 52)

patient evaluation, (Clinical Volume 3, Chapter 49)

progression, (Clinical Volume 3, Chapter 49)

assessment, (Clinical Volume 3, Chapter 49)

in gliomas of chiasm, (Clinical Volume 2, Chapter 6)

global indices, (Clinical Volume 3, Chapter 49)

in Graves’ disease, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 36)

gun-barrel, (Clinical Volume 2, Chapter 5)

hemifield, abnormalities in remaining visual field with, (Clinical Volume 2, Chapter 7)

hemifield analysis, (Clinical Volume 3, Chapter 49)

with hyaline bodies, (Clinical Volume 2, Chapter 5)

hysterical, (Clinical Volume 2, Chapter 2)

intereye comparisons, (Clinical Volume 3, Chapter 49)

malingering and, (Clinical Volume 2, Chapter 2)

in migraine, (Clinical Volume 2, Chapter 16)

retinal, (Clinical Volume 2, Chapter 5)

in myopia, (Clinical Volume 1, Chapter 42)

numeric printouts, (Clinical Volume 3, Chapter 49)

in optic nerve disease, acquired, (Clinical Volume 2, Chapter 5)

in optic nerve gliomas, (Clinical Volume 2, Chapter 42)

in optic nerve hypoplasia, (Clinical Volume 2, Chapter 5)

in optic neuritis, (Clinical Volume 2, Chapter 5)

in optic neuropathies, (Clinical Volume 2, Chapter 5)

ethambutol-induced, (Clinical Volume 2, Chapter 5)

in palinopsia, (Clinical Volume 2, Chapter 7)

in papilledema, (Clinical Volume 2, Chapter 5)

paracentral, (Clinical Volume 3, Chapter 49)

photocoagulation and, (Clinical Volume 6, Chapter 76)

physiologic considerations, (Clinical Volume 2, Chapter 2)

in pituitary tumors, (Clinical Volume 2, Chapter 6)

point-by-point comparisons, (Clinical Volume 3, Chapter 49)

in pregnancy, (Clinical Volume 2, Chapter 6)

probability plots, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 49)

progression, assessment, (Clinical Volume 3, Chapter 49)

in progressive cone degenerations, (Clinical Volume 2, Chapter 5)

in pseudotumor cerebri, (Clinical Volume 2, Chapter 5)

reading ability affected by, (Clinical Volume 2, Chapter 7)

in retinal arterial occlusion, (Clinical Volume 2, Chapter 5)

in retinal migraine, (Clinical Volume 2, Chapter 5)

in striate lesions, (Clinical Volume 2, Chapter 7)

in temporal lobe lesions, (Clinical Volume 2, Chapter 7)

with temporal pits, (Clinical Volume 2, Chapter 5)

tubular fields, (Clinical Volume 2, Chapter 5)

Field hockey, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Field of view

in direct ophthalmoscopy, (Clinical Volume 1, Chapter 63)

in indirect ophthalmoscopy, (Clinical Volume 1, Chapter 63)

Field of vision. See Visual field

anatomy, (Clinical Volume 2, Chapter 2)

area of conscious regard and, (Clinical Volume 1, Chapter 5)

in choroideremia, (Clinical Volume 3, Chapter 25A)

defects in. (See Field defects)

depth, (Clinical Volume 1, Chapter 33 )

calculation, (Clinical Volume 1, Chapter 33)

drugs affecting, (Clinical Volume 5, Chapter 37)

examination, (Clinical Volume 2, Chapter 2 )

factitious, (Clinical Volume 2, Chapter 2)

functional, (Clinical Volume 2, Chapter 2)

glaucoma, (Clinical Volume 3, Chapter 49) (Clinical Volume 3, Chapter 52) See also Field defects, in glaucomain

measurement methods, (Clinical Volume 3, Chapter 49) See also Perimetry

normal, (Clinical Volume 3, Chapter 49)

physiology, (Clinical Volume 2, Chapter 2)

in pregnancy, (Clinical Volume 5, Chapter 32)

in thyroid orbitopathy, (Clinical Volume 2, Chapter 36)

Fifth cranial nerve. See Trigeminal nerve

Filamentary keratitis, (Clinical Volume 1, Chapter 56) (Clinical Volume 4, Chapter 17)

Filariasis, (Foundations Volume 2, Chapter 79)

Filiform dystrophy, deep, (Clinical Volume 4, Chapter 16)

Filter, red. See Red filter

Filtering bleb, (Foundations Volume 1, Chapter 29)

endophthalmitis associated with, (Foundations Volume 3, Chapter 3)

failed, bacterial inflammation and, (Foundations Volume 3, Chapter 6)

Filtering operations for glaucoma. See Glaucoma, filtering surgery

Filtration

guarded. (See Guarded filtration procedures)

overfiltration, tube shunts and, (Clinical Volume 6, Chapter 17)

Fimbriae. See Pili

Fine-needle aspiration biopsy. See Biopsy

Finger counting, (Clinical Volume 2, Chapter 2) (Clinical Volume 2, Chapter 10)

Finger mimicking, (Clinical Volume 2, Chapter 2) (Clinical Volume 2, Chapter 10)

Fireworks, eye injuries from, (Clinical Volume 5, Chapter 56)

First Purkinje-Sanson image, (Clinical Volume 1, Chapter 65)

First trimester ultrasound, (Foundations Volume 3, Chapter 56)

Fisher syndrome, (Clinical Volume 2, Chapter 12)

Fish-eye disease, (Clinical Volume 5, Chapter 30)

Fishing, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Fish-strike sign, (Clinical Volume 6, Chapter 56)

Fissure(s), orbital

inferior, (Foundations Volume 1, Chapter 32)

superior, (Foundations Volume 1, Chapter 32)

Fistula

arteriovenous, (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 17) (Clinical Volume 2, Chapter 37) (Foundations Volume 3, Chapter 17)

dural, (Clinical Volume 2, Chapter 37)

carotid cavernous, (Foundations Volume 3, Chapter 17)

carotid-cavernous, (Foundations Volume 1, Chapter 32) (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 17) (Clinical Volume 2, Chapter 37) (Foundations Volume 3, Chapter 6)

arteriography, (Clinical Volume 2, Chapter 37)

classification, (Clinical Volume 2, Chapter 17)

clinical features, (Clinical Volume 2, Chapter 37)

color Doppler imaging, (Foundations Volume 2, Chapter 102)

computed tomography, (Clinical Volume 2, Chapter 37)

diagnosis, (Clinical Volume 2, Chapter 37)

differential diagnosis, (Clinical Volume 2, Chapter 37)

proptosis in, (Clinical Volume 2, Chapter 28)

thyroid orbitopathy versus, (Clinical Volume 2, Chapter 36)

treatment, (Clinical Volume 2, Chapter 17) (Clinical Volume 2, Chapter 37)

ultrasonography, (Clinical Volume 2, Chapter 37)

congenital, of lacrimal sac, (Foundations Volume 3, Chapter 7)

dural cavernous, (Foundations Volume 3, Chapter 17)

dural-cavernous, (Clinical Volume 2, Chapter 29)

dural-sinus, (Foundations Volume 1, Chapter 32)

lacrimal, congenital, (Clinical Volume 5, Chapter 79)

perilymphatic, (Clinical Volume 2, Chapter 18)

Fistula, arteriovenous, (Clinical Volume 2, Chapter 37)

direct arteriovenous fistula, (Clinical Volume 2, Chapter 37)

clinical features, (Clinical Volume 2, Chapter 37)

differential diagnosis, (Clinical Volume 2, Chapter 37)

investigations, (Clinical Volume 2, Chapter 37)

treatment, (Clinical Volume 2, Chapter 37)

indirect arteriovenous fistula, (Clinical Volume 2, Chapter 37)

clinical features, (Clinical Volume 2, Chapter 37)

differential diagnosis, (Clinical Volume 2, Chapter 37)

investigations, (Clinical Volume 2, Chapter 37)

management natural history, (Clinical Volume 2, Chapter 37)

treatment, (Clinical Volume 2, Chapter 37)

FITC (fluorescein isothiocyanate), (Foundations Volume 2, Chapter 40)

Fixation, (Clinical Volume 2, Chapter 3) (Clinical Volume 2, Chapter 9) (Clinical Volume 2, Chapter 10) (Foundations Volume 2, Chapter 40)

binocular, in amblyopia, (Clinical Volume 1, Chapter 10)

disengagement of, (Foundations Volume 1, Chapter 38)

eccentric, (Clinical Volume 1, Chapter 6)

in amblyopia, (Clinical Volume 1, Chapter 10)

involuntary, (Clinical Volume 2, Chapter 3)

losses, in automated perimetry, (Foundations Volume 2, Chapter 109)

mechanism, (Foundations Volume 1, Chapter 38)

disturbance of, nystagmus due to, (Foundations Volume 1, Chapter 38)

miniature eye movements and, (Foundations Volume 2, Chapter 23)

monitoring, in automated perimetry, (Foundations Volume 2, Chapter 109)

monocular, in amblyopia, (Clinical Volume 1, Chapter 10)

monofixation syndrome, (Clinical Volume 1, Chapter 6)

near, (Clinical Volume 1, Chapter 6)

in perimetric testing, losses, (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 49)

posterior. (See Fadenoperation)

spasm of, (Foundations Volume 1, Chapter 38) (Clinical Volume 2, Chapter 7) (Clinical Volume 2, Chapter 10)

testing, (Clinical Volume 2, Chapter 3)

Fixation disparity, (Clinical Volume 1, Chapter 5) (Foundations Volume 2, Chapter 24)

Fixation losses, (Clinical Volume 2, Chapter 10)

Fixation neurons, (Clinical Volume 2, Chapter 10)

Fixation procedures, in infection diagnosis, (Foundations Volume 2, Chapter 40)

Fixation reflex, (Clinical Volume 1, Chapter 4)

Fixed, dilated pupil, (Foundations Volume 2, Chapter 9)

Fixed-area tonometers, (Foundations Volume 2, Chapter 7)

Fixed-force tonometers, (Foundations Volume 2, Chapter 7)

FK506. See Tacrolimus (FK506)

FK506, in ocular inflammation, (Foundations Volume 2, Chapter 31)

Flaccid canaliculus syndrome, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 79)

Flagella, gram-negative bacilli, (Foundations Volume 2, Chapter 52)

Flame hemorrhages, in chronic glaucoma, (Clinical Volume 2, Chapter 5)

Flap replacement, (Clinical Volume 6, Chapter 49)

Flaps

avulsion, (Clinical Volume 5, Chapter 75)

bilobed, (Clinical Volume 5, Chapter 88)

composite, (Clinical Volume 5, Chapter 88)

conjunctival

in bacterial keratitis, (Clinical Volume 6, Chapter 33)

in bullous keratopathy, (Clinical Volume 6, Chapter 33)

closure, double-plate shunt placement and, (Clinical Volume 6, Chapter 17)

in corneal disease, (Clinical Volume 6, Chapter 33 )

advantages, (Clinical Volume 6, Chapter 33)

complications, (Clinical Volume 6, Chapter 33)

disadvantages, (Clinical Volume 6, Chapter 33)

indications, (Clinical Volume 6, Chapter 33)

results, (Clinical Volume 6, Chapter 33)

variations, (Clinical Volume 6, Chapter 33)

in corneal ulcerations, noninfected, (Clinical Volume 6, Chapter 33)

fornix-based, dissection, (Clinical Volume 6, Chapter 3)

in fungal keratitis, (Clinical Volume 6, Chapter 33)

in herpes simplex keratitis, (Clinical Volume 4, Chapter 19) (Clinical Volume 6, Chapter 33)

keratoplasty after, (Clinical Volume 6, Chapter 33)

in preparation for cosmetic shell, (Clinical Volume 6, Chapter 33)

in pterygium excision, (Clinical Volume 6, Chapter 35)

surgical technique, (Clinical Volume 6, Chapter 33)

variations, (Clinical Volume 6, Chapter 33)

full-thickness, (Clinical Volume 5, Chapter 88)

hinged, in keratomileusis, 6, (Clinical Volume 6, Chapter 46)

in lid reconstruction, (Clinical Volume 5, Chapter 88 )

median forehead, (Clinical Volume 5, Chapter 88)

Mustarde, (Clinical Volume 5, Chapter 88)

myocutaneous, (Clinical Volume 5, Chapter 88)

semicircle, lid coloboma and, (Clinical Volume 6, Chapter 110)

pivot point, (Clinical Volume 5, Chapter 88)

rhomboid, (Clinical Volume 5, Chapter 88)

scleral, disinsertion, glaucoma filtering surgery and, (Clinical Volume 6, Chapter 24)

skin, after lid repair, 25-27

sliding/rotation, (Clinical Volume 5, Chapter 88)

subcutaneous pedicle, 5, (Clinical Volume 5, Chapter 88)

tarsoconjunctival, (Clinical Volume 5, Chapter 88)

Tenzel, (Clinical Volume 5, Chapter 88)

V-T closure, (Clinical Volume 5, Chapter 88)

V-Y glabellar, (Clinical Volume 5, Chapter 88)

V-Y plasty, 4, (Clinical Volume 5, Chapter 88)

V-Y-S plasty, (Clinical Volume 5, Chapter 88)

Y-V plasty, 4; (Clinical Volume 6, Chapter 110) (Clinical Volume 5, Chapter 88)

Z-plasty, (Clinical Volume 5, Chapter 88) (Clinical Volume 6, Chapter 110)

Flare and cells, in uveitis, (Clinical Volume 4, Chapter 32)

Flash electroretinogram, (Clinical Volume 2, Chapter 2)

retinal physiology and, (Clinical Volume 3, Chapter 2)

Flashlight test, swinging, for light reflex. See Pupil of eye, light reflex

Flash visual evoked potential (FVEP), (Foundations Volume 2, Chapter 105)

Flash visual evoked potentials, in visual function assessment, (Clinical Volume 2, Chapter 2)

Flat anterior chamber, glaucoma surgery and, (Clinical Volume 6, Chapter 15)

Flat-top bifocals, (Clinical Volume 1, Chapter 44)

Flavivirus, (Foundations Volume 2, Chapter 85)

Fleck dystrophy, (Clinical Volume 4, Chapter 16) (Foundations Volume 3, Chapter 9) (Foundations Volume 3, Chapter 63)

Flecked retina syndrome, (Clinical Volume 3, Chapter 9)

Fleischer, corneal verticillata of, (Clinical Volume 4, Chapter 16)

Fleurettes, in retinoblastoma, (Clinical Volume 6, Chapter 75) (Foundations Volume 3, Chapter 21)

Flexner-Wintersteiner rosettes, (Foundations Volume 3, Chapter 21)

Flicker perimetry, (Foundations Volume 2, Chapter 17)

Flieringa ring, in penetrating keratoplasty, (Clinical Volume 6, Chapter 26)

Flies, Lyme disease, (Foundations Volume 2, Chapter 75)

Floaters, (Foundations Volume 2, Chapter 20) (Foundations Volume 3, Chapter 14)

vitreous, (Clinical Volume 2, Chapter 1)

Flocculonodular lobe, eye movements and, (Foundations Volume 1, Chapter 38) (Foundations Volume 2, Chapter 23)

Flocculus, ocular motility and, (Foundations Volume 2, Chapter 23)

Floor hockey, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Floppy eyelid syndrome, (Clinical Volume 5, Chapter 73)

Floppy valve syndrome. See Mitral valve prolapse

Flora

bacterial. (See also Bacteria)

host factors affecting, (Foundations Volume 2, Chapter 41)

normal, (Foundations Volume 2, Chapter 41)

anaerobic, of external eye, (Foundations Volume 2, Chapter 57)

of external eye, (Foundations Volume 2, Chapter 45) (Foundations Volume 2, Chapter 57)

formation, (Foundations Volume 2, Chapter 41)

mollicutes in, (Foundations Volume 2, Chapter 59)

taxonomy and techniques, (Foundations Volume 2, Chapter 41)

nonbacterial, normal, (Foundations Volume 2, Chapter 41)

normal, (Foundations Volume 2, Chapter 41 )

as host defense against bacterial and fungal disease, (Foundations Volume 2, Chapter 45)

preoperative antibiotic effects on, (Foundations Volume 2, Chapter 64)

preoperative culture testing, (Foundations Volume 2, Chapter 64)

Floriform cataract, (Foundations Volume 1, Chapter 15)

Floropryl. See Isoflurophate (DFP, Floropryl)

Floxuridine, ocular toxicity, (Clinical Volume 5, Chapter 37)

Fluconazole, (Foundations Volume 2, Chapter 62)

intracameral administration, (Foundations Volume 2, Chapter 62)

pharmacokinetics, (Foundations Volume 2, Chapter 62)

structural formula, (Foundations Volume 2, Chapter 62)

subconjunctival administration, (Foundations Volume 2, Chapter 62)

systemic administration, (Foundations Volume 2, Chapter 62)

topical administration, (Foundations Volume 2, Chapter 62)

Flucytosine, (Foundations Volume 2, Chapter 62)

efficacy and spectrum of activity, (Foundations Volume 2, Chapter 62)

pharmacokinetics and pharmacology, (Foundations Volume 2, Chapter 62)

structural formula, (Foundations Volume 2, Chapter 62)

toxicity, (Foundations Volume 2, Chapter 62)

Fludrocortisone

ocular toxicity, (Clinical Volume 5, Chapter 37)

in orthostatic hypotension, (Clinical Volume 2, Chapter 18)

Fluid balance, ocular, (Foundations Volume 3, Chapter 1)

Fluid management, intraoperative, in children, (Clinical Volume 6, Chapter 81)

Fluid transport, corneal endothelial, (Foundations Volume 2, Chapter 4)

Flunarizine, neuroprotection of axons and, (Clinical Volume 3, Chapter 57)

Fluorescein, (Clinical Volume 1, Chapter 31)

aqueous humor circulation studies. (See Fluorophotometryin)

in lacrimal drainage evaluation, (Clinical Volume 4, Chapter 13)

systemic toxicity, (Clinical Volume 5, Chapter 37)

use of, in eye with bandage lens, (Clinical Volume 4, Chapter 11)

Fluorescein angiography, (Clinical Volume 3, Chapter 4) (Clinical Volume 5, Chapter 32)

abnormal vessels in, (Clinical Volume 4, Chapter 57)

acute multifocal placoid pigment epitheliopathy, (Foundations Volume 2, Chapter 113E)

in acute retinal necrosis syndrome, (Clinical Volume 3, Chapter 28) (Clinical Volume 4, Chapter 57)

in AIDS, (Clinical Volume 4, Chapter 57)

in angioid streaks, (Clinical Volume 3, Chapter 36) (Clinical Volume 5, Chapter 27)

anterior segment, (Clinical Volume 4, Chapter 23)

arterial phase, (Clinical Volume 4, Chapter 23)

capillary phase, (Clinical Volume 4, Chapter 23)

conjunctival circulation, 4, (Clinical Volume 4, Chapter 23)

episcleral arterial circle, 4, (Clinical Volume 4, Chapter 23)

episcleral circulation, 4, (Clinical Volume 4, Chapter 23)

iris vessels, (Clinical Volume 4, Chapter 23)

limbal arcades, (Clinical Volume 4, Chapter 23)

venous phase, (Clinical Volume 4, Chapter 23)

in benign concentric annular macular dystrophy, (Clinical Volume 3, Chapter 9)

in birdshot retinochoroidopathy, (Clinical Volume 4, Chapter 49) (Clinical Volume 4, Chapter 57)

blocked fluorescence in, 2, (Clinical Volume 4, Chapter 57)

in butterfly-shaped pigment dystrophy of fovea, (Clinical Volume 3, Chapter 9)

in Candida endophthalmitis, (Clinical Volume 4, Chapter 57)

in central areolar choroidal dystrophy, (Clinical Volume 3, Chapter 9)

in central areolar pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9)

chorioretinal dystrophies, (Foundations Volume 2, Chapter 113B )

in chorioretinal folds, (Clinical Volume 3, Chapter 36)

of choroid, (Clinical Volume 4, Chapter 31)

choroidal, (Foundations Volume 2, Chapter 113)

blood flow, (Foundations Volume 2, Chapter 5)

infectious and inflammatory diseases, (Foundations Volume 2, Chapter 113E )

metastatic carcinoma, (Foundations Volume 2, Chapter 113A)

nevus, (Foundations Volume 2, Chapter 113A)

osteoma, (Foundations Volume 2, Chapter 113A)

tumors, (Foundations Volume 2, Chapter 113A )

in choroidal rupture, (Clinical Volume 3, Chapter 31) (Clinical Volume 3, Chapter 36)

choroidal vascular disease, (Foundations Volume 2, Chapter 113E)

choroidal vessels in, hemangioma, (Clinical Volume 3, Chapter 22)

choroideremia, (Foundations Volume 2, Chapter 113B)

in choroideremia, (Clinical Volume 3, Chapter 25A) (Clinical Volume 4, Chapter 66)

cilioretinal artery, (Clinical Volume 3, Chapter 8)

cilioretinal artery obstruction, (Foundations Volume 2, Chapter 113C)

Coats’ disease, (Foundations Volume 2, Chapter 113C :)

cone dystrophies, (Foundations Volume 2, Chapter 113B)

in congenital optic pits, (Clinical Volume 3, Chapter 8)

congenital stationary night blindness, (Foundations Volume 2, Chapter 113B)

crystalline retinopathy, (Foundations Volume 2, Chapter 113B)

cysticercosis, (4)57: 27–28in

in cystoid macular edema, (Clinical Volume 3, Chapter 7)

in cytomegalovirus retinitis, (Clinical Volume 4, Chapter 57)

diabetic retinopathy, (Foundations Volume 2, Chapter 113D )

in diabetic retinopathy, (Clinical Volume 5, Chapter 20)

in diffuse scleritis, (Clinical Volume 4, Chapter 23)

diffuse unilateral subacute neuroretinitis, (Foundations Volume 2, Chapter 113E)

in diffuse unilateral subacute neuroretinitis, (Clinical Volume 4, Chapter 57)

in dominant cystoid macular dystrophy, (Clinical Volume 3, Chapter 9)

dominant drusen of Bruch’s membrane, (Foundations Volume 2, Chapter 113B)

in dominant slowly progressive macular dystrophy, (Clinical Volume 3, Chapter 9)

drugs affecting, (Clinical Volume 5, Chapter 37)

Eale disease, (Foundations Volume 2, Chapter 113E)

in Eales’ disease, 2–3, (Clinical Volume 3, Chapter 16)

in familial drusen, (Clinical Volume 3, Chapter 9)

in familial foveal retinoschisis, (Clinical Volume 3, Chapter 9)

fiberoptics in, blood flow measurement, (Foundations Volume 2, Chapter 5)

in foveomacular vitelliform dystrophy, (Clinical Volume 3, Chapter 9)

fundus camera in. (See Fundus camera)

fundus flavimaculatus, (Foundations Volume 2, Chapter 113B)

in fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

gyrate atrophy, (Foundations Volume 2, Chapter 113B)

in gyrate atrophy, (Clinical Volume 3, Chapter 25)

hereditary chorioretinal dystrophies, (Foundations Volume 2, Chapter 113B )

in herpes zoster, (Clinical Volume 4, Chapter 57)

histoplasmosis, (Foundations Volume 2, Chapter 113E)

hyperfluorescence in, (Clinical Volume 3, Chapter 4) (Clinical Volume 4, Chapter 57)

in hypertensive choroidopathy, (Clinical Volume 3, Chapter 13)

in hypertensive retinopathy, (Clinical Volume 3, Chapter 13)

hypofluorescence in, 2, (Clinical Volume 4, Chapter 57)

in hypoperfusion retinopathy, (Clinical Volume 3, Chapter 14)

ICG angiography versus. (See Indocyanine green (ICG) angiography)

in idiopathic retinal vasculitis, aneurysms, and neuroretinitis, (Clinical Volume 3, Chapter 22)

of iris, in exfoliation syndrome, (Clinical Volume 3, Chapter 54B)

in ischemic optic neuropathy, common versus arteritic, (Clinical Volume 2, Chapter 5)

leak in, (Clinical Volume 4, Chapter 31) (Clinical Volume 4, Chapter 57)

in macular disease, (Clinical Volume 3, Chapter 9)

neuroretinopathy, (Clinical Volume 4, Chapter 57)

macular diseases

acquired, (Foundations Volume 2, Chapter 113F )

quantitation of, (Foundations Volume 2, Chapter 113E)

macular dystrophies, (Foundations Volume 2, Chapter 113B )

macular edema, diabetic retinopathy and, (Foundations Volume 2, Chapter 113D)

pseudophakia versus, (Foundations Volume 2, Chapter 113D)

in membranoproliferative glomerulonephritis, (Clinical Volume 5, Chapter 31)

microaneurysms, (Clinical Volume 3, Chapter 7)

multifocal choroiditis, (Foundations Volume 2, Chapter 113E)

in multifocal choroiditis, (Clinical Volume 4, Chapter 57)

multiple evanescent white dot syndrome, (Foundations Volume 2, Chapter 113E)

in multiple evanescent white-dot syndrome, (Clinical Volume 4, Chapter 49) (Clinical Volume 4, Chapter 57)

in necrotizing scleritis, (Clinical Volume 4, Chapter 23)

in North Carolina macular dystrophy, (Clinical Volume 3, Chapter 9)

ocular ischemic syndrome, (Foundations Volume 2, Chapter 113C)

in ocular ischemic syndrome, (Clinical Volume 3, Chapter 12)

ophthalmic artery obstruction, (Foundations Volume 2, Chapter 113C)

in ophthalmic artery obstruction, (Clinical Volume 3, Chapter 14)

optic nerve disease, (Foundations Volume 2, Chapter 113E)

in papilledema, (Clinical Volume 2, Chapter 5)

in pars planitis, (Clinical Volume 4, Chapter 43)

in pattern dystrophy of pigment epithelium, (Clinical Volume 3, Chapter 9)

in pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9)

pigment pattern dystrophies, (Foundations Volume 2, Chapter 113B)

in placoid pigment epitheliopathy, (Clinical Volume 4, Chapter 49) (Clinical Volume 4, Chapter 57)

in posterior scleritis, (Clinical Volume 4, Chapter 57)

in pregnancy, (Clinical Volume 5, Chapter 32)

of prepapillary vascular loops, (Clinical Volume 3, Chapter 8) (Clinical Volume 3, Chapter 22)

in presumed ocular histoplasmosis syndrome, (Clinical Volume 4, Chapter 57)

principles of, (Foundations Volume 2, Chapter 113E)

in progressive cone-rod dystrophies, (Clinical Volume 3, Chapter 9)

in progressive outer retinal necrosis syndrome, (Clinical Volume 3, Chapter 28)

in pseudoxanthoma elasticum, (Clinical Volume 5, Chapter 27)

in radiation retinopathy, (Clinical Volume 3, Chapter 36A)

in reticulum cell sarcoma, (Clinical Volume 4, Chapter 57)

retinal, (Foundations Volume 2, Chapter 113)

arterial obstructive disease, (Foundations Volume 2, Chapter 113C )

hemangioma

capillary, (Foundations Volume 2, Chapter 113A)

cavernous, (Foundations Volume 2, Chapter 113A)

infectious and inflammatory diseases, (Foundations Volume 2, Chapter 113E )

tumors, (Foundations Volume 2, Chapter 113A )

vascular diseases, (Foundations Volume 2, Chapter 113C )

vascular dystrophies, (Foundations Volume 2, Chapter 113B)

venous obstructive disease, (Foundations Volume 2, Chapter 113C )

retinal artery obstruction, (Foundations Volume 2, Chapter 113C)

in retinal artery occlusion

branch, (Clinical Volume 3, Chapter 15)

central, (Clinical Volume 3, Chapter 14) (Clinical Volume 3, Chapter 15)

in retinal artery tortuosity, hereditary, (Clinical Volume 3, Chapter 22)

of retinal hemangioma

capillary, (Clinical Volume 3, Chapter 22)

cavernous, (Clinical Volume 3, Chapter 22)

of retinal macroaneurysm, (Clinical Volume 6, Chapter 76)

of retinal macrovessels, (Clinical Volume 3, Chapter 22)

retinal necrosis, (Foundations Volume 2, Chapter 113E)

in retinal pigment epitheliitis, (Clinical Volume 4, Chapter 57)

of retinal pigment epithelium tears, (Clinical Volume 3, Chapter 36)

in retinal telangiectasis, juxtafoveal, (Clinical Volume 3, Chapter 22)

retinal vein obstruction

branch, (Foundations Volume 2, Chapter 113C)

central, (Foundations Volume 2, Chapter 113C)

retinitis pigmentosa, 2, (Foundations Volume 2, Chapter 113B)

retinoblastoma, (Foundations Volume 2, Chapter 113A)

retinopathy

crystalline, (Foundations Volume 2, Chapter 113B)

diabetic, (Foundations Volume 2, Chapter 113D )

proliferative, peripheral, (Foundations Volume 2, Chapter 113C)

in rod monochromaticism, (Clinical Volume 3, Chapter 9)

in sarcoidosis, (Clinical Volume 4, Chapter 57)

sarcoid retinal vasculitis, (Foundations Volume 2, Chapter 113E)

in scleritis

diffuse, (Clinical Volume 4, Chapter 23)

necrotizing, (Clinical Volume 4, Chapter 23)

posterior, (Clinical Volume 4, Chapter 57)

serpiginous choroiditis, (Foundations Volume 2, Chapter 113E)

in serpiginous choroiditis, (Clinical Volume 4, Chapter 57)

in Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9)

Stargardt’s disease, (Foundations Volume 2, Chapter 113B)

in Stargardt’s disease, (Clinical Volume 3, Chapter 9)

in subacute sclerosing panencephalitis, (Clinical Volume 4, Chapter 57)

in sympathetic ophthalmia, (Clinical Volume 4, Chapter 51) (Clinical Volume 4, Chapter 57)

in syphilis, (Clinical Volume 4, Chapter 57)

in toxoplasmosis, (Clinical Volume 4, Chapter 46) (Clinical Volume 4, Chapter 57)

transmitted fluorescence in, 3, (Clinical Volume 4, Chapter 57)

in tuberculosis, (Clinical Volume 4, Chapter 57)

tumors, (Foundations Volume 2, Chapter 113A )

in uveitis, (Clinical Volume 4, Chapter 37) (Clinical Volume 4, Chapter 57 )

bacterial, (Clinical Volume 4, Chapter 57)

fungal, (Clinical Volume 4, Chapter 57)

intermediate, (Clinical Volume 4, Chapter 57)

interpretation, (Clinical Volume 4, Chapter 57)

parasitic, (Clinical Volume 4, Chapter 57)

protozoal, (Clinical Volume 4, Chapter 57)

of unknown etiology, (Clinical Volume 4, Chapter 57)

viral, (Clinical Volume 4, Chapter 57)

in vitelliform dystrophy, (Clinical Volume 3, Chapter 9)

vitreotapetoretinal dystrophies, (Foundations Volume 2, Chapter 113B)

Vogt-Koyanagi-Harada syndrome, (Foundations Volume 2, Chapter 113E)

in Vogt-Koyanagi-Harada syndrome, (Clinical Volume 4, Chapter 57) (Clinical Volume 4, Chapter 57)

in X-linked juvenile retinoschisis, (Clinical Volume 3, Chapter 9)

Fluorescein-conjugated stains, (Foundations Volume 2, Chapter 40)

Fluorescein isothiocyanate (FITC), (Foundations Volume 2, Chapter 40)

Fluorescein pattern, Soper keratoconus lens, (Clinical Volume 1, Chapter 54)

Fluorescence, (Clinical Volume 1, Chapter 31)

Fluorescence microscopy, (Foundations Volume 2, Chapter 40)

acridine orange, (Foundations Volume 2, Chapter 40)

calcofluor white, (Foundations Volume 2, Chapter 40)

fluorescein-conjugated stains, (Foundations Volume 2, Chapter 40)

rhodamine-auramine, (Foundations Volume 2, Chapter 40)

Fluorescent antibody test, indirect (IFA), in toxoplasmosis, (Clinical Volume 4, Chapter 46)

Fluorescent light, (Foundations Volume 2, Chapter 15)

Fluorescent microscopy, (Foundations Volume 2, Chapter 40)

Fluorescent stains, in infection diagnosis, (Foundations Volume 2, Chapter 40)

Fluorescent treponemal antibody absorption (FTA-ABS) test, (Foundations Volume 2, Chapter 32) (Foundations Volume 2, Chapter 40) (Foundations Volume 2, Chapter 70)

Fluorochrome-conjugated antibodies, (Foundations Volume 2, Chapter 40)

Fluorometholone, ocular toxicity, (Clinical Volume 5, Chapter 37)

Fluorophotometry, (Clinical Volume 3, Chapter 46)

in measurement of aqueous formation, (Foundations Volume 2, Chapter 6)

in pars planitis, (Clinical Volume 4, Chapter 43)

Fluoroquinolones, (Clinical Volume 4, Chapter 26) (Foundations Volume 2, Chapter 61)

adverse effects, (Foundations Volume 3, Chapter 39) (Foundations Volume 3, Chapter 43)

in bacterial keratitis, (Clinical Volume 4, Chapter 18) (Clinical Volume 4, Chapter 26)

chemistry, (Foundations Volume 3, Chapter 39)

clinical uses, (Foundations Volume 3, Chapter 39)

for conjunctivitis, (Foundations Volume 3, Chapter 39)

for keratitis, (Foundations Volume 3, Chapter 36) (Foundations Volume 3, Chapter 39)

ophthalmic preparation, (Foundations Volume 3, Chapter 39)

in penetrating keratoplasty, (Clinical Volume 6, Chapter 26)

pharmacologic action, (Foundations Volume 3, Chapter 39)

prophylactic

corneal abrasions and, (Foundations Volume 2, Chapter 64)

postoperative, (Foundations Volume 2, Chapter 64)

preoperative, (Foundations Volume 2, Chapter 64)

resistance to, (Foundations Volume 2, Chapter 64)

5-Fluorouracil (5-FU)

administration of, (Foundations Volume 3, Chapter 33)

diabetic vitrectomy and, (Clinical Volume 6, Chapter 57)

glaucoma surgery and, (Clinical Volume 6, Chapter 15)

in human papillomavirus, (Foundations Volume 2, Chapter 95)

ocular toxicity, (Clinical Volume 5, Chapter 37)

risk of bleb-related infection and, (Clinical Volume 4, Chapter 55)

side effects and toxicity, (Foundations Volume 3, Chapter 33)

topical, (Foundations Volume 3, Chapter 33)

Fluothane. See Halothane

Fluoxetine, for migraine, (Clinical Volume 2, Chapter 16)

Fluprednisolone, ocular toxicity, (Clinical Volume 5, Chapter 37)

Flurazepam, ocular toxicity, (Clinical Volume 5, Chapter 37)

Flurbiprofen. See Nonsteroidal anti-inflammatory drugs (NSAIDs)

for allergic conjunctivitis, (Clinical Volume 4, Chapter 2)

for episcleritis, (Clinical Volume 4, Chapter 23)

for migraine, (Clinical Volume 2, Chapter 16)

for scleritis, (Clinical Volume 4, Chapter 23)

Flurometry, redox, (Clinical Volume 1, Chapter 31)

Flutter, ocular, (Clinical Volume 1, Chapter 4) (Clinical Volume 2, Chapter 11) (Foundations Volume 1, Chapter 38)

congenital, (Clinical Volume 2, Chapter 13)

Flynn-Aird syndrome, (Foundations Volume 3, Chapter 13)

FM-100 test, (Clinical Volume 3, Chapter 6)

Foam cells, in Niemann-Pick disease, (Clinical Volume 3, Chapter 29)

Focal dermal hypoplasia syndrome, (Clinical Volume 5, Chapter 27)

Focal electroretinogram (FERG), (Foundations Volume 2, Chapter 14) (Foundations Volume 2, Chapter 103) (Clinical Volume 2, Chapter 2) (Clinical Volume 3, Chapter 2)

Focal electroretinography, (Clinical Volume 2, Chapter 10)

Focal lengths, (Clinical Volume 1, Chapter 33)

equivalent, (Clinical Volume 1, Chapter 33)

refractive power of reduced eye and, (Clinical Volume 1, Chapter 33)

Focal length variability, lens, (Clinical Volume 1, Chapter 71B)

Focal photocoagulation of ciliary processes, (Clinical Volume 1, Chapter 69B)

Focal planes, infinite conjugates and, (Clinical Volume 1, Chapter 30)

Focal points, (Clinical Volume 1, Chapter 33) (Clinical Volume 1, Chapter 42)

primary, (Clinical Volume 1, Chapter 30)

secondary, (Clinical Volume 1, Chapter 30)

Focimeters. See Lensmeters

Focus, depth, (Clinical Volume 1, Chapter 33)

Foerster-Fuchs’ spots, (Clinical Volume 3, Chapter 36)

Fogging of glasses

principles, (Clinical Volume 1, Chapter 39)

problems, (Clinical Volume 1, Chapter 39)

in subjective refraction, (Clinical Volume 1, Chapter 39 )

technique, (Clinical Volume 1, Chapter 39)

Folate, deficiency, (Clinical Volume 5, Chapter 23)

Foldable lenses, (Clinical Volume 6, Chapter 11)

Folds

chorioretinal, (Clinical Volume 3, Chapter 36)

clinical correlation, (Clinical Volume 3, Chapter 36)

differential diagnosis, (Clinical Volume 3, Chapter 36)

etiology, (Clinical Volume 3, Chapter 36)

fluorescein angiography, (Clinical Volume 3, Chapter 36)

formation, mechanism, (Clinical Volume 3, Chapter 36)

ophthalmoscopy, 2, (Clinical Volume 3, Chapter 36)

retinal folds versus, (Clinical Volume 3, Chapter 36)

choroidal, in papilledema, (Clinical Volume 2, Chapter 5)

epicanthal, repair, (Clinical Volume 5, Chapter 88)

retinal, chorioretinal folds versus, (Clinical Volume 3, Chapter 36)

Folic acid

anencephaly and, (Foundations Volume 3, Chapter 2)

Folic acid analogs, (Foundations Volume 3, Chapter 33) See also Methotrexate

side effects, (Foundations Volume 3, Chapter 41)

Folic acid antagonists, teratogenicity, (Clinical Volume 5, Chapter 39)

Folic acid deficiency, (Clinical Volume 2, Chapter 5) (Clinical Volume 5, Chapter 29)

Folinic acid, in toxoplasmosis, (Clinical Volume 4, Chapter 46) (Foundations Volume 2, Chapter 66)

Follicle, microanatomy, (Clinical Volume 4, Chapter 7)

Follicle center cell lymphoma, (Clinical Volume 2, Chapter 39)

Follicles, conjunctival, (Foundations Volume 1, Chapter 29)

Follicular carcinoma, (Foundations Volume 3, Chapter 7)

Follicular carcinomas, (Foundations Volume 3, Chapter 7)

Follicular conjunctivitis, (Clinical Volume 4, Chapter 7) See also Conjunctivitis, follicular

Follicular cysts, “hybrid, ”, (3) 7: 16

Follicular keratosis, inverted, (Foundations Volume 3, Chapter 7)

Follicular tumors, (Foundations Volume 3, Chapter 7)

benign, (Foundations Volume 3, Chapter 7)

malignant, (Foundations Volume 3, Chapter 7)

Fomivirsen, (Foundations Volume 2, Chapter 100) (Foundations Volume 3, Chapter 37)

efficacy, (Foundations Volume 2, Chapter 100)

mechanism of action, (Foundations Volume 2, Chapter 100)

ophthalmic uses, (Foundations Volume 3, Chapter 37)

penetration and pharmacokinetics, (Foundations Volume 2, Chapter 100)

pharmacology, (Foundations Volume 3, Chapter 37)

resistance, (Foundations Volume 2, Chapter 100)

structure, (Foundations Volume 2, Chapter 100)

toxicity, (Foundations Volume 2, Chapter 100) (Foundations Volume 3, Chapter 39)

Fomivirsen (Vitravene), intravitreal, in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A)

Food and Drug Administration (FDA), intraocular lenses and, for use in children, (Clinical Volume 6, Chapter 101)

Food poisoning, facial paralysis in, (Clinical Volume 2, Chapter 8)

Football, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Foot pedals, positioning, in microsurgery, (Clinical Volume 6, Chapter 3)

Foramina

orbital apex, (Foundations Volume 1, Chapter 32)

scleral, (Foundations Volume 1, Chapter 1) (Foundations Volume 1, Chapter 23)

Foramina, scleral, (Foundations Volume 1, Chapter 23)

anterior scleral foramen, (Foundations Volume 1, Chapter 23)

posterior scleral foramen, (Foundations Volume 1, Chapter 23)

Forced choice test

blindsight and, (Clinical Volume 2, Chapter 7)

contrast sensitivity and, (Clinical Volume 1, Chapter 35)

Forced duction test, (Clinical Volume 1, Chapter 21) (Clinical Volume 2, Chapter 3) (Clinical Volume 2, Chapter 14)

in Brown tendon sheath syndrome, (Clinical Volume 6, Chapter 96)

orbital disease and, (Clinical Volume 2, Chapter 22)

in sixth nerve palsy, (Clinical Volume 6, Chapter 84)

Forceps

angle-tooth, (Clinical Volume 6, Chapter 3)

for iris tissue, (Clinical Volume 6, Chapter 3)

multipurpose, (Clinical Volume 6, Chapter 3)

smooth, (Clinical Volume 6, Chapter 3)

Sutherland De Juan, (Clinical Volume 6, Chapter 56)

for tissue suturing, (Clinical Volume 6, Chapter 3)

toothed, (Clinical Volume 6, Chapter 3)

tying, (Clinical Volume 6, Chapter 3)

vitreoretinal, (Clinical Volume 6, Chapter 56)

Forehead

aging and disease states, (Foundations Volume 2, Chapter 1)

function, (Foundations Volume 2, Chapter 1)

structure of, (Foundations Volume 2, Chapter 1)

Foreign bodies, (Foundations Volume 3, Chapter 6)

in anterior chamber, (Clinical Volume 4, Chapter 62) (Clinical Volume 6, Chapter 39)

choroiditis caused by, (Clinical Volume 4, Chapter 62)

composition, (Foundations Volume 3, Chapter 6)

corneal, under contact lens, (Clinical Volume 1, Chapter 55)

in eyelid, (Clinical Volume 5, Chapter 75)

intraocular

computed tomography of, (Clinical Volume 6, Chapter 56)

localization, (Clinical Volume 6, Chapter 56)

prognosis for, (Clinical Volume 6, Chapter 56)

removal, vitrectomy for, (Clinical Volume 6, Chapter 56)

introduced during cataract extraction, (Foundations Volume 3, Chapter 6)

iritis caused by, (Clinical Volume 4, Chapter 62)

iron, fixed dilated pupil, (Clinical Volume 2, Chapter 15)

orbital, (Foundations Volume 1, Chapter 32) (Clinical Volume 2, Chapter 24) (Clinical Volume 2, Chapter 35) (Clinical Volume 5, Chapter 87)

proptosis in, (Clinical Volume 2, Chapter 28)

siderosis and, glaucoma and, (Clinical Volume 3, Chapter 54E)

surgery

indications, (Clinical Volume 6, Chapter 66)

penetrating injuries and, (Clinical Volume 6, Chapter 66)

preoperative evaluation, (Clinical Volume 6, Chapter 66)

prognosis, (Clinical Volume 6, Chapter 66)

technique, (Clinical Volume 6, Chapter 66)

ultrasonography, (Foundations Volume 2, Chapter 108)

biomicroscopic, (Foundations Volume 2, Chapter 106)

vitrectomy for, (Clinical Volume 6, Chapter 66)

vitreous, ultrasonography, (Clinical Volume 3, Chapter 3)

Foreign body giant cell, (Foundations Volume 3, Chapter 1)

Foreign body granulomas, (Foundations Volume 3, Chapter 4)

Form perception, in blindsight, (Foundations Volume 2, Chapter 22)

Fornix, (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 29)

Fornix-based conjunctival flap, dissection, (Clinical Volume 6, Chapter 3)

Fornix foreshortening, in cicatricial pemphigoid, (Clinical Volume 5, Chapter 27)

Fornix incision, in rectus muscle surgery

recession procedure, (Clinical Volume 6, Chapter 83 )

resection procedure, (Clinical Volume 6, Chapter 83 )

Forsius-Eriksson syndrome, (Clinical Volume 4, Chapter 38)

Forskolin, aqueous humor formation and, (Clinical Volume 3, Chapter 45)

Fort Bragg fever. See Leptospirosis

Fortification spectrum, (Foundations Volume 2, Chapter 22)

Foscarnet (trisodium phosphonoformate hexahydrate), (Foundations Volume 2, Chapter 100)

for CMV retinitis, (Clinical Volume 3, Chapter 28A)

efficacy, (Foundations Volume 2, Chapter 100)

induction therapy, (Foundations Volume 3, Chapter 37)

intravitreal, in cytomegalovirus retinitis, (Clinical Volume 3, Chapter 28A)

maintenance therapy, (Foundations Volume 3, Chapter 37)

mechanism of action, (Foundations Volume 2, Chapter 100) (Foundations Volume 3, Chapter 37)

ophthalmic uses, (Foundations Volume 3, Chapter 37)

penetration and pharmacokinetics, (Foundations Volume 2, Chapter 100)

pharmacology, (Foundations Volume 3, Chapter 37)

for progressive outer retinal necrosis syndrome, (Clinical Volume 3, Chapter 28)

resistance, (Foundations Volume 2, Chapter 100)

SOCA study, (Foundations Volume 3, Chapter 37)

structure, (Foundations Volume 2, Chapter 100)

systemic uses, (Foundations Volume 3, Chapter 37)

toxicity, (Foundations Volume 2, Chapter 100) (Foundations Volume 3, Chapter 37)

Fossa glandulae lacrimalis, (Clinical Volume 2, Chapter 40)

Foster Kennedy syndrome, (Clinical Volume 2, Chapter 5)

acute disc infarction versus, (Clinical Volume 2, Chapter 5)

in meningiomas, (Clinical Volume 2, Chapter 6)

Fourth cranial nerve. See Trochlear nerve

Fovea

anatomy, (Foundations Volume 1, Chapter 19) (Foundations Volume 1, Chapter 19) (Foundations Volume 1, Chapter 34)

central, (Foundations Volume 1, Chapter 19)

cones, (Foundations Volume 1, Chapter 19)

dystrophy, (Foundations Volume 3, Chapter 60)

hyperplasia of, (Foundations Volume 1, Chapter 40)

retinal, (Clinical Volume 3, Chapter 1) (Clinical Volume 3, Chapter 1)

anatomy, (Clinical Volume 2, Chapter 4)

in autosomal dominant fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

butterfly-shaped pigment dystrophy of, (Clinical Volume 3, Chapter 9)

in central areolar choroidal dystrophy, (Clinical Volume 3, Chapter 9)

in central areolar pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9)

cysts, (Clinical Volume 3, Chapter 8)

distance from optic disc, 3, (Clinical Volume 3, Chapter 26)

in dominant slowly progressive macular dystrophy, (Clinical Volume 3, Chapter 9)

familial, retinoschisis, (Clinical Volume 3, Chapter 9)

in foveomacular vitelliform dystrophy, (Clinical Volume 3, Chapter 9)

functional assessment, (Clinical Volume 2, Chapter 2)

in fundus flavimaculatus, (Clinical Volume 3, Chapter 9)

halo around, in Niemann-Pick disease, (Clinical Volume 3, Chapter 29)

in metachromatic leukodystrophy, (Clinical Volume 3, Chapter 29)

in North Carolina macular dystrophy, (Clinical Volume 3, Chapter 9)

in rod monochromaticism, (Clinical Volume 3, Chapter 9)

in Stargardt’s disease, (Clinical Volume 3, Chapter 9)

in vitelliform dystrophy, (Clinical Volume 3, Chapter 9)

vitreous adhesion to, (Foundations Volume 3, Chapter 14)

Foveal avascular zone

abnormalities, fluorescein angiography, (Foundations Volume 2, Chapter 113D)

anatomy of, (Foundations Volume 1, Chapter 1)

Foveal cone electroretinogram, (Foundations Volume 2, Chapter 14)

Fovea lentis, (Foundations Volume 1, Chapter 15)

Foveal function, tests of, (Clinical Volume 2, Chapter 10)

Foveal images, (Clinical Volume 1, Chapter 5)

Foveal pit, (Foundations Volume 1, Chapter 19)

Foveal reflex

in pigment epithelial dystrophy, (Clinical Volume 3, Chapter 9)

in progressive cone-rod dystrophies, (Clinical Volume 3, Chapter 9)

Foveation, acuity and, in nystagmus, (Clinical Volume 2, Chapter 11)

Foveation periods, (Foundations Volume 1, Chapter 38)

Foveation reflex, (Clinical Volume 2, Chapter 2)

Foveola, retinal, (Clinical Volume 3, Chapter 1) See Fovea

Foveomacular abnormalities, congenital, (Foundations Volume 3, Chapter 13)

Foveomacular dystrophy, adult type, (Foundations Volume 3, Chapter 60)

Foveomacular retinitis, (Clinical Volume 3, Chapter 37)

Foville syndrome, (Foundations Volume 1, Chapter 37)

Fractional inhibitory concentration (FIC), (Foundations Volume 2, Chapter 40)

Fracture, orbital, (Foundations Volume 3, Chapter 17)

Fractures

internal, treatment, (Clinical Volume 2, Chapter 48)

midfacial, and lacrimal apparatus disorders, (Clinical Volume 4, Chapter 13)

orbital, (Clinical Volume 1, Chapter 20) (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 48 )

anatomic considerations, (Clinical Volume 2, Chapter 48)

blowout, (Clinical Volume 2, Chapter 24) (Clinical Volume 5, Chapter 87)

surgery for, (Clinical Volume 2, Chapter 48)

treatment, (Clinical Volume 2, Chapter 48) (Clinical Volume 5, Chapter 87) (Clinical Volume 6, Chapter 111)

classification, (Clinical Volume 2, Chapter 48)

clinical examination, (Clinical Volume 2, Chapter 48)

complex, (Clinical Volume 5, Chapter 87)

computed tomography, (Clinical Volume 2, Chapter 24) (Clinical Volume 2, Chapter 48)

evaluation, (Clinical Volume 2, Chapter 48)

floor

saccadic velocity in, (Clinical Volume 1, Chapter 21)

and simulated sheath syndrome, (Clinical Volume 1, Chapter 20)

mechanisms of injury, (Clinical Volume 2, Chapter 48)

medial wall, (Clinical Volume 5, Chapter 87)

proptosis in, (Clinical Volume 2, Chapter 28)

radiologic imaging, (Clinical Volume 2, Chapter 48)

rim, (Clinical Volume 2, Chapter 48)

inferior, (Clinical Volume 2, Chapter 48)

lateral, (Clinical Volume 2, Chapter 48)

medial, (Clinical Volume 2, Chapter 48)

superior, (Clinical Volume 2, Chapter 48)

roof, (Clinical Volume 5, Chapter 87)

treatment, (Clinical Volume 2, Chapter 48)

postoperative complications, (Clinical Volume 2, Chapter 48)

Fragile-X syndrome, (Foundations Volume 3, Chapter 59)

Fragilitas ossium. See Osteogenesis imperfecta

Francisella tularensis, (Foundations Volume 2, Chapter 32) (Foundations Volume 3, Chapter 4)

Francois-Neetens, fleck dystrophy of, (Clinical Volume 4, Chapter 16)

Franklin-style bifocal lenses, (Clinical Volume 1, Chapter 44)

Fraser syndrome, (Foundations Volume 1, Chapter 40)

Freckling, in neurofibromatosis, (Clinical Volume 5, Chapter 36)

Freeman-Sheldon syndrome, (Foundations Volume 3, Chapter 59)

Freezing, in microbiology laboratory, (Foundations Volume 2, Chapter 47)

Frequency, of light, (Foundations Volume 2, Chapter 15)

Frequency and duration of light stimulus, (Clinical Volume 1, Chapter 5)

Frequency doubling perimetry, (Clinical Volume 2, Chapter 10)

Frequency-doubling perimetry, (Foundations Volume 2, Chapter 109)

Frequency doubling technology, in perimetry, (Clinical Volume 3, Chapter 49)

Frequency response curve, (Clinical Volume 1, Chapter 30)

Fresnel optics, (Clinical Volume 1, Chapter 52 )

in anisophoria, (Clinical Volume 1, Chapter 52)

in basic principles, (Clinical Volume 1, Chapter 52)

construction, (Clinical Volume 1, Chapter 52)

lenses, (Clinical Volume 1, Chapter 52)

in ametropia, (Clinical Volume 1, Chapter 52)

in aphakia, (Clinical Volume 1, Chapter 52)

for bifocals, (Clinical Volume 1, Chapter 52)

in esophoria, (Clinical Volume 1, Chapter 52)

for near magnification, (Clinical Volume 1, Chapter 52)

performance, (Clinical Volume 1, Chapter 52)

in prepresbyopia, (Clinical Volume 1, Chapter 52)

in presbyopia, (Clinical Volume 1, Chapter 52)

for refractive errors, (Clinical Volume 1, Chapter 52)

for trifocals, (Clinical Volume 1, Chapter 52)

types, (Clinical Volume 1, Chapter 52)

uses, (Clinical Volume 1, Chapter 52)

prism, (Clinical Volume 1, Chapter 30) (Clinical Volume 1, Chapter 52)

in amblyopia, (Clinical Volume 1, Chapter 52)

in anisorphoria, (Clinical Volume 1, Chapter 52)

astigmatism from, (Clinical Volume 1, Chapter 52)

for bedridden patients, (Clinical Volume 1, Chapter 52)

compared to conventional prisms, (Clinical Volume 1, Chapter 52)

in diplopia, (Clinical Volume 1, Chapter 52)

in esophoria, (Clinical Volume 1, Chapter 52)

in exophoria, (Clinical Volume 1, Chapter 52)

in field defects, (Clinical Volume 1, Chapter 52)

inverse, (Clinical Volume 1, Chapter 52)

in nystagmus, (Clinical Volume 1, Chapter 52)

in ocular torticollis, (Clinical Volume 1, Chapter 52)

performance, (Clinical Volume 1, Chapter 52)

in phoria, (Clinical Volume 1, Chapter 52)

in presbyopia, (Clinical Volume 1, Chapter 52)

in strabismus, (Clinical Volume 1, Chapter 52)

types, (Clinical Volume 1, Chapter 52)

uses, (Clinical Volume 1, Chapter 52)

Frey syndrome, (Clinical Volume 2, Chapter 8) (Clinical Volume 2, Chapter 12)

Friedenwald formula, (Foundations Volume 2, Chapter 7)

Friedenwald nomogram, (Foundations Volume 2, Chapter 7)

Friedreich ataxia, retinal degeneration, (Clinical Volume 2, Chapter 5) (Clinical Volume 3, Chapter 24) (Foundations Volume 2, Chapter 105) (Foundations Volume 3, Chapter 13)

Frisbee, eye injuries from, protective device effectiveness and, (Clinical Volume 5, Chapter 45)

Frontal artery, (Foundations Volume 1, Chapter 5)

Frontal bone, 2, (Clinical Volume 2, Chapter 21) (Foundations Volume 1, Chapter 32)

Frontal cortex, dorsolateral, ocular motility and, (Foundations Volume 1, Chapter 38)

Frontal eye fields, (Clinical Volume 1, Chapter 4)

ocular motility and, (Foundations Volume 1, Chapter 38) (Foundations Volume 2, Chapter 23)

saccades and, (Clinical Volume 1, Chapter 4) (Clinical Volume 2, Chapter 10)

Frontalis sling technique, in ptosis surgery, (Clinical Volume 5, Chapter 72 )

Frontalis suspension

ptosis surgery and, (Clinical Volume 5, Chapter 78)

silicone rod, (Clinical Volume 5, Chapter 78)

Frontal nerve, (Clinical Volume 6, Chapter 1) (Foundations Volume 1, Chapter 5) (Foundations Volume 1, Chapter 29)

Frontal sinus, (Foundations Volume 1, Chapter 32) (Clinical Volume 2, Chapter 21) (Clinical Volume 2, Chapter 24)

fractures, (Clinical Volume 2, Chapter 24)

mucoceles, (Clinical Volume 2, Chapter 5) (Clinical Volume 2, Chapter 31)

osteoma, and simulated sheath syndrome, (Clinical Volume 1, Chapter 20)

surgery, and simulated sheath syndrome, (Clinical Volume 1, Chapter 20)

Frontal vein, (Foundations Volume 1, Chapter 5)

Frontoethmoidal orbitotomy, (Clinical Volume 5, Chapter 86) See also Orbitotomy

Frontoparallel horopter, (Foundations Volume 2, Chapter 24) See also Horopter

Frontoparietal lesions, bilateral, acute, (Clinical Volume 2, Chapter 10)

Frontosphenoid foramina, (Foundations Volume 1, Chapter 32)

Frosted cataract, (Foundations Volume 1, Chapter 15)

Frovatriptan, for migraine, (Clinical Volume 2, Chapter 16)

FTA-ABS (fluorescent treponemal antibody absorption) test, (Foundations Volume 2, Chapter 32) (Foundations Volume 2, Chapter 40) (Foundations Volume 2, Chapter 70)

5-FU. See 5-Fluorouracil

Fuchs’ adenoma, (Foundations Volume 3, Chapter 11)

Fuchs’ coloboma, (Clinical Volume 3, Chapter 8)

Fuchs’ crypts, (Foundations Volume 1, Chapter 11)

Fuchs’ dystrophy, (Clinical Volume 3, Chapter 55) (Clinical Volume 4, Chapter 16A) (Foundations Volume 3, Chapter 1) (Foundations Volume 3, Chapter 9) (Foundations Volume 3, Chapter 63)

cataracts in, (Clinical Volume 3, Chapter 55)

clinical manifestations, (Clinical Volume 4, Chapter 16A)

epidemiology, (Clinical Volume 4, Chapter 16A)

glaucoma in, (Clinical Volume 3, Chapter 54F) (Clinical Volume 3, Chapter 55)

histopathology, (Clinical Volume 4, Chapter 16A)

history, (Clinical Volume 4, Chapter 16A)

postoperative, (Foundations Volume 3, Chapter 6)

treatment, (Clinical Volume 4, Chapter 16A)

Fuchs’ heterochromic iridocyclitis, (Foundations Volume 3, Chapter 3) (Clinical Volume 3, Chapter 55) (Clinical Volume 3, Chapter 19) See Fuchs’ syndrome

Fuchs’ inferior coloboma, (Clinical Volume 2, Chapter 5)

Fuchs’ spot, in pathologic myopia, (Clinical Volume 3, Chapter 36)

Fuchs’ spurs, (Foundations Volume 1, Chapter 11)

Fuchs’ syndrome, (Clinical Volume 4, Chapter 37) (Clinical Volume 4, Chapter 42)

cataracts in, (Clinical Volume 3, Chapter 54D) (Clinical Volume 3, Chapter 55) (Clinical Volume 4, Chapter 42)

glaucoma in, (Clinical Volume 3, Chapter 54D) (Clinical Volume 3, Chapter 55) (Clinical Volume 4, Chapter 42)

toxoplasmosis and, (Clinical Volume 4, Chapter 46)

uveitis in, (Clinical Volume 4, Chapter 64)

Fucosidosis, (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 54B)

genetics, (Clinical Volume 5, Chapter 19)

ocular features, (Clinical Volume 5, Chapter 19)

phenotypes, (Clinical Volume 5, Chapter 19)

Fukuda stepping test, (Clinical Volume 2, Chapter 18)

positive, (Clinical Volume 2, Chapter 18)

Full-thickness macular holes, (Clinical Volume 6, Chapter 61) See also Macula, holes

Full-thickness procedures, in lid repair, (Clinical Volume 5, Chapter 88)

Full threshold strategy, in automated perimetry, (Clinical Volume 3, Chapter 49)

Fumagillin, for microsporidiosis, (Foundations Volume 2, Chapter 66)

Functional acuity score, (Clinical Volume 5, Chapter 51)

Functional cloning, (Foundations Volume 3, Chapter 55)

Functional field score, (Clinical Volume 5, Chapter 51)

Functional normal, occupational ophthalmology and, (Clinical Volume 5, Chapter 47)

Functional Vision Score, (Clinical Volume 5, Chapter 51)

Functional visual loss in child, 62–65

Fundus

color, (Clinical Volume 1, Chapter 31)

color code, 2, (Clinical Volume 3, Chapter 26)

congenital abnormalities, (Clinical Volume 3, Chapter 8 )

disorders, (Clinical Volume 3, Chapter 36 )

dystrophy, Sorsby’s, (Clinical Volume 4, Chapter 66)

genetics, (Clinical Volume 3, Chapter 2)

examination, (Clinical Volume 2, Chapter 14) (Clinical Volume 2, Chapter 22)

ophthalmoscopic. (See Ophthalmoscopy)

in uveitis, (Clinical Volume 4, Chapter 32)

in hypertensive retinopathy, (Clinical Volume 3, Chapter 13)

lesions, (Clinical Volume 1, Chapter 63)

in membranoproliferative glomerulonephritis, (Clinical Volume 5, Chapter 31)

in neurofibromatosis, (Clinical Volume 3, Chapter 34)

in sickle cell disease, (Clinical Volume 3, Chapter 17)

vasoproliferative tumors, (Clinical Volume 3, Chapter 22)

localization in, (Clinical Volume 1, Chapter 63)

myopia, (Clinical Volume 3, Chapter 36) See also Myopiain

normal appearance, (Clinical Volume 3, Chapter 7)

opportunistic infections, in AIDS, (Clinical Volume 2, Chapter 5)

photography. (See also Fundus camera)

in glaucoma screening, (Clinical Volume 5, Chapter 54)

in retinal migraine, (Clinical Volume 2, Chapter 5)

with rod monochromaticism, (Clinical Volume 3, Chapter 9)

salt-and-pepper. (See Salt-and-pepper fundus)

in Sjorgren’s reticular dystrophy of retinal pigment epithelium, (Clinical Volume 3, Chapter 9)

in Stargardt’s disease, (Clinical Volume 3, Chapter 9)

in Sturge-Weber syndrome, (Clinical Volume 3, Chapter 34)

vascular anomalies, (Clinical Volume 3, Chapter 22) See also specific anomalies

congenital, (Clinical Volume 3, Chapter 8)

Fundus albipunctatus, (Foundations Volume 2, Chapter 103)

Fundus camera

angiographic system, (Clinical Volume 3, Chapter 4)

indocyanine green angiography based on, (Clinical Volume 3, Chapter 4A)

Fundus chart, 2, (Clinical Volume 3, Chapter 26)

Funduscopy, of retinal pigment epithelium tears, (Clinical Volume 3, Chapter 36)

optic nerve in glaucoma, (Clinical Volume 3, Chapter 48)

Fundus dystrophy, Sorsby, (Foundations Volume 3, Chapter 11)

Fundus flavimaculatus, (Clinical Volume 3, Chapter 9) (Foundations Volume 3, Chapter 13) (Foundations Volume 3, Chapter 60)

autosomal dominant, (Clinical Volume 3, Chapter 9)

fluorescein angiography, (Foundations Volume 2, Chapter 113B)

molecular genetics, (Foundations Volume 3, Chapter 55)

Stargart’s disease versus, (Clinical Volume 3, Chapter 9)

Fundus photography, (Clinical Volume 1, Chapter 63)

Fundus xerophthalmicus, (Clinical Volume 5, Chapter 59)

Fungal infections, (Foundations Volume 3, Chapter 7)

orbit, (Clinical Volume 2, Chapter 34)

aspergillosis, (Clinical Volume 2, Chapter 34)

mucormycosis, (Clinical Volume 2, Chapter 34)

Fungi, (Foundations Volume 2, Chapter 54)

aerobic actinomycetes, (Foundations Volume 2, Chapter 54)

characteristics, (Foundations Volume 2, Chapter 54)

identification, (Foundations Volume 2, Chapter 54)

contact lenses and, (Foundations Volume 2, Chapter 53)

culture isolation, (Foundations Volume 2, Chapter 40) (Foundations Volume 2, Chapter 54)

dematiaceous, (Foundations Volume 2, Chapter 54)

direct microscopic examination, (Foundations Volume 2, Chapter 54)

histopathological stains, (Foundations Volume 2, Chapter 54)

hyaline, (Foundations Volume 2, Chapter 54)

normal, of lids and conjunctiva, (Foundations Volume 2, Chapter 41)

reproduction, (Foundations Volume 2, Chapter 54)

yeast and yeastlike, (Foundations Volume 2, Chapter 54)

zygomycetes, (Foundations Volume 2, Chapter 54)

Fungizone. See Amphotericin B

Fungus disease, (Clinical Volume 5, Chapter 33 )

endophthalmitis, (Clinical Volume 3, Chapter 11) (Clinical Volume 4, Chapter 55)

histoplasmosis, (Clinical Volume 4, Chapter 48) See also Histoplasmosis

keratitis, (Clinical Volume 4, Chapter 21) See also Keratitis, fungal

laboratory diagnosis, (Clinical Volume 4, Chapter 1)

of lids, (Clinical Volume 4, Chapter 22)

optic neuropathy due to, (Clinical Volume 2, Chapter 5)

orbital, (Clinical Volume 2, Chapter 34 )

cellulitis, (Clinical Volume 4, Chapter 25) See also Cellulitis, orbital

polymerase chain reaction in, (Clinical Volume 4, Chapter 1)

serology, (Clinical Volume 4, Chapter 1)

sinusitis, (Clinical Volume 2, Chapter 14)

uveitis, (Clinical Volume 4, Chapter 56) (Clinical Volume 4, Chapter 57) See also Uveitis

Furosemide, for pseudotumor cerebri, (Clinical Volume 2, Chapter 5)

Furrow degeneration, corneal, (Clinical Volume 4, Chapter 16)

Fusarium, (Foundations Volume 2, Chapter 54)

Fusarium solani, (Foundations Volume 2, Chapter 54)

Fusarium spp., endophthalmitis, (Clinical Volume 4, Chapter 55)

Fusiform aneurysms, (Clinical Volume 2, Chapter 17)

carotid system, (Clinical Volume 2, Chapter 17)

vertebrobasilar system, (Clinical Volume 2, Chapter 17)

Fusiform aneurysms. See Aneurysms, fusiform

Fusiform cataracts, (Foundations Volume 1, Chapter 15)

Fusion, (Clinical Volume 1, Chapter 5) (Clinical Volume 2, Chapter 2)

acquired central defects of, (Clinical Volume 2, Chapter 13)

breakpoint, (Clinical Volume 1, Chapter 7)

color, (Clinical Volume 1, Chapter 5)

congenital anomalies of, (Clinical Volume 2, Chapter 13)

dichoptic, (Foundations Volume 2, Chapter 24)

extramacular versus macular, (Clinical Volume 1, Chapter 5)

lens fiber cell-to-cell, (Clinical Volume 1, Chapter 71A)

lid, (Foundations Volume 1, Chapter 5)

peripheral, (Clinical Volume 1, Chapter 5)

physiologic basis of, (Foundations Volume 2, Chapter 24)

red filter test, (Clinical Volume 1, Chapter 6)

restoration point, (Clinical Volume 1, Chapter 7)

spatial limits of, (Foundations Volume 2, Chapter 24)

stereopsis versus, (Clinical Volume 1, Chapter 5)

temporal aspects of, (Foundations Volume 2, Chapter 24)

visual evoked potentials and, (Foundations Volume 2, Chapter 24)

Worth’s degrees of, (Clinical Volume 1, Chapter 5)

Fusional convergence, (Clinical Volume 1, Chapter 7)

Fusional divergence, (Clinical Volume 1, Chapter 7)

amplitude in accommodative esodeviations, (Clinical Volume 1, Chapter 12)

Fusional reflex, (2)13: 20

Fusional vergence, (Clinical Volume 1, Chapter 5) See also under Vergence, 13; (Clinical Volume 1, Chapter 7)

Fusion horopter, (Foundations Volume 2, Chapter 24) (Foundations Volume 2, Chapter 24) See also Horopter

Fusion maldevelopment nystagmus syndrome, (Clinical Volume 2, Chapter 11)

Fusobacteria, (Foundations Volume 2, Chapter 57)

Future of, (Clinical Volume 6, Chapter 6)

FVEP (flash visual evoked potential), (Foundations Volume 2, Chapter 105)